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ABSTRACT 
17β-estradiol (E2), the most potent form of the steroid hormone class, the estrogens, is a 
known regulator of hippocampal function and is capable of being synthesised within 
hippocampal neurons. E2 can modulate glutamatergic synaptic transmission and 
hippocampal synaptic plasticity, as well as enhance hippocampal dependent learning in 
rodent models. However, not all effects of estradiol are mediated by the two canonical 
estrogen receptors, ERα and ERβ. Recently, a novel estrogen-sensing G protein coupled 
receptor (GPR30) was identified, and hippocampal expression of GPR30 indicates a 
potential role for this receptor in modulating hippocampal function.  
Thus, the primary aims of this thesis were to clarify the effects of E2 on glutamatergic 
synaptic transmission and establish whether activation of GPR30 is involved. Using 
evoked population EPSP recordings within the dendritic field of hippocampal region 
CA1, we show that acute application of a physiologically relevant concentration of E2 
modulates excitatory synaptic transmission in a bi-directional manner; the most 
consistent effect however was the induction of a novel form of LTD. Moreover, we 
show that the GPR30 agonist (G1) mimics the bi-directional effects of E2 on excitatory 
synaptic transmission. Subsequent characterisation of the E2 and G1 induced LTD 
revealed that both forms of agonist-induced plasticity are expressed post-synaptically, 
correlating with findings in hippocampal cultures in which treatment with these agonists 
resulted in a reduction in the relative density of GluA1-containing AMPA receptors 
expressed at synapses. In addition, further investigation into the pharmacology of the 
G1-induced LTD revealed that this effect was not prevented by selective antagonists for 
GPR30, ERα or ERβ, however could be attenuated by a selective estrogen receptor 
downregulator and putative ligand for GPR30, ICI 182 780. Furthermore, we establish 
that in hippocampal neurons, the G1-induced LTD and reduction in surface AMPA 
receptor expression is mediated via the ERK 1/2 signalling pathway.  
In summary, the data presented here suggests that at CA3 to CA1 synapses, E2 and the 
GPR30 agonist can induce a novel form of LTD in adult hippocampal tissue.  
Considering the multifaceted role of estrogens in human physiology, pharmaceuticals 
which modulate this system in a site specific manner (either by influencing estrogen 
synthesis or targeting estrogen receptors) could be of benefit in hippocampal dependent 
learning and memory processes in health and disease.  
xiv 
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PKC   Protein Kinase C 
PKA   Protein Kinase A 
PLC    Phospholipase C 
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PP1   Protein Phosphatase 1 
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pp-LFS  paired-pulse low frequency stimulation  
PREG   Pregnenolone 
PSD   Post-synaptic density 
PSD-95  Post-synaptic density-95 
RAMP   Receptor activity modifying protein  
RNA   Ribonucleic Acid  
ROCK   Rho-associated protein kinase 
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction 
SEM   Standard Error of the Mean  
siRNA   short-interfering RNA 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor  
StAR   steroidogenic acute regulatory protein 
Sub.   Subiculum 
TARP   Transmembrane AMPAR regulator protein 
TGN   Trans-Golgi Network 
OVX   Ovariectomised  
vGluT   vesicular Glutamate Transporter 
5-HT1aR  5-hydroxy-tryptophan-1a receptor  
 
1 
 
 
 
Chapter One 
 
Introduction 
 
 
 
  
 
 
2 
1.1: The Hippocampus  
The hippocampus is part of a group of structures within the limbic system, and is 
classically known as the structure associated with the formation of new memories and 
spatial learning. The cellular anatomy of the hippocampus was studied in great detail in 
the late 1800’s by Santiago Ramòn y Cajal. However, the physiological role of this 
structure only became apparent in the late 1950’s, when Scoville and Milner (1957) 
noted complete loss of new “declarative” (episodic) memory formation from patient 
H.M. following bilateral removal of the hippocampus, suggesting that the hippocampus 
is vital for new memory formation. The basic curved structure and organisation of the 
hippocampus is conserved between all mammals, it is formed by two interlocking sheets 
of cortex which consist of a single layer of tightly packed pyramidal neurons, 3 – 5 cells 
deep. The laminar structure of hippocampus makes the hippocampal slice preparation an 
ideal structure to study synaptic transmission as circuitry and synaptic contacts are 
largely preserved.  
 
1.1.2: Circuitry of the hippocampus 
The hippocampal formation is organised into distinct regions (Figure 1.1 A), cornu 
ammonis (CA) regions 1 – 3, the dentate gyrus (DG), subiculum (Sub.), and entorhinal 
cortex (EC). The primary input into the hippocampus occurs via the EC and follows a 
unidirectional flow of neuronal communication. This is often termed the tri-synaptic 
loop: EC -> DG via the perforant path, DG -> CA3 via mossy fibres and CA3 -> CA1 
via schaffer collateral fibres. The main excitatory output from the hippocampus occurs 
via principal cells of the CA1, via the subiculum.  
A single CA1 pyramidal neuron receives about 30,000 excitatory and 1,700 inhibitory 
synaptic inputs (Megías et al., 2001). The main excitatory inputs to CA1 pyramidal 
neurons arise from axons of CA3 neurons, which synapse on apical dendrites in the 
stratum radiutum layer. Excitatory inputs to CA1 also occur at the stratum lacunosum-
molecular which receives direct inputs from EC and the thalamus. Local inhibition is 
provided by a host of interconnected GABAergic interneurons (Klausberger and 
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Somogyi, 2008). Integration of these excitatory and inhibitory signals determines the 
level of excitatory output. 
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Figure 1.1: Neural circuitry of the rodent hippocampus and structure of a CA1 
pyramidal neuron.  A, Drawing by Santiago Ramón y Cajal, illustrating the tri-
synaptic circuit and the laminar structure of the rodent hippocampus: E.C, entorhinal 
cortex; DG, dentate gyrus; CA1 and CA3, area cornu ammonis 1 and 3; Sub., 
subiculum. B, Drawing of an adult rat CA1 pyramidal neuron adapted from Megías 
et al., 2001; S., stratum; scale bar = 100µm. 
A: Original drawing published in: Histologie du Système Nerveux de l’Homme et 
des Vertèbrès (Paris: Maloine, 1909-1911).  
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1.1.3:  Glutamatergic Synaptic Transmission  
The amino acid glutamate, is the primary excitatory neurotransmitter in the mammalian 
central nervous system (CNS). Glutamatergic synaptic transmission occurs primarily 
within the tripartite synapse (Fig 1.2). Briefly, calcium sensitive protein complexes 
(SNARE; Südhof and Rothman, 2009) facilitate the release of glutamate from the pre-
synaptic terminal in response to a rise in intracellular calcium ([Ca2+]i). Once released 
within the synaptic cleft, glutamate then may activate ionotropic glutamate receptors 
(iGluR) and metabotropic glutamate receptors (mGluR) at synaptic or extrasynaptic 
sites on post-synaptic neurons to mediate post-synaptic responses (depolarisation, local 
protein synthesis, activation of intracellular signalling cascades etc.), or at pre-synaptic 
sites to mediate transmitter release. The concentration of glutamate within the synapse 
is tightly regulated such that after release, glutamate is rapidly removed from the 
synaptic cleft via excitatory amino acid transporters (EAAT) within glia, where 
glutamate is converted to glutamine by glutamine synthase. Glutamine is then 
transported out of the glia cell, and taken up by presynaptic neurons, where it is 
converted back into glutamate by glutaminase and packaged into vesicles by vesicular 
glutamate transporters (vGluTs) ready for release (Rousseaux et al., 2008).  
Thus, modulation of glutamergic neurotransmission can occur at a number of sites 
within triparte synapse:  
- Glutamate release 
o Influenced by the probability of vesicle release  
o Influenced the by the number of vesicles available for release (the ready 
releasable pool).  
- Glutamate uptake (relative expression of EAAT) 
- Glutamate metabolism – the rate at which glutamine/ glutamate cycle occurs.  
- Expression levels of post-synaptic glutamate receptors  
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Figure 1.2: The Glutamatergic Synapse. Cartoon depicting glutamatergic synaptic 
transmission within the tripartite synapse. Glutamate is released from presynaptic 
terminals into the synaptic cleft and binds to post-synaptic NMDAR, AMPAR and 
mGluRs to mediate excitatory synaptic responses at the post-synaptic neuron. 
Glutamate is removed from the synaptic cleft by glia through glutamate transporters 
(EAAT). 
Figure adapted from Popoli et al., (2012) 
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1.1.4: Ionotropic Glutamate Receptors 
There are three classes of iGluR, named after the ligands they preferentially bind to: N-
methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropoinic acid 
(AMPA) and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (Kainate). As well 
as a less-characterized class of δ receptors (delta: “orphan”) (Traynelis et al., 2010). 
iGluR are tetrameric ligand gated ion channels, the individual subunits of which share 
similar architecture and several common features. Briefly, each subunit comprises of an 
extracellular amino terminal, three transmembrane domains (M1, M3 and M4), an 
extracellular ligand binding domain (formed from extracellular loops between M1 and 
M3), a cytoplasm facing re-entrant membrane loop (pore forming; M2) and an 
intracellular carboxyl terminal (as reviewed in: Dingledine et al., 1999; Traynelis et al., 
2010). The general topology of an iGluR subunit is depicted below in Figure 1.3. 
 
 
 
 
 
Figure 1.3: Cartoon depicting the general topology of ionotropic glutamate 
receptors. Ionotropic glutamate receptors are tetrameric ligand gated cation 
channels. Each subunit comprises of three membrane-spanning domains, a re-entrant 
pore forming domain and extracellular N-terminus, and an intracellular C-terminus.  
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1.1.4.1: AMPA Receptors 
AMPAR are responsible for the majority of fast glutamatergic synaptic transmission in 
the mammalian CNS, and can be composed of homomeric or heteromeric combinations 
of subunits GluA1 – GluA4. In general, AMPAR channels display fast kinetics (fast 
activation and deactivation coupled with rapid desensitization) such that signalling via 
these ion channels occurs within milliseconds (Mosbacher et al., 1994; Jackson and 
Nicoll, 2011). AMPAR are permeable to sodium (Na
+
), potassium (K
+
) and calcium 
(Ca
2+
); however calcium permeability is governed by incorporation of the GluA2 
subunit (Hollmann et al., 1991; Jonas and Burnashev, 1995). The majority of GluA2-
subunits are post-transcriptionally edited prior to mRNA splicing. This editing at the 
QRN site at the tip of the re-entrant pore loop (M2) results in a switching of an 
uncharged glutamine (Q) to a positively charged arginine (R) which renders GluA2-
containing AMPAR impermeable to Ca
2+
 and favours heteromerization (Sommer et al., 
1991; Greger et al., 2002, 2003). GluA2-containig AMPAR are characterised by a linear 
current-voltage relationship. In contrast, AMPAR lacking the GluA2 subunit (ie: 
homomeric or heteromeric combinations of GluA1, GluA3 or GluA4), which are 
permeable to Ca
2+
, are sensitive to voltage-dependant block by intracellular polyamines, 
and are generally characterised by having an inwardly rectifying current-voltage 
relationship (as reviewed in: Traynelis et al., 2010). At  CA3 - CA1 synapses, the 
majority of fast-glutatmatergic synaptic transmission is governed by activation 
GluA2/GluA1 heteromers (Na
+
 influx; Lu et al., 2009), however recent evidence 
suggests that synaptic GluA2-lacking AMPAR may also contribute to basal synaptic 
responses (Rozov et al., 2012).  
Contributing to desensitization characteristics of AMPAR is the capacity for all subunits 
to undergo alternative splicing. Alternative splicing yields two variants (flip and flop) 
and occurs at a region of the extracellular loop adjacent to the last transmembrane 
domain (M4). Flip variants desensitize more slowly and to a lesser extent than their flop 
counterparts, which can influence total AMPA current (Sommer et al., 1990; Dingledine 
et al., 1999). C-terminal phosphorylation (Boehm and Malinow, 2005; Lee, 2006) and 
association with auxiliary proteins, such as transmembrane AMPAR regulatory proteins 
(TARP’s; Jackson and Nicoll, 2011) can also influence channel properties. Trafficking 
of AMPAR to and from excitatory synapses underlies long-term alterations in synaptic 
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strength (section 1.1.6.3 and for comprehensive reviews see: Malinow and Malenka, 
2002; Henley et al., 2011).  
 
1.1.4.2.: NMDA Receptors 
NMDAR are permeable to Na
+
, K
+
 and importantly, readily permeable to Ca
2+
. 
However, unlike AMPAR, binding of glutamate alone is insufficient for NMDAR 
channel opening and ion flux, as at resting membrane potential the channel pore is 
blocked by physiological concentrations of extracellular Mg
2+ 
(Mayer et al., 1984). 
Only concurrent glutamate (and glycine / D-serine) binding, coupled with strong 
membrane depolarization can remove this voltage-dependant block, and permit cation 
flux. Thus NMDAR have a unique role as molecular coincidence detectors (Cull-Candy 
and Leszkiewicz, 2004; Traynelis et al., 2010; Sanz-Clemente et al., 2013). Three 
families of NMDAR subunits have been identified (GluN1; GluN2A –D and GluN3A 
and B). Functional NMDAR are composed of two obligatory GluN1 subunits (of which 
there are eight splice variants and which contain the co-agonist glycine / D-serine 
binding sites) and two regulatory subunits (GluN2A-D or GluN3A or B) and in most 
cases assemble as dimers of dimers. Glutamate binding occurs only at GluN2 subunits 
(Henson et al., 2010). In general, NMDARs channel kinetics are much slower than that 
of AMPARs, and like AMPARs, the subunit composition of NMDAR determines 
channel properties (Cull-Candy and Leszkiewicz, 2004). 
Hippocampal neurons largely express GluN1 / GluN2 heteromers, with the current 
model suggesting that in adult,  GluN2A containing NMDAR predominate at synaptic 
sites, whereas GluN2B containing NMDAR predominate at extrasynaptic sites (Groc et 
al., 2009). The activity of NMDAR at synaptic and extrasynaptic sites determines the 
level of Ca
2+
 influx and depending on levels of activity can initiate intracellular 
signalling cascades which may induce different forms of synaptic plasticity, changes in 
neuronal morphology or induce excitotoxicity.  
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1.1.5: Metabotropic Glutamate receptors 
Metabotropic glutamate receptors are a family of class C G-protein coupled receptors 
(GPCRs), consisting of eight different receptor subtypes, categorised into three distinct 
groups (Groups I – III) which mediate synaptic transmission and plasticity (Niswender 
and Conn, 2010). Group I mGluRs (mGluR1 and mGluR5) are located predominantly at 
post-synaptic sites, they are coupled to Gq G-proteins and through phospholipase C 
(PLC) activation, inositol triphosphate (IP3) generation and Ca
2+ 
release from 
intracellular stores as well as activation of kinase signalling (PKC, MAPK), can 
influence the activity of voltage gated ion channels and effect neuronal excitability 
(Niswender and Conn, 2010). Whereas Group II (mGluR2 and mGluR3) and Group III 
(mGluR4, mGluR6, mGluR7 and mGluR8) mGluRs are located predominantly at pre-
synaptic sites and modulate transmitter release by negatively coupling to adenylyl 
cyclase through Gi/o G-proteins.  
 
1.1.6: Synaptic Plasticity 
Synaptic plasticity is defined as experience-dependent changes in synaptic connectivity. 
The idea that communication between two neurons could be strengthened if both 
neurons were active at the same time was first posed by Donald Hebb (Hebbian 
plasticity; (Hebb, 1949)). Bliss and Lomo (1973) experimentally illustrated this idea at 
the perforant path to granule cell synapse within the anaesthetised rabbit hippocampus. 
Brief trains of high-frequency stimulation at this synapse initiated a long-lasting (30 min 
– 10 hours) potentiation in the efficacy of excitatory synaptic transmission; a 
phenomenon which was termed long term potentiation (LTP; Bliss and Lomo, 
1973).Since then, the cellular mechanisms underlying this type of plasticity and the 
converse (long lasting depression of synaptic transmission; LTD) have been extensively 
studied at many excitatory synapses. These long lasting changes in the efficacy of 
synaptic transmission are thought to be the cellular mechanisms for information storage 
(Bliss and Collingridge, 1993). Moreover, it is now recognised that a number of 
hormones including leptin (Moult and Harvey, 2011), insulin (Huang et al., 2004), 
estrogen (Foy, 2001) and the glucocorticoids (Popoli et al., 2012) can influence 
glutamatergic synaptic transmission and induce or regulate long lasting changes in 
synaptic efficacy.  
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1.1.6.1: Long term potentiation: CA3 – CA1 synapses 
High frequency afferent stimulation at excitatory synapses triggers large quantities of 
glutamate release and subsequent depolarisation of the post-synaptic cell to a threshold 
which allows for the voltage dependent relief of the NMDAR Mg
2+ 
block. A sufficient 
rise in dendritic calcium is required for the initiation of signalling cascades which leads 
to the induction (early phase) and maintenance (late phase) of LTP. Specifically, during 
the induction phase, calcium-dependent autophosphorylation of calcium / calmodulin-
dependent kinase II (CAMKII) occurs; an event which is critical for LTP (except very 
early in postnatal development; Malenka and Bear, 2004). Subsequent activation of a 
host of other kinase signalling enzymes including extracellular signal-regulated kinase 
(ERK), protein kinase A (PKA), protein kinase C (PKC; specifically protein kinase M 
ζ), phosphoinositide-3kinase (PI3K), and the receptor tyrosine kinase Src, have all been 
implicated in mediating the expression and maintenance of LTP (Malenka and Bear, 
2004). It is now generally accepted that expression of LTP requires the increase in 
conductance and number of synaptic AMPAR, driven by activation of protein kinases. 
For example PKC / CAMKII-dependent phosphorylation at Ser 831 of GluA1-
containing receptors increases single channel conductance of these receptors 
(Kristensen et al., 2011), and PKA dependant phosphorylation of GluA1 at Ser 845 
enhances surface delivery and incorporation of GluA1-containing AMPAR into 
synaptic sites (Man et al., 2007). Moreover incorporation of AMPAR into previously 
AMPA “silent” synapses (i.e: synapses which do not conduct current at resting 
membrane potential) contributes to enhancement of excitatory synaptic transmission 
during LTP (Liao et al., 1995; and reviewed in Kerchner and Nicoll, 2008). In addition, 
lateral diffusion of AMPAR into synapses may also play a role in the regulation of 
synaptic AMPAR content (as reviewed  in Malinow and Malenka, 2002). The 
maintenance phase of LTP requires gene transcription and new protein synthesis which 
is mediated by the activation of transcription factor, cAMP response element binding 
protein (CREB) and transcription of immediate early genes (IEG) such as zif268, arc 
and c-fos. Activation of CREB (via PKA and indirectly through MAPK signalling) and 
the increase in IEG transcription results in the transcription of scaffolding proteins 
important for stabilization of synaptic AMPAR, enlargement of dendritic spines and 
cytoskeletal rearrangement; morphological changes that permit the sustained 
enhancement of excitatory synaptic transmission.  
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1.1.6.2: Long term depression  
Long term depression of synaptic transmission is the activity dependent long lasting 
decrease in synaptic efficacy. Induction of de-novo LTD at hippocampal schaffer-
collateral to CA1 synapses is age dependent and is more readily induced in slices from 
juvenile rodents. Although more difficult to induce in the adult hippocampus, LTD is 
thought to be important for certain types of learning. Two main types of LTD at these 
synapses have been identified, and are distinguished by their induction mechanisms; 
NMDAR-dependent and mGluR-dependent. As well as differing low frequency 
stimulation protocols, application of selective agonists for NMDAR (Lee et al., 1998) or 
Group I mGluR (Palmer et al., 1998; Fitzjohn et al., 1999, 2001; Moult et al., 2006), 
can induce these mechanistically distinct forms of LTD. For example, LTD induced by 
application of NMDA requires Ca
2+
 influx, as reducing the concentration of 
extracellular Ca
2+
 prevents expression of NMDA-induced LTD (Lee et al., 1998). 
Whereas, LTD induced by pharmacological activation of Group I mGluRs (by DHPG) 
is independent of Ca
2+
 signalling, such that LTD is still expressed when DHPG is 
applied in conditions where extracellular Ca
2+
 has been eliminated; after intracellular 
Ca
2+
 stores have been depleted and after intracellular incorporation of a calcium 
chelator (Fitzjohn et al., 2001). Despite this, both forms of LTD are expressed 
postsynaptically and involve a reduction in synaptic AMPAR (Collingridge et al., 
2010).  
Activation of serine/threonine protein phosphatases (protein phosphatase 2B and protein 
phosphatase 1), dephosphorylation of Ser 845 on GluA1-containing AMPAR and 
subsequent internalization of AMPAR has been implicated in NMDAR-dependent LTD. 
In addition, activation of tyrosine kinases, subsequent phosphorylation and 
internalisation of GluA2-containing AMPAR is also implicated in NMDAR-dependent 
LTD (Collingridge et al., 2010). Conversely, mGluR-dependent LTD is dependent on 
the activation of protein tyrosine phosphatases and tyrosine dephosphorylation of 
GluA2-containing AMPAR (Moult et al., 2006). Although dephosphorylation of 
AMPAR subunits appears to be an important common mechanism in the initiating 
AMPAR internalization, the exact downstream signalling events required for initiation 
and maintenance of NMDAR- and mGluR-LTD are still unclear. Moreover, studies 
utilizing inhibitors of protein kinases including p38 MAPK, PI3K, PKA, ERK1/2 and 
glycogen-synthase kinase-3 (GSK-3) have implicated all of these kinase signalling 
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pathways as important downstream effectors activated during the induction and required 
for the maintenance phases of LTD (Collingridge et al., 2010). In addition, rapid 
dendritic protein synthesis (Huber et al., 2000), cytoskeletal rearrangement, spine 
shrinkage and alterations in the transcription of IEGs (such as arc (Plath et al., 2006)) 
are important for the maintenance of this form of synaptic plasticity (Hanley, 2008). 
 
1.1.6.3: Trafficking of AMPAR 
A key factor in determining the efficacy of glutamatergic synaptic transmission is the 
relative quantity and subtype composition of synaptic AMPAR. During basal states, 
AMPAR are continually trafficked into and out of the plasma membrane via constitutive 
rounds of clathrin-mediated endocytosis and through recycling endosomes, reinserted 
into the plasma membrane via SNARE-mediated exocytosis (Lüscher et al., 1999; 
Ehlers, 2000) at extrasynaptic sites. Moreover, AMPAR are highly mobile and can 
diffuse laterally into and out of synaptic sites (as reviewd in Shepherd and Huganir, 
2007). These concepts have been validated experimentally as inhibition of SNARE-
mediated membrane fusion events, inhibits LTP expression in hippocampal slices 
(Lledo et al., 1998) and in hippocampal cultures (Lu et al., 2001). Moreover, promoting 
membrane fusion potentiates synaptic transmission in hippocampal slices (Lledo et al., 
1998) and importantly it has been demonstrated that AMPAR within recycling 
endosomes provide the source for the increase in AMPAR expression during LTP (Park 
et al., 2004). Similarly, agents which disrupt clathrin-mediated endocytosis inhibit LTD 
(Man et al., 2000), and chemical induction of LTD in hippocampal slices with DHPG, 
NMDA or insulin promotes the internalisation of AMPAR in culture (Beattie et al., 
2000; Lin et al., 2000; Snyder et al., 2001). Thus, modulation of the trafficking of 
AMPAR and their stability at synaptic sites during activity dependent synaptic plasticity 
underlies the relative expression of AMPAR within the synapse. 
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1.2: Estrogen 
17β-estradiol (E2) is the most potent and biologically prevalent steroid in a class of 
steroid compounds called the estrogens: which consists of E2, estrone (E1) and estriol 
(E3). Classically, E2 is regarded as the main female sex-hormone in mammals which is 
synthesised in the ovaries, and is primarily responsible for mediating the reproductive 
cycle. However, this is a highly simplified view of the actions of this incredibly diverse 
lipophilic compound.  
Aside from contributing to CNS sexual dimorphism (notably within the hypothalamus) 
and female sexual reproduction, E2 (both peripheral and centrally derived) influences 
many other cognitive functions such as: mood (reviewed in Joffe and Cohen, 1998), 
executive function and stress (reviewed in Shansky and Lipps, 2013), learning and 
memory (below and reviewed in Luine and Frankfurt, 2012), as well as energy 
regulation and homeostasis (reviewed in Sinchak and Wagner, 2012).  
Moreover, evidence for centrally derived (ie: synthesised from cholesterol de novo or by 
aromatisation of testosterone) non-genomic effects of estrogen in the CNS is growing 
rapidly, implicating this hormone as an important neuromodulator (Balthazart and Ball, 
2006; Srivastava et al., 2011). Understanding the mechanisms by which E2 exerts its 
various effects within the CNS is vital in our attempt to understand its role in cognition.  
 
1.2.1 Estrogen Biosynthesis and Metabolism 
Unlike peptides, steroids are synthesised on demand and are not stored. Therefore, an 
essential part in understanding how E2 acts as a neuromodulator, is an appreciation of 
its biosynthesis (Fig 1.4) and metabolism. Factors which influence expression or 
activity of key enzymes in E2 biosynthesis and inactivation/metabolism would 
ultimately affect concentrations of available E2 and therefore, its actions.  
Biosynthesis of all five classes of steroid hormones; glucocorticoids, 
mineralocorticoids, androgens, progestogens and estrogens, begin with the precursor, 
cholesterol. The key step for the synthesis of all steroid hormones is the conversion of 
cholesterol into pregnenolone (PREG), an event catalysed by the enzyme cytochrome 
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P450 side-chain cleavage (P450scc). However, P450scc is localised to the inner 
mitochondrial membrane and so the rate limiting step for all steroid synthesis is the 
delivery of cholesterol from the outer mitochondrial membrane to the inner membrane 
by the steroidogenic acute regulatory protein (StAR; Clark et al., 1994). Once 
synthesised, PREG leaves the mitochondria and can be converted into a host of steroidal 
end products. Illustrated are the key enzymatic steps for estrogen synthesis (Fig 1.4). 
The key enzymes involved in the conversion of PREG to 17β-E2 (enzymes which are 
located in the smooth endoplasmic reticulum) are 3β-hydroxysteroid dehydrogenase 
(3β-HSD), P450-C17, 17β-hydroxysteroid dehydrogenase (17β-HSD) and P450-
aromatase (aromatase) (Do Rego et al., 2009).  
The metabolism and excretion of plasma E2 into less active, water-soluble metabolites 
involves multiple and complex oxidative and conjugation pathways, and occurs 
primarily in the liver (Zhu and Conney, 1998). Briefly, E2 and estrone can be 
hydroxylated by numerous P450 enzymes and the 2- and 4- hydroxylated catechol 
estrogen metabolites can be O-methylated by catechol-O-methylstransferase. Moreover, 
esterification by estrogen acyltransferase or conjugation by β-glucuronidase or sulfatase 
of E2 and its hydroxyl metabolites may also occur (Zhu and Conney, 1998).  
Classically, the synthesis of steroids was thought to be restricted to endocrine organs 
such as the adrenals, testis and ovaries. Due to their lipophilic nature, steroids were 
thought to reach the brain exclusively via circulation and act as neuromodulators via 
this mechanism (covered in, McEwen, 2001). However, in last 30 or so years, evidence 
has built to suggest that the brain itself is a steroidogenic organ and can synthesis 
steroids in situ (extensively reviewd in: Baulieu, 1998; Plassart-Schiess and Baulieu, 
2001; Do Rego et al., 2009).  
The term ‘neurosteroids’ was first proposed by Etienne-Emile Baulieu’s group in 1981, 
to describe steroids synthesised de novo (from cholesterol) within the central nervous 
system, independently (at least in part) from peripheral endocrine sources (Corpéchot et 
al., 1981). Over the past decade, evidence has built to suggest that E2 may indeed be 
classified as a neurosteroid. Supporting this, is that maximum ovarian derived 
circulating levels of E2 in the adult female rat reaches only approximately 100 pM  
(Smith et al., 1975; Woolley, 2007), whereas basal levels of E2 in acute freshly isolated 
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hippocampal slices reaches approximately 8 nM (Hojo et al., 2009), suggesting the 
hippocampus may be a site for E2 biosynthesis.  
 
 
 
 
1.2.2: Estrogen synthesis in the Hippocampus: 
Expression of enzymes responsible for estrogen biosynthesis are expressed within 
hippocampal principal neurons (reviewed in Hojo et al., 2011) and importantly StAR 
colocalises with aromatase within the rat hippocampus (Wehrenberg et al., 2001). This 
suggests that principal cells within the hippocampus have the necessary machinery for 
Figure 1.4: Estrogen Biosynthesis pathway.  
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de novo E2 biosynthesis, which would allow newly synthesised hippocampal derived 
E2 to act in a local autocrine or paracrine manner to modulate hippocampal function.  
Direct evidence of E2 synthesis from cholesterol ex vivo was established by Hojo et al., 
in 2004. In this study they elegantly show the conversion from [
3
H]-PREG to [
3
H]-
DHEA, from [
3
H]-DHEA to [
3
H]-testosterone and to [
3
H]-E2 via HPLC analysis in 
adult (12week) male rats. Moreover, specifically blocking P45017α and aromatase, 
abolished the conversion of [
3
H]-PREG to [
3
H]-DHEA and from [
3
H]-DHEA to [
3
H]-
E2, respectively. Supporting this, Prange-Kiel et al. (2003) provided evidence for de 
novo synthesis of E2 in cultured hippocampal neurons. Using pure neuronal 
hippocampal cultures from adult hippocampi in serum- and steroid-free conditions, they 
established that estrogens were released into the culture media over a period of 11 days. 
Moreover, estrogen synthesis under these conditions was inhibited by the aromatase 
inhibitor, letrozol, and subsequent studies found this to be a dose dependent effect 
(Kretz et al., 2004).  
Importantly, P450-C17 and aromatase expression is found within pre- and post-synaptic 
compartments of principal neurons within CA1 area of the hippocampus (Hojo et al., 
2004). Interestingly, stimulation of hippocampal slices with NMDA increases levels of 
hippocampal derived E2 two fold (Hojo et al., 2004) and aromatase activity can be 
influenced by calcium dependent phosphorylation events, at least in the quail brain 
(Balthazart et al., 2003), thus suggesting not only that synaptic estrogen biosynthesis 
may occur but that this also may occur in an activity dependent manner. Therefore, the 
concentration of E2 within the hippocampus may be influenced not only via circulating 
estrogens but via local E2 biosynthesis as well.  
How local concentrations of E2 are regulated within the brain is less well understood. 
However catabolic enzymes have been detected in brain regions of the male African 
catfish (Timmers et al., 1988) and the quail (Balthazart et al., 1994). Due to the high 
lipophilicity of E2, rapid diffusion into surrounding neurons, glia and blood vessels may 
be the mechanism by which effective local concentrations are lowered.  
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1.2.3: Estrogenic effects within the hippocampus 
E2, via a plethora of genomic and non-genomic mechanisms can elicit a multitude of 
effects within the hippocampus. The focus here will be on the propensity for E2 to 
mediate changes in hippocampal dendritic morphology, neuronal excitability and 
glutamatergic synaptic transmission, which ultimately lends this hormone to influence 
hippocampal synaptic plasticity and hippocampal dependent learning tasks.  
The ability for E2 to modulate dendritic morphology has been known for a number of 
years. For example, ovariectomy reduces dendritic spine number in the CA1 region of 
the adult rodent hippocampus, an effect which is reversed by treatment with E2 (Gould 
et al., 1990; Woolley et al., 1997). The density and shape of dendritic spines in female 
rodents also fluctuates over the course of the 4 – 5 day rat estrus cycle, as during 
proestrus the number of spines and the percentage of thin and mushroom type spines is 
significantly greater than during estrus (González-Burgos et al., 2005). Moreover, the 
effects of E2 on spine morphology are not limited to female rodents as exogenous E2 
treatment increases the number of spines by approximately 1.6 – 1.7 fold in 
hippocampal slices from adult male rodents (Mukai et al., 2007), and in primary 
hippocampal cultures (Murphy and Segal, 1996). This suggests that both peripheral and 
local (brain derived) sources may contribute to E2-induced modulation of spine 
morphology. Furthermore, acute treatment with E2 influences the expression of synaptic 
proteins (spinophillin and PSD-95) in the adult male and female rodent hippocampus, 
and in hippocampal cultures (Akama and McEwen, 2003; Lee et al., 2004; Zhao et al., 
2005). E2 signalling through RhoA and ROCK also regulates actin dynamics in 
hippocampal slices (Kramár et al., 2009).  
In correlation with changes in synaptic proteins and synapse number; it is well 
established that E2 influences the excitability of hippocampal neurons and modulates 
glutamatergic synaptic transmission, presumably via membrane initiated signalling 
events. Acute E2 effects on hippocampal excitability were first demonstrated by Teyler 
et al., (1980), who found that 100 pM E2 could rapidly (5-10min) potentiate the 
amplitude of the CA1 population spike in hippocampal slices from adult male rodents. 
Since this study, many groups have also observed that E2 rapidly potentiates 
intracellularly recorded excitatory post-synaptic potentials (EPSPs) and excitatory post-
synaptic currents (EPSCs) in hippocampal neurons (Wong and Moss, 1992; Foy et al., 
1999; Rudick and Woolley, 2003; Smejkalova and Woolley, 2010), and increases the 
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magnitude of dendritic fEPSP in CA1 of male (Fugger et al., 2001; Kramár et al., 2009; 
Zadran et al., 2009) and female (Fugger et al., 2001; Sharrow et al., 2002; Lebesgue et 
al., 2009) rodents. The E2-induced increase in fEPSP magnitude has also recently been 
extended to other hippocampal regions, the CA3 and DG (Kim et al., 2006).  
Not surprisingly, E2 can influence activity dependent hippocampal plasticity. For 
example, the stage of estrus cycle in adult rats influences the magnitude of high 
frequency stimulation (HFS)-induced LTP such that the magnitude of LTP is greater in 
rats at proestrus than at diestrus (Bi et al., 2001). Acute E2 administration can also 
enhance the magnitude of HFS-induced hippocampal LTP  (Foy et al., 1999) and 
chronic E2 treatment facilitates the induction of LTP in OVX awake rats (Córdoba 
Montoya and Carrer, 1997). Conversely, acute application of E2 can influence the 
magnitude of chemically-induced hippocampal LTD in adult male rats (Shiroma et al., 
2005; Mukai et al., 2007) and alter the frequency threshold for LTD induction in OVX 
adult female rats (Zamani et al., 2000). Moreover, E2 can attenuate the magnitude of 
low-frequency stimulation (LFS) induced LTD in hippocampal slices from aged (18 – 
24 months) males. 
Considering the influence of E2 on hippocampal synaptic plasticity, the cellular 
correlates for learning and memory, it is not surprising that hippocampal dependent 
learning tasks are also influenced by this steroid. Indeed, OVX rats perform less well in 
object recognition memory tasks compared to control animals (Luine et al., 2003; 
Wallace et al., 2006), and the deficits in performance can be corrected by E2 
replacement (Luine et al., 2003; Sandstrom and Williams, 2004; Luine and Frankfurt, 
2012). Moreover, administration of estradiol immediately after training for 
hippocampal-dependent tasks (for example the Morris water maze task and novel object 
recognition) enhances memory consolidation (as reviewed in Frick, 2013). Thus there is 
unequivocal evidence suggesting that estradiol is a key modulator of hippocampal 
function.  
 
1.2.4: Estrogen receptors 
Within the CNS, E2 exerts its cornucopia of effects through two distinct mechanisms, 
namely genomic (nuclear-initiated) or non-genomic (membrane or non-nuclear 
initiated). The classical genomic mechanism is mediated via two distinct nuclear 
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estrogen receptors; estrogen receptor α (ERα; White et al., 1987) and estrogen receptor 
β (ERβ; Kuiper et al., 1996). These receptors are ligand-activated transcription factors 
which upon ligand binding, dimerization and translocation to the nucleus, bind to 
estrogen response elements (EREs) at the promoter region of target genes, resulting in 
the modulation (enhancement or suppression) of estrogen-responsive genes.  
However, signalling via E2 also occurs via “non-genomic” mechanisms which involve 
the activation of a number of different intracellular signalling cascades resulting in 
alterations in cellular function, including the transcription of genes without an upstream 
ERE site. Non-genomic effects of E2 have been attributed to plasma-membrane 
associated variants of ERα and ERβ (mERα/β; Levin, 2009), mER-X (Toran-Allerand, 
2005),  a  Gq coupled mER (Roepke et al., 2009), and the recently identified G-protein 
coupled receptor, GPR30 (Revankar et al., 2005; Thomas et al., 2005). It should be 
noted that mER-X and the Gq coupled mER have not yet been cloned. Signalling via 
these non-nuclear ER includes: accumulation of second messengers such as 3’-5’-cyclic 
adenosine monophosphate (cAMP) and Ca
2+ 
; activation of kinase signalling pathways 
such as phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase 
(ERK); regulation of transcription factors (cAMP response binding protein; CREB); and 
immediate early gene transcription (c-Fos) (Vasudevan and Pfaff, 2007).  
 
1.2.5: Expression of estrogen receptors within the hippocampus 
Classic in situ hybridisation studies of the rat CNS revealed expression of both ERα and 
ERβ transcripts within the adult rat hippocampal formation (Shughrue et al., 1997), 
moreover, immunohistochemical studies in murine hippocampal tissue revealed 
expression of nuclear and extra-nuclear estrogen receptors within all regions of the 
hippocampus (Mitra, 2003). 
ERα immunoreactivity was thought to be exclusively within nuclei of a select 
population of interneurons within the dentate gyrus and stratum radiatum of the CA1 
region (Weiland et al., 1997). However expression of ERα within the hippocampus 
extends to extra-nuclear sites of principal neurons (such as at dendritic spines) and also 
within glia cells (Milner et al., 2001; Towart et al., 2003). Moreover, electron 
microscopy (EM) reveals that ERα is expressed in both pre- and post-synaptic 
compartments of principal cells at the stratum radiatum layer at the CA1 (Mukai et al., 
20 
2007). The pattern of ERβ expression within the hippocampus is generally similar to 
that of ERα in that it is localised at both nuclear and extra-nuclear sites (Milner et al., 
2005). However in contrast to ERα, the relative distribution of ERβ is predominantly 
extranuclear, more widespread and can be observed at axon terminals at the CA3 
(Milner et al., 2005).  
GPR30 immunoreactivity has also been detected within the rodent hippocampal 
formation. Specifically, in the cell body layer of the CA3-CA1 regions and granule cells 
of the dentate gyrus (Brailoiu et al., 2007; Matsuda et al., 2008; Hazell et al., 2009; 
Hammond et al., 2011), suggesting an abundant expression within principal cells across 
the different subregions of the hippocampus. Moreover, recent evidence revealed 
GPR30 expression in synaptosomes from whole hippocampal lysates of rats, and using 
electron microscopy, GPR30 labelling was observed in various types of spines profiles 
(thin, mushroom-shaped and concaved spines) within the stratum radiutum layer of the 
CA1 region (Akama et al., 2013).   
The expression and distribution of these estrogen receptors within the hippocampal 
formation suggests that E2 has an important role in both mediating the transcription of 
estrogen responsive genes and inducing non-nuclear initiated cellular responses. This 
expression pattern also correlates well with the ability of E2 to acutely modulate 
neuronal excitability and excitatory synaptic transmission as well as its ability to 
modulate dendritic structural plasticity and influence the number of synaptic proteins.  
By which receptors E2 is mediating effects on hippocampal synaptic transmission is 
unclear. In both ERα knockout (Fugger et al., 2001; Foster et al., 2008) and ERβ 
knockout (Foster, 2012) mice, the magnitude of acute E2-responses are reduced, but not 
eliminated, suggesting additional estrogen sensitive receptor/s are responsible for 
mediating the acute effects E2 on hippocampal synaptic transmission. The focus of this 
thesis will be on GPR30.  
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1.3: GPR30 
GPR30 is a member of the class A rhodopsin-like G-Protein coupled receptor (GPCR) 
superfamily. Human GPR30 has five transcripts, four of which encode a 375 amino acid 
protein, and one which encodes a truncated 73 amino acid version (Ensembl; gene ID: 
ENSG00000164850). Since it was cloned between 1996 and 1998 (Owman et al., 1996, 
Carmeci et al., 1997, Feng and Gregor, 1997, Takada et al., 1997 and O’Dowd et al., 
1998), it has been given a number of different names, for example: CEPR, GPCR-Br, 
CMKRL2, DRY12, FEG-1, LERGU, GPR30, GPER-1 and GPER. 
For the purposes of this thesis, the receptor will be referred to as GPR30; however the 
International Union of Basic and Clinical Pharmacology (IUPHAR) has renamed and 
classified GPR30 as “G-protein coupled estrogen receptor” (GPER; http://www.iuphar-
db.org/DATABASE/ObjectDisplayForward?objectId=221).  
 
1.3.1: Discovery  
During the late 1990’s, several independent groups reported and cloned a novel GPCR, 
the gene for which is mapped to chromosome 7p22 in human and encodes a protein of 
375 amino acids and a predicted molecular mass of 42 kDa  (Owman et al., 1996; 
Carmeci et al., 1997; Feng and Gregor, 1997; Takada et al., 1997; O’Dowd et al., 
1998). GPR30 was found to have highest homology (30%) to the chemokine receptor 
CXCR1 (Owman et al., 1996 and O’Dowd et al., 1998) and the angiotensin II receptor 
(Feng and Gregor., 1997 and Takada et al., 1997), suggesting that GPR30 was a 
member of the chemokine GPCR family. However, Feng and Gregor, (1997) found 
negligible binding with both I125 angiotensin II and I125 angiotensin IV in COS-7 
cells transiently expressing GPR30. Moreover, Owman et al, (1996) found that GPR30 
did not respond to a variety of chemotactic peptides (concentrations up to 100µM) in 
both cAMP and intracellular calcium mobilization assays. Thus, these studies imply that 
GPR30 is not a member of the chemokine receptor family, despite its significant 
homology.  
Carmeci et al. (1997), one of the first groups to clone GPR30, used differential cDNA 
library screening and identified and isolated a cDNA clone (GPR30) that was over 
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expressed in the MCF-7 (ER +VE breast cancer cell line) but not expressed in the 
MDA-MB-231 (ER -VE breast cancer cell line). The authors found a pattern of 
expression where three out of four ER +VE breast cancer cell lines expressed GPR30 
mRNA (MCF-7, T-47D and MDA-MB-361), whereas there was no evidence of 
expression in the ER -VE cell lines (BT-20, MDA-MB-231 and HBL-100) or in 
normal human mammary epithelial cells (HMEC). The authors suggest from this 
expression pattern one could speculate that this receptor may contribute to physiological 
responses in tissues that are modulated by hormones, specifically, estrogen (Carmeci et 
al., 1997). 
Thus, opening up the possibility of a G-protein coupled estrogen receptor.  
 
1.3.2: GPR30, an estrogen-sensing receptor? 
The first evidence to suggest that GPR30 may be involved in E2-mediated signalling 
was presented by Filardo and colleagues (2000). This group observed ERK1/2 
phosphorylation in response to E2 in SKBr3 breast cancer cells, a cell line which does 
not express ERα or ERβ, but does express GPR30 (Filardo et al., 2000). This group 
postulated that stimulation of this signalling pathway occurred via E2-induced 
activation of GPR30 and subsequent transactivation of EGFR.  
However, it was not until 2005 that specific binding of E2 to GPR30 was reported. 
Evidence for this came from two independent groups (Thomas et al., 2005; Revankar et 
al., 2005). In the first study from Edward Fildardo’s group, specific, saturable binding 
of tritium labelled E2 ([H
3
]-E2) was observed in SKBr3 breast cancer cells and in HEK-
293 cells stably transfected with untagged GPR30 (hGPR30-HEK293). Dissociation 
constants were calculated as approximately 2.7 nM in SKBr3 cells and 3.3 nM in the 
hGPR30-HEK293 cells. Moreover, untransfected HEK293 cells and SKBr3 cells treated 
with GPR30 small interfering RNA (siRNA), showed negligible [H
3
]-E2 binding. In 
addition, binding was specific for E2, as other steroids (testosterone, cortisol and 
progesterone) were unable to compete with [H
3
]-E2 (Thomas et al., 2005). In the second 
study, the Prossnitz group used a novel approach to demonstrate binding, rather than 
radioactive E2, this group utilised membrane impermeable Alexa-fluoro 546 or 633 
conjugated estadiol (E2-Alexa 546/633). In COS-7 cells stably transfected with GFP-
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tagged GPR30 and permeabilized with saponin, specific intracellular co-localisation of 
GPR30 and E2-Alexa 546 fluorescent signals, and a direct-linear relationship between 
E2-Alexa 633 binding and GPR30-GFP expression was observed.  Moreover, using 
intracellular fluorescence as a readout, unconjugated E2 competed with E2-Alexa 633 
(2 nM) in these cells, with a Ki of 6.6 nM (Revankar et al., 2005). 
These binding studies stemmed an explosion of research into the putative role for 
GPR30 in non-genomic E2 signalling mediated via this receptor (See section 1.3.3). 
However, not long after these initial studies, independent groups began to question the 
above studies and conflicting reports began to emerge.  
In studies using endothelial cells expressing GPR30 from ERα/ERβ double knockout 
mice, Pedram and colleagues (2006) demonstrated that E2 failed to activate non-
genomic E2 mediated cAMP accumulation, ERK phosphorylation and 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) accumulation (Pedram et al., 2006). 
This group was also unable to detect saturable binding of radio-labelled E2 in SKBr3 
cells, which directly contradicted the work by Edward Filardos group (Thomas et al., 
2005). In addition, E2-induced signalling in MCF-7 cells could not be prevented by 
knockdown of GPR30, whereas silencing ERα gene expression prevented rapid 
signalling, suggesting that membrane ERα was responsible for rapid E2-induced 
signalling events and that GPR30 was not an estrogen-sensing receptor (Pedram et al., 
2006). These data were later supported by Madak-Erdogan and co-workers (2008) who 
found membrane-initiated signalling in MCF-7 cells were exclusively mediated via ERα 
(Madak-Erdogan et al., 2008). Similarly, in a study comparing [H
3
]-E2 binding in COS-
7 cells transiently overexpressing ER or GPR30 it was found that specific saturable 
binding only occurred in cells expressing ERα (Otto et al., 2008). Importantly, this 
group could not reproduce rapid E2-induced intracellular signalling responses such as 
cAMP accumulation and mobilization of intracellular calcium, demonstrated by others 
to be mediated via GPR30 (Otto et al., 2008).   
Furthermore, GPR30 knockout animals exhibit no detrimental effects in classically 
estrogen-responsive tissue (Isensee et al., 2009; Mårtensson et al., 2009; Otto et al., 
2009), supporting evidence that GPR30 may not be an estrogen-sensing receptor. 
Moreover, non-classical E2 signalling in breast cancer cells and heterologous GPR30-
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expressing cells has been attributed to an ERα splice variant (ERα-36; see section 1.3.5) 
rather than GPR30 (Kang et al., 2010). 
Again challenging the estrogen-sensitivity of GPR30 is the recent evidence presented by 
Gros and coworkers (2011, 2013). This group show that the endogenous ligand for 
GPR30 may be the steroid aldosterone and action of this steroid at GPR30 may be more 
physiologically relevant than E2, at least in vasculature  (Gros et al., 2011, 2013). 
Indeed, in freshly isolated aortic ring segments from rats, both aldosterone and the 
GPR30 agonist, G1, can stimulate ERK phosphorylation and importantly, the effects of 
aldosterone are blocked by the GPR30 antagonist, G15 (Gros et al., 2011). Moreover in 
vascular endothelial cells devoid of mineralocorticoid receptors, aldosterone mediates 
pro-apoptotic and anti-proliferative effects via GPR30 (Gros et al., 2013). However, in 
both report specific binding studies of aldosterone to GPR30 are missing.  
Despite the apparent controversies in the field, the majority of studies support the 
concept that GPR30 acts as a G-protein coupled estrogen-sensing receptor (Reviewed in 
:Prossnitz et al., 2008a; Prossnitz and Barton, 2011; Filardo and Thomas, 2012).  
 
1.3.3: GPR30 mediated signalling  
GPR30-induced signalling has been extensively studied in breast cancer cells and 
recombinant cell lines (Prossnitz et al., 2008b). In the original studies from Filardo and 
colleagues (2000), E2 induced ERK1/2 signalling via GPR30 in SKBr3 cells was found 
to be initiated via the transactivation of epidermal growth factor receptor (EGFR) 
(Filardo et al., 2000). Specifically, stimulation of GPR30 results in the activation of Src 
tyrosine kinases through G-protein Gβγ-mediated mechanisms. Src activation promotes 
the formation of α5β1 integrin complexes with signalling adaptor protein Shc which 
enables the metalloproteinase (MMP)-dependant cleavage and release of heparin bound 
epidermal growth factor (HB-EGF) which subsequently binds to and activates EGFR 
(Filardo et al., 2000, 2002; Quinn et al., 2009). Transactivation of EGFR and 
subsequent initiation of ERK1/2 signalling is considered the primary mechanism by 
which GPR30 signals in breast cancer cell lines. In addition, activation of GPR30 
results in the accumulation of cAMP through Gαs-mediated stimulation of adenylyl 
cyclase in SKBr3 breast cancer cells and heterologously expressing HEK-293 cells 
(Filardo et al., 2002; Thomas et al., 2005), as well as activation of PI3K and subsequent 
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accumulation of PIP3, initiation of Akt signalling has also been reported (Revankar et 
al., 2005; Bologa et al., 2006; Blasko et al., 2009). Activation of GPR30 by both E2 and 
the GPR30 agonist (G1) can also stimulate a rise in intracellular Ca
2+
 in a number of 
different cell types (Revankar et al., 2005; Bologa et al., 2006; Filardo et al., 2007; 
Dennis et al., 2009; Noel et al., 2009), however the mechanisms by which GPR30 does 
this are not well understood. GPR30 signal transduction can also stimulate gene 
transcription, for example in SKBr3 cells, E2-induced MAPK signalling through 
GPR30 stimulates the expression of c-fos (Maggiolini et al., 2004).  
  
1.3.4: GPR30 selective and non-selective ligands 
Until recently, studying the function of GPR30 was problematic, as it was difficult to 
pharmacologically isolate GPR30 from other estrogen-sensing receptors, due to the lack 
of selective GPR30 ligands. However, in 2006, Bologa et al., identified a potent 
selective agonist for GPR30 (G1; (±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-
5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone). Competitive 
binding assays with fluorescent-E2 revealed a Ki of 11 nM for G1 at GPR30 and in 
intracellular calcium mobilization assays, an EC50 of 2 nM (Bologa et al., 2006). 
Moreover, G1 (at a concentration of 10 µM) was unable to bind to a panel of 25 known 
GPCRs or nuclear ERα and ERβ, supporting the specificity of this compound for 
GPR30 (Blasko et al., 2009). Study of GPR30 function intensified when a selective 
antagonist, G15 (3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-
cyclopenta[c]quinolone), was developed (Dennis et al., 2009). However, at high 
concentrations (> 1 µM), weak ERα mediated estrogenic activity was reported, and 
subsequently an antagonist with improved GPR30 selectivity (G36; (±)-
(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-8-(1-methyle-
thyl)-3H cyclopenta[c]quinoline) was developed (Dennis et al., 2011). 
GPR30 pharmacology is not simple, and according to numerous reports, this receptor 
appears to be quite promiscuous. For example, both Tamoxifen and ICI 182,780 two 
classical synthetic estrogen receptor antagonists have been identified as having agonist 
activity at GPR30. Specifically, Tamoxifen (or rather more accurately the active 
metabolite of Tamoxifen; 4-hydroxytamoxifen [4-OHT]) was originally developed as an 
estrogen receptor antagonist however has now been classified as a selective estrogen 
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receptor modulator (SERM) as it binds to nuclear estrogen receptors (ERα and ERβ) 
however has the properties of an antagonist and the properties of a transcription 
promoter in a tissue specific manner (Shiau et al., 1998). 4-OHT also competes with E2 
at GPR30 (Thomas et al., 2005) and stimulates PI3K and MAPK signalling via GPR30 
(Revankar et al., 2005; Vivacqua et al., 2006). Whereas ICI 182,780 (Fulvestrant) 
which was originally developed as a selective estrogen receptor down-regulator (SERD) 
interacts with nuclear ERα and ERβ, prevents dimerization, inhibits nucleocytoplasmic 
shuffling, destabilises the receptors and promotes estrogen receptor degradation 
(Osborne et al., 2004). ICI 182,780 also competes with E2 at GPR30 (Thomas et al., 
2005) and stimulates cAMP production via GPR30 (Filardo et al., 2002). Moreover, the 
E2 metabolite, estriol (E3) has antagonist properties at GPR30 (Lappano et al., 2010), 
and a panel of xenoestrogens have also been shown to bind to GPR30 (Thomas and 
Dong, 2006). Moreover, agonist activity of these environmental estrogens has also been 
reported, most notably from the phytoestrogens; genistein and quercetin (Maggiolini et 
al., 2004), and synthetic xenoestrogen; Bisophenol A (BPA; Dong et al., 2011). Thus 
the potential for mediating GPR30 activity in vivo is not only limited to compounds that 
regulate the synthesis and metabolism of its (putative) endogenous ligand, E2 (eg: 
aromatase inhibitors), but also extends to estrogen receptor ligands currently being used 
as therapeutics (Tamoxifen and Fulvestrant) as well as exogenous estrogens found in the 
environment.  
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1.3.5: A potential role for ERα-36? 
ERα-36 is a 36kDa variant of the classical ERα, generated from a promoter located in 
the first intron of the ERα66 gene (Wang et al., 2005; Zou et al., 2009). This variant 
lacks the AF-1 and AF-2 transcription activation domains of the classical 66kDa ERα 
and has the capacity to reach the plasma membrane and mediate rapid E2 induced 
ERK1/2 phosphorylation (Wang et al., 2005, 2006). Moreover, this variant possesses a 
truncated ligand binding domain, suggesting a different ligand binding spectrum from 
the classic ERα-66 (Wang et al., 2005).  
Figure 1.5: Structure of GPR30 ligands. The selective synthetic GPR30 ligands 
(G1, G15 and G36) are all modelled on the structure of the proposed endogenous 
agonist at GPR30, the steroid hormone E2. G1, ICI 182,780 and 4-hydroxytamoxifen 
are GPR30 agonists, whereas G15 and G36 are GPR30 antagonists.  
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In 2010, Kang and co-workers suggested that this novel 36kDa variant of ER was 
responsible for rapid non-genomic effects of E2, and that the selective GPR30 agonist, 
G1, activated signalling via this ERα variant rather than GPR30 itself (Kang et al., 
2010). This study provided compelling evidence which suggests that heterologous 
expression of GPR30 promoted the expression of ERα-36 in HEK-293 and COS-7 cells. 
Importantly, inhibiting the binding capacity of ERα-36 with an antibody specific for the 
ligand binding domain of this protein, inhibited G1- and E2- induced activation of the 
MAPK/ERK1/2 pathway in SKBr3 cells (GPR30 and ERα-36 positive, ERα/β 
negative). In addition, the E2- and G1- induced effects could be inhibited via specific 
knockdown of ERα-36; although this effect could also be inhibited by GPR30 siRNA, it 
was found that knockdown of native GPR30 subsequently inhibited ERα-36 expression 
as well.  
However, MCF-7 cells, (which express GPR30, but which do not strongly express ER-
36 (Zou et al., 2009)), still respond to G1 (1 µM) as demonstrated in an intracellular 
calcium assay by Ariazi et al., (2010), and selective knockdown of GPR30 can abolish 
this effect. Moreover, G1-induced effects on oocyte maturation are observed in 
zebrafish, a species which does not possess a truncated variant of ERα, homologous to 
ERα-36 (Peyton and Thomas, 2011). Thus the role in which ERα-36 plays in G1 
stimulated- or GPR30 mediated effects, is controversial.  
 
1.3.6: GPR30 Knockout Mice 
In the quest for establishing a physiological role for GPR30, transgenic GPR30 deficient 
mouse models have been developed and there are currently four which have been 
described (Wang et al., 2008; Isensee et al., 2009; Mårtensson et al., 2009; Otto et al., 
2009). Each group used different targeting strategies, mice of genetic backgrounds and 
mating schemes for the development of the GPR30 deficient mice. However, the 
observed phenotypes of the four knockouts only partially overlap, with a potential role 
for GPR30 in the vascular system and immune cell functions suggested. In the strain 
described by Wang et al., (2008) vasodilatory effects of G1 were absent in mutant mice 
and in the model described by Mårtensson et al., (2009) an elevated mean arterial blood 
pressure was observed in female knockout mice; these effects overlap with the strong 
reporter expression in vasculature seen in the GPR30-LacZ strain by Isensee et al., 
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(2009). With respect to immune function, the GPR30 knockout mice described by Wang 
et al., (2008) exhibit impaired E2-induced thymic atrophy which relates to the impaired 
production of T-cells in the model described by Isensee et al., (2009). However in the 
model described by Otto et al., (2009) no change in T-cell production was observed.  
Although the different approaches used to generate the mouse models could account for 
the differences in the observed phenotypes, due to lack of specific antibodies for murine 
GPR30, true knockdown of the gene has not been verified in these transgenic mice. 
Overall, general health of the four knockout strains is maintained, with two strains 
presenting changes in body weight (Wang et al., 2008; Mårtensson et al., 2009), and 
one strain exhibiting impaired glucose tolerance (Mårtensson et al., 2009). Unlike ERα 
knockout strains, all four GPR30 knockout strains remain fertile, and estrogen 
stimulated responses in mammary and uterus are still maintained (Otto et al., 2009) 
suggesting that GPR30 does not play a vital role in the classical estrogen responsive 
tissues in mice (Langer et al., 2010).  
 
1.3.7: GPR30 tissue distribution and potential roles in the periphery 
The mRNA expression profile of this receptor was first reported when GPR30 was 
initially cloned, using both northern blotting and RT-PCR, GPR30 expression was seen 
in a wide variety of  human and rodent tissues, including: brain, lung, heart, placenta, 
liver, skeletal muscle, kidney and pancreas (Feng and Gregor 1997, Owman et al., 1996 
and Carmeci et al., 1997).  
However, due to the inconsistencies with knockout models, establishing physiological 
roles for GPR30 within the periphery have relied on pharmacological tools and gene 
silencing. GPR30 has been implicated in many physiological processes in the periphery 
(see Fig 1.6) including having roles in inflammation, cardiovascular and renal function 
as well as having roles in pancreatic-β cell function and glucose metabolism (as 
reviewed in Prossnitz and Barton, 2011). Thus, targeting GPR30 may have benefits in 
pathophysiological conditions such as multiple sclerosis (Blasko et al., 2009), cardiac 
ischemia/reperfusion injury (Nilsson et al., 2011), insulin resistance and type II diabetes 
(Tiano and Mauvais-Jarvis, 2012) and in hypertension associated renal injury (Lindsey 
and Chappell, 2011; Lindsey et al., 2011). Moreover, GPR30 is expressed in many 
cancer cell lines and primary tumours of breast, endometrium, ovaries, lung and 
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prostate, and has a role in cancer cell growth and metastasis (Prossnitz and Barton, 
2011). However, a detailed overview of this literature is beyond the scope of this thesis. 
For comprehensive reviews of the putative in vivo roles see:  Olde and Leeb-Lundberg, 
2009, Prossnitz and Barton, 2011 or Barton, 2012.  
 
 
  
1.3.8: Expression of GPR30 within the nervous system 
In addition to its expression in peripheral tissues GPR30 mRNA has been detected in 
many areas of human CNS tissue including: cerebellum, medulla, spinal cord, 
hypothalamus, hippocampus, thalamus, frontal cortex, amygdala, caudate nucleus and 
putamen (Owman et al., 1996; Feng and Gregor, 1997; O’Dowd et al., 1998), indicating 
a diverse role for this receptor within the nervous system.  
Figure 1.6: GPR30: Putative in vivo roles within the periphery. In black, general 
overview of physiological responses potentially mediated by GPR30. In red, potential 
diseases for which GPR30 could be used as a therapeutic target.  
Figure adapted from Prossnitz and Barton, (2011): The G-protein coupled estrogen 
receptor GPER in health and disease  
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Since then, GPR30 immunoreactivity has been detected in many regions of the rodent 
nervous system including: magnocellular neurons within the paraventricular nucleus 
and supraoptic nucleus of the hypothalamus (Brailoiu et al., 2007; Xu et al., 2009), 
Purkinje cells and granule cells of the cerebellum (Hazell et al., 2009), in both large and 
small diameter cells of rat dorsal root ganglion (Dun et al., 2009), neurons in the pars 
reticular and pars compacta of the Substantia nigra (Brailoiu et al., 2007; Hazell et al., 
2009), cholinergic neurons within the striatum and medial septum (Hammond et al., 
2011), and within principal cells from all regions of the hippocampus (Brailoiu et al., 
2007; Hazell et al., 2009; Hammond et al., 2011). 
 
1.3.9: GPR30 may be implicated in Estrogen-mediated CNS physiology 
Considering the almost omnipresent expression of GPR30 within the CNS and despite 
the controversies surrounding GPR30, it is not surprising that evidence has been rapidly 
accumulating to suggest that this receptor may have multiple roles in E2-mediated 
physiology.  
In brief, GPR30 has been implicated in: 
 E2-induced pain sensitivity. For example G1 increases cytosolic calcium and 
induces reactive oxygen species (ROS) accumulation in cultured spinal sensory 
neurons (Deliu et al., 2012). G1 administration can also mimic E2-mediated 
PKCε dependant mechanical hyperglasia in adult male rats (Kuhn et al., 2008).  
 
 E2 modulation of the serotonin system. For example, GPR30 knockdown 
inhibits, and G1 mimics, E2-induced desensitisation of 5-HT1aR signalling in the 
paraventricular nucleus in rats (Xu et al., 2009; Rossi et al., 2010; McAllister et 
al., 2012).  
 
 E2-induced modulation of gonadotropin releasing hormone (GnRH) secretion. 
For example, G1 stimulates [Ca
2+
]i  oscillations and GnRH secretion in primate 
GnRH neurons in a manner similar to E2, an effect which can be abolished by 
siRNA knockdown of GPR30 (Noel et al., 2009; Terasawa and Kenealy, 2012). 
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 E2 modulation of cholinergic inputs into the hippocampus. Specifically, G1 can 
mimic the E2-induced enhancement of K
+ 
stimulated acetylcholine release in the 
hippocampus and the rate of acquisition in spatial learning tasks in female rats 
(Hammond et al., 2009, 2011). Moreover, the vast majority of cholinergic 
neurons which send afferents to the hippocampus, express GPR30 (Hammond et 
al., 2011).  
 
 Neuroprotective effects of E2. For example, G1 mimics the E2-mediated 
protection against glutamate toxicity in immortalised murine hippocampal 
cultures (Gingerich et al., 2010), in cortical cultures G1 and E2 attenuate 
NMDA-induced excitotoxicity and knockdown of GPR30 reduces the E2- and 
G1-induced neuroprotection (Liu et al., 2012, however see Bryant and Dorsa, 
2010). Chronic administration of G1 can also improve neuronal survival in 
murine models of experimental stroke (Zhang et al., 2010) and global ischemia 
following cardiac arrest (Kosaka et al., 2012). Moreover, in adult rats, a single 
infusion of G1 after induction of transient global ischemia can rescue CA1 
pyramidal neurons from cell death to a similar degree as E2 (Lebesgue et al., 
2009, 2010; Etgen et al., 2011).   
 
1.3.10: Could GPR30 have a role in mediating the estrogenic effects on 
glutamatergic synaptic transmission in the hippocampus? 
For over 40 years it has been known that E2 can modulate glutamatergic synaptic 
transmission and yet the mechanisms by which E2 exerts its actions, and the roles for 
the receptors responsible still have not been fully described or elucidated. 
If GPR30 is involved in the E2-induced effects on excitatory hippocampal synaptic 
transmission then there should be evidence which suggests: 
1) Estrogenic effects involve G-protein signalling: 
o The classic study by Gu and Moss (1996) elegantly demonstrates that 
E2-induced enhancement of kainate induced-currents (predominately 
AMPAR-mediated) in CA1 neurons requires a G-protein dependant 
cAMP-mediated phosphorylation event.  
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2) Estrogenic effects cannot be explained purely via activation of extra-nuclear / 
synaptic ERα and/or ERβ: 
o Rapid estrogenic  effects are still observed in hippocampi of ERα (Gu et 
al., 1999; Fugger et al., 2001) and ERβ (reviewed in Foster, 2012) 
knockout mice.  
3) GPR30 is expressed in the hippocampus 
o See section 1.2.5 
Thus, it is highly feasible that this receptor may be involved in estrogenic effects on 
glutamateric synaptic transmission. 
 
 
 
1.4: Aims 
Thus the aims of this study were to: 
1) Firstly, clarify the cellular localisation of  GPR30 in hippocampal neurons and 
glia from rodents; 
2) Establish a model for examining effects of the GPR30 agonist (G1) on CA3 - 
CA1 glutamatergic synaptic transmission; 
3) Characterise the G1-induced effects and compare them with E2; 
4) Use pharmacological tools and genetic manipulation to validate the receptor/s 
responsible for G1-induced effects.   
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Chapter Two 
 
Materials and Methods 
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2.1:  Materials 
2.1.1: Reagents 
Calcium chloride (CaCl2), D-(+)-Glucose, dimethyl sulphoxide (DMSO), glycine, 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), papain (from papaya latex), 
paraformaldehyde, potassium chloride (KCl), sodium bicarbonate (NaHCO3), sodium 
phosphate monobasic monohydrate (NaH2PO4) and sucrose were obtained from Sigma 
Aldrich Company Ltd (Dorset, United Kingdom).  Magnesium chloride (MgCl2) was 
obtained from VWR International Ltd (Leicestershire, United Kingdom). Magnesium 
sulphate (MgSO4) and sodium chloride (NaCl) were obtained from Fisher Scientific UK 
Ltd (Loughborough, United Kingdom). Triton X-100 was obtained from BDH 
laboratory supplies (Poole, United Kingdom).  
 
Table 2.1: Pharmacological Tools  
Compound Source Vehicle 
Stock 
concentration 
17β-Estradiol (E2) Sigma Aldrich DMSO 10 mM 
Adenosine Sigma Aldrich aCSF N/A 
Brefeldin A Sigma Aldrich DMSO 10 mM 
D-AP5 Ascent Scientific dH2O 50 mM 
G1 Tocris Bioscience DMSO 10 mM 
G15 Tocris Bioscience DMSO 10 mM 
G36 Kind gift from Prof. 
JB Arterburn, 
University of New 
Mexico Heath 
Sciences Centre, 
Alburquerque, USA  
DMSO 10 mM 
ICI 182,780 Ascent Scientific DMSO 10 mM 
LY 341495 Tocris Bioscience DMSO 10 mM 
LY 294002 Ascent Scientific DMSO 10 mM 
MPP Dihydrochloride Tocris Bioscience dH2O 5 mM 
PD98059 Tocris Bioscience DMSO 25 mM 
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PHTPP Tocris Bioscience DMSO 10 mM 
U0124 Calbiochem DMSO 5 mM 
U0126 Abcam DMSO 5 mM 
Wortmannin Calbiochem DMSO 500 µM 
 
 
Table 2.2: Primary antibodies for immunocytochemistry 
Antibody Species (clone) Source Dilution 
Anti-rGluA1  Sheep (polyclonal) In house 1:100 
Anti-hGPR30 Goat (polyconal) R&D Systems 1:500 
Anti-hGPR30 Rabbit (polyclonal) Abcam 1:300 or 
1:1000 
Anti-KDEL Mouse (monoclonal) Abcam 1:200 
Anti-MAP2 Mouse (monoclonal) Sigma-Aldrich 1:1000 
Anti-c-Myc  Sheep (polyclonal)  In house 1:1000 
Anti-synapsin1  Rabbit (polyclonal) Sigma-Aldrich 1:250 
Anti-TGN-46 Mouse (monoclonal) Abcam 1:200 
 
 
Table 2.3: Secondary antibodies for immunocytochemistry 
Antibody Source Dilution 
Alexa Fluor 488-conjugated donkey anti sheep Invitrogen 1:250–1:500 
Alexa Fluor 488-conjugated donkey anti mouse Invitrogen 1:500 
Alexa Fluor 488-conjugated donkey anti rabbit Invitrogen 1:500 
Alexa Fluor 555-conjugated donkey anti mouse Invitrogen 1:500 
Alexa Fluor 555-conjugated donkey anti rabbit Invitrogen 1:500 
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Cy3-conjugated donkey anti goat Jackson Immuno 
Research 
1:500 
Alexa Fluor 546-conjugated phalloidin Intvitrogen 1:250 
  
2.1.2:  Cell culture material 
Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12 (1:1 DMEM-F12), 
Dulbecco’s Phosphate-Buffered Saline (DPBS), Neurobasal-A Medium and B-27 
supplement were obtained from Gibco, Life Technologies Ltd. (Paisly, United 
Kingdom). Trypsin-EDTA solution, L-glutamine solution, and poly-d-lysine were 
obtained from Sigma Aldrich Company Ltd. (Dorset, United Kingdom). Sterile, heat 
inactivated EU-approved Foetal Bovine Serum (FBS) was obtained from Sera 
Laboratories (West Sussex, United Kingdom). Glass coverslips 9mm and 13mm 
diameter were obtained from VWR International Ltd. (Leicestershire, United Kingdom). 
Lipofectamine 2000 transfection reagent and Opti-MEM reduced serum media were 
obtained from Invitrogen, Life Technologies Ltd. (Paisly, United Kingdom).  
 
2.1.3: Genetic Material  
The OriGene Myc-DDK-tagged ORF clone of Rattus norvegicus G protein-coupled 
estrogen receptor 1 (rGPR30-myc) cloned into a pCMV6 vector was obtained from 
Insight Biotechnology Ltd. (RR201182; Middlesex, United Kingdom). ON-TARGET 
plus SMART pool rat GPER (GPR30) siRNA (L-093123-02-0005), rat Gria-1 (GluA1) 
siRNA (L-097755-02-0005) and human GPR55 siRNA (L-005581-00-0005) were 
obtained from Thermo Fisher Scientific, Inc. (Waltham, United States). 
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2.1.4: siRNA target sequences 
 
hGPR55 siRNA SMARTpool: 
Target sequence: J-005581-09 GCUACUACUUUGUCAUCAA 
Target sequence: J-005581-08 AAGAACAGGUGGCCCGAUU 
Target sequence: J-005581-07 GAGAAACAGCUUUAUCGUA 
Target sequence: J-005581-06 GAAUUCCGCAUGAACAUCA 
 
rGPER siRNA SMARTpool: 
Target sequence: J-093123-08 GCAGUCAGAUGUCAAGUUC 
Target sequence: J-093123-07 GACGAGCAGUAUUACGAUA 
Target sequence: J-093123-06 GGGACAAGCUCAGGCUGUA 
Target sequence: J-093123-05 GGAUGAGCUUCGACAGGUA 
 
rGria-1 siRNA SMARTpool:  
Target sequence: J-097755-12 GCAGUCAGAUGUCAAGUUC 
Target sequence: J-097755-11 GACGAGCAGUAUUACGAUA 
Target sequence: J-097755-10 GGGACAAGCUCAGGCUGUA 
Target sequence: J-097755-09 GGAUGAGCUUCGACAGGUA 
 
2.2: Methods 
2.2.1: Cell maintenance and generation of primary cultures 
2.2.1.1: HEK-293 cell maintenance 
Human embryonic kidney 293 (HEK-293) cells were maintained in DMEM-F12 media, 
supplemented with 10 % FBS and 2 mM L-glutamine in 25 cm
2
 cell culture treated 
flasks (Greiner Bio-One Ltd., Stonehouse, UK) at 37°C and 95 % O2 / 5 % CO2. Once 
cells had reached 80 – 90 % confluency, they were rinsed twice with calcium and 
magnesium free DPBS and exposed to 0.5 – 1 ml Trypsin-EDTA solution. Once cells 
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had detached, 3 ml of maintenance media was added and cells were passaged at a v/v 
ratio of 1:5. For experimental purposes, cells were plated onto sterile glass coverslips (9 
mm diameter) coated with poly-d-lysine (20 µg/ml in sterile dH2O for 1 hour) in sterile 
vented cell culture dishes (35 mm or 145 mm diameter; Greiner Bio-One Ltd., 
Stonehouse, UK) and left overnight at 37°C and 95 % O2 / 5 % CO2 in maintenance 
media, before transfection.  
 
2.2.1.2: Primary culture of rat hippocampal neurons 
Neonatal Sprague-Dawley rats (postnatal days (P) 1 - 2) were sacrificed by cervical 
dislocation in accordance with Schedule 1 of the UK Scientific Procedures Act, 1986. 
After decapitation, hippocampi were dissected out and washed with ice-cold HEPES 
buffered saline (HBS) containing (in mM): NaCl 135; KCl 5; CaCl2 1; MgCl2 1; 
HEPES 10; D-glucose 25, at pH 7.4. Tissue was finely chopped, suspended in HBS 
supplemented with 1.5 mg/ml papain and incubated at 37ºC for 20 min. Tissue was then 
transferred into 1 ml fresh HBS and triturated with a series of flame-polished glass 
pasture pipettes of decreasing diameter, until cells were dissociated. The cell suspension 
was then centrifuged at 1,200 x g for 3 min, supernatant was discarded and the 
remaining cell pellet was resuspended in neuronal culture medium consisting of: 
Neurobasal-A culture medium supplemented with 2 % (v/v) B-27 and 2 mM L-
glutamine, at a density of 5 x 10
5 
cells/ml. Cells were then plated onto sterilized glass 
coverslips (13 mm diameter) coated with poly-d-lysine (20 µg/ml in sterile dH2O; for at 
least 1 hour) at a density of 3.76 x 10
4
 cells/cm
2
 in sterile vented cell culture dishes (35 
mm diameter; Greiner Bio-One Ltd., Stonehouse, UK). Cultures were incubated at 37ºC 
in a humidified atmosphere of 5% CO2 and 95% O2 for one hour to allow the cells to 
settle onto the coverslips. After settling, cultures were removed from the incubator, and 
2 ml of neuronal culture medium (as above) was added. Cultures were then returned to 
the incubator for up to 3 weeks. It is worth noting here that neurobasal culture medium 
is a serum- and estrogen- free media containing inorganic slats, glucose, HEPES, 
vitamins and amino-acids and supplementation with B-27 supports the growth and 
survival of neurons without the need for addition of serum (Brewer et al., 1993). 
Moreover, B-27 supplementation inhibits the proliferation of glia, thus the use of the 
Neurobasal/B-27 combination should, in theory, enable an almost pure neuronal culture 
(Brewer et al., 1993).  
40 
2.2.2: Incorporation of genetic material 
2.2.2.1:  Transient Transfection of HEK-293 cells 
Adhered HEK-293 cells on coverslips were transferred into serum free media (DMEM-
F12 media supplemented with 2 mM L-glutamine) and transiently transfected using 
Lipofectamine 2000. Briefly, 2 µl Lipofectamine 2000 reagent was diluted in 48 µl 
Opti-MEM, and ~2 µg of hGPR30-SEP or rGPR30-myc cDNA was diluted in Opti-
MEM (final volume 50 µl) and left for 5 min at room temperature. The lipofectamine 
2000 - Opti-MEM and cDNA- Opti-MEM solutions were then combined (total volume 
100 µl), mixed gently and incubated for 20 min at room temperature to allow the DNA-
lipofectamine 2000 complexes to form. 100 µl of the transfection complex was added to 
the HEK-293 cells in serum free media, mixed gently and incubated at 37 °C and 95 % 
O2 / 5 % CO2 for 12 - 24 hours to allow for protein expression.  
 
2.2.2.2:  siRNA treatment of hGPR55-HEK-293 cells 
The hGPR55-HEK-293 cell line are a stable cell line expressing hGPR55 with a triple 
hemagglutinin epitope (HA) at the N-terminus, generated as described in Henstridge et 
al., (2009). Adhered cells on coverslips were transferred into serum free media 
(DMEM-F12 media supplemented with 2 mM L-glutamine) and transfected with On-
TARGETplus SMARTpool hGPR55 or rGPR30 siRNA (100 nM) using Dharmafect 1 
(Thermo Fisher Scientific, Inc). Briefly, 3 µl Dharmafect 1 was diluted in 97 µl serum 
free media and 5 µl siRNA was diluted in 95 µl  serum free media (from a 20 µM stock 
concentration, to a final concentration of 100 nM in a total 1 ml serum free media) and 
left for 15 min at room temperature. The Dharmafect 1 solution and the siRNA solution 
were then combined and gently mixed (200 µl), and left for 20 min at room temperature 
to allow for Dharmafect 1 and siRNA complexes to form. Coverslips were placed into 
800 µl serum free media and the Dharmafect 1 and siRNA complex solution was added 
to hGRP55-HEK cells in a drop wise manner and gently mixed. Cells were incubated at 
37 °C and 95 % O2 / 5 % CO2 for 68 – 72 hours to allow for efficient knockdown.  
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2.2.2.3: siRNA treatment of primary cultured rat hippocampal neurons 
Primary cultures of rat hippocampal neurons 5 days in vitro (DIV) were transfected 
using with On-TARGETplus SMARTpool hGPR55, rGPER or rGria1 siRNA (100 nM) 
using Dharmafect 1 (Thermo Fisher Scientific, Inc), as described above (2.2.2.2). 
However, with the following modification: in place of serum free media, cells were 
transfected in and maintained in fresh maintenance media (Neurobasal-A culture 
medium supplemented with 2 % (v/v) B-27 and 2 mM L-glutamine). Cells were then 
incubated at 37°C and 95 % O2 / 5 % CO2 for 46 – 96 hours. 
 
2.2.3:  Immunocytochemistry 
2.2.3.1: HEK-293 Cells: GPR30 localisation and co-staining 
Transfected HEK-293 cells were removed from the incubator and washed three times in 
2 ml pre-warmed HBS (37ºC) containing (in mM): NaCl 135; KCl 5; CaCl2 1; MgCl2 1; 
HEPES 10; D-glucose 10, at pH 7.4. Cells were fixed with 4% paraformaldehyde (PFA) 
containing 200 mM sucrose, and permeabilized with 0.2% Triton X-100 in HBS (5 - 
10min) at room temperature. To validate antibodies against the tagged receptor, cells 
were washed and labelled with either anti-hGPR30 (R+D systems; 1:500 in HBS for 1 
hour at room temperature) or anti-hGPR30 (Abcam; 1:300 or 1:1000 in HBS for 3 hours 
or overnight, respectively at 4 ºC). GPR30 antibody staining was visualised by addition 
of Alexa-555-conjugated donkey anti-rabbit secondary antibody or Cy3-conjugated 
donkey anti-goat secondary antibody (1:500 in HBS for 30min at room temperature). 
For cells transiently transfected with rGPR30-myc, localisation of the tagged protein 
was determined by labelling with a primary antibody directed against the c-terminus-
myc tag (sheep anti-myc; in house antibody against synthetic peptide 
AEEQKLISEEDLL; 1:1000 in HBS for 1 hour at room temperature) and visualised by 
addition of Alexa-488-conjugated donkey anti-sheep secondary antibody (1:500 in HBS 
for 30min at room temperature). In some cases, GPR30 localisation in transfected cells 
was determined using intracellular markers; mouse anti-KDEL (1:200 in HBS for 3 
hours at 4 ºC) and visualised by addition of Alexa-555-conjugated donkey anti-mouse 
secondary antibody (1:500 in HBS for 30 min at room temperature) or Alexa-fluor 546 
conjugated phalloidin (1:250 in HBS for 30 min at room temperature) .  In some cases 
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transfected HEK-293 cells were subjected to drug treatment (30min – 2 hours at 37 ºC 
in HBS) before fixation, permeabilization and staining.  
 
2.2.3.2: Total hGPR55 staining of hGRP55-HEK-293 cells after siRNA 
treatment 
Knockdown of hGPR55 protein expression using the same protocol and target siRNA 
sequences has been previously described in our laboratory (Henstridge, unpublished), 
therefore this protocol was utilised as a positive control, to validate efficiency of 
siRNA. After 68 – 72 hours siRNA treatment, hGPR55-HEK-293 cells were fixed with 
4 % PFA containing 200 mM sucrose (10 min, room temperature) and permeabilized 
with 0.2% Triton X-100 in HBS (5 - 10min, room temperature). Cells were then 
labelled with a primary antibody against HA (1:1000 in HBS; 1 hour; room 
temperature) followed by Alexa-488-conjugated donkey anti-mouse secondary antibody 
(1:500; 30 min; room temperature). Cells were imaged as detailed below (see section 
2.2.7.6). Efficient protein knockdown was confirmed as whole cell HA-staining was 
dramatically reduced in hGPR55 siRNA treated cells (Fig 2.1) 
 
 
 
 
Figure 2.1: siRNA against hGPR55 reduces total hGPR55 expression in 
hGPR55-HEK-293 cells. Cells were treated with siRNA for hGPR55, rGPR30 
or Dharmafect-1 alone for 68 – 72 hours in serum-free media, scale bars 20 µM. 
Images represent 3 individual experiments, conducted in collaboration with June 
Penman.  
 
Untreated Dharmafect 1 hGPR55 siRNA rGPR30 siRNA 
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2.2.3.4: Primary cultured rat hippocampal neurons: GPR30 localisation and 
co-staining 
Primary hippocampal neurons (DIV 8 – 16) were removed from the incubator and 
washed three times in 2 ml HBS containing glycine (0.01mM; room temperature).  Cells 
were fixed with 4% PFA containing 200 mM sucrose, and permeabilized with 0.2 % 
Triton X-100 in HBS (5 - 10min) at room temperature. Neurons were washed and 
labelled with anti-hGPR30 (Abcam; 1:300 or 1:1000 in HBS for 3 hours or overnight, 
respectively, at 4 ºC), followed by intracellular markers; mouse anti-KDEL, mouse anti-
TGN-46 (1:200 in HBS for 3 hours at 4 ºC), Alexa-fluor 546 conjugated phalloidin 
(1:500 in HBS for 30 min at room temperature) or rabbit anti synapsin-1 (1:250 in HBS 
for 30 min at room temperature). GPR30 staining was visualised by addition of Alexa-
488-conjugated donkey anti-rabbit secondary antibody (1:500 in HBS for 30min at 
room temperature) and staining of the intracellular markers was visualised by addition 
of Alexa-555-conjugated donkey anti-mouse or donkey anti-rabbit secondary antibody 
(1:500 in HBS for 30min at room temperature).  In some cases neurons were subjected 
to drug treatment (30min – 2 hours at 37 ºC in HBS) before fixation, permeabilization 
and staining. A marker for microtubule-associated protein 2 (mouse anti-MAP2; 1:1000 
in HBS for 1 hour at room temperature) was utilized to distinguish between neuronal 
and non-neuronal cells (Izant and McIntosh, 1980; Dehmelt and Halpain, 2005) and 
visualised by the addition of Alexa-555-conjugated donkey anti-mouse secondary 
antibody (1:500 in HBS for 30 min at room temperature).  
 
2.2.3.5: Primary cultured rat hippocampal neurons: Surface GluA1 staining 
after drug treatment 
Primary hippocampal neurons (DIV 8 – 16) were removed from the incubator and 
washed three times in 2 ml HBS containing glycine (0.01 mM). Neurons in HBS were 
allowed to equilibrate to room temperature (10 min) and then subjected to drug 
treatment (21 - 23 ºC). As most agents, including E2 and G1, were solubilised in DMSO 
(see table 2.1), control cultures (vehicle treated) were always treated with an equivalent 
volume of DMSO (either 0.01 % or 0.1 % of the final volume, as indicated). For 
inhibitor/antagonist experiments, neurons were pre-treated for the indicated times before 
addition of E2 or G1. After drug treatment, living neurons were gently washed with 
HBS and labelled with primary antibody directed against the N-terminal region of the 
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GluA1 subunit of cell surface AMPA-receptors (Sheep anti-GluA1; in house antibody 
against synthetic peptide RTSDSRDHTRVDWKR corresponding to 253 - 267 residues 
of rat GluA1; Pickard et al., 2001) 1:100 in HBS for 30 minutes at 4ºC. Cells were then 
washed with HBS and fixed with 4 % PFA containing 200 mM sucrose for 5 - 10 min at 
room temperature. Surface GluA1 staining was visualized by addition of Alexa 488-
conjugated donkey anti-sheep secondary antibody (1:250 in HBS for 30 min at room 
temperature). To compare surface GluA1 expression relative to synapsin-1 labelling, 
after fixation, cells were permeablized with 0.2% Triton X-100 in HBS (5 – 10 min) and 
labelled with primary antibody against synapsin-1 (rabbit anti-synapsin-1; 1:250 in HBS 
for 30 min at room temperature). Synapsin-1 is phosphoprotein which associates with 
the cytoplasmic surface of synaptic vesicles, the synapsin family has a role in the 
formation and maintenance of synaptic contacts, thus antibodies directed against this 
protein can be used as a marker for synapse location (Südhof, 1990; Ferreira and 
Rapoport, 2002). Synapsin-1 labelling was visualised by addition of Alexa-555 
conjugated donkey anti-rabbit secondary antibody (1:500 in HBS for 30 min at room 
temperature). No staining was observed after incubation with either secondary antibody 
alone (30  min).  
 
2.2.3.6: Image Acquisition for immunocytochemistry 
Cells were imaged using a Zeiss LSM510 laser scanning confocal microscope. Laser 
lines (488 and 543 nm) were used to excite the Alexa-488 and Alexa-555/ Alexa-546 / 
Cy3 fluorphores, respectively. Dual labelling images were obtained in multi-tracking 
mode using a 15 s scan speed. Images of at least four randomly selected cells for each 
condition were collected. For surface GluA1 staining of hippocampal neurons, all data 
were obtained from at least three different cultures from different animals. For GPR30 
localisation studies, data from hippocampal neurons and HEK-293 cells were obtained 
from at least two different cultures from different animals or cell passages. Within a 
given experiment, all imaging conditions were kept constant; including illumination 
intensity and photomultiplier gains.  
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2.2.3.7:  A note about phenol red containing media 
Media used for all cell culture in this thesis contained phenol red, a pH indicator. Phenol 
red has putative estrogenic activity in estrogen responsive cancer cell lines, particularly 
in MCF-7’s (a breast cancer cell line that is GPR30 positive), and competes with 
estradiol in binding studies of cytosolic estrogen receptor (Welshons et al., 1988). 
Therefore, to ensure that the presence of phenol red does not affect GPR30 expression 
in our studies, hGPR30-SEP and rGPR30-myc were transfected into HEK-293 cells and 
plated in phenol red or phenol red free media. Fig. 2.1 illustrates that the intracellular 
distribution of human and rat GPR30 is not affected by the presence of phenol red.  
 
 
 
 
2.2.4: Electrophysiology 
2.2.4.1:  Animal care 
Sprague-Dawley rats were housed under a 12 hour light/dark cycle and had access to 
food and water ad libitum. After weaning, male rats were caged with male litter mates 
(3-4 animals per cage). All efforts were made to minimise the number of animals used 
and their suffering.  
Figure 2.2: The presence of phenol red in cell culture media does not affect 
the intracellular expression pattern of GPR30. Images represent at least 2 
individual experiments, scale bars 10 µm.  
hGPR30-SEP 
rGPR30-myc 
Phenol red Phenol red free 
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2.2.4.2: Hippocampal slice preparation 
Male Sprague-Dawley rats aged P11 - 18 or three to five months (12 -20 weeks) were 
either sacrificed by cervical dislocation (P11-18) or anaesthetized with isoflurane until 
unconscious and then sacrificed by decapitation (12-20 weeks) in accordance with the 
UK Scientific Procedures Act, 1986. Following decapitation, the brain was carefully 
removed and placed into oxygenated (95 % O2/ 5% CO2 ; pH 7.4)  ice-cold modified 
high-sucrose artificial cerebral spinal fluid (aCSF) containing (in mM): Sucrose 75; 
NaCl 87; KCl 2.5; NaHCO3 26; NaH2PO4 1.25; MgSO4 7; CaCl2 0.5 and D-glucose 10. 
The brain was then placed onto filter paper soaked in the above solution and the 
cerebellum, olfactory bulbs and a small portion of the lateral sides of the cortex were 
removed. The brain was cut down the intrahemispheric fissure and parasagittal 
hippocampal slices (350 µm) were cut using a Campden Instruments 7000 smz 
vibrating microtome (Campden Instruments Ltd., Loughborough, UK). Slices were 
allowed to recover in a holding chamber containing aCSF (in mM): NaCl 124; KCl 3; 
NaHCO3 26; NaH2PO4 1.25; MgSO4 1; CaCl2 2 and D-glucose 10, oxygentated (95 % 
O2/ 5% CO2 ; pH7.4) and at 33-34 ºC for at least one hour. 
 
2.2.4.3:  Basal synaptic transmission 
Hippocampal slices were transferred to a submerged recording chamber perfused with 
oxygenated (95% O2/ 5% CO2; pH7.4) aCSF (5 - 6ml.min
-1
; 31-32 ºC). Extracellular 
field excitatory postsynaptic potentials (fEPSPs) were recorded from dendrites of 
pyramidal neurons of the stratum radiatum layer in area CA1 using glass 
microelectrodes (Harvard Apparatus Ltd, Kent, UK) filled with aCSF (resistance = 
~1MΩ). Responses were evoked by stimulation of the Schaffer collateral-commissural 
(Scc) pathway using a handmade bi-polar electrode (twisted nickel-chromium wire) at a 
frequency of 0.0333 Hz from a constant voltage isolated stimulator (DS2A-MKII, 
Digitimer Ltd., Hertfordshire, UK) at a stimulus intensity that produced a 40 - 60% 
maximal response. Figure 2.3 depicts the positioning of electrodes in hippocampal 
slices and Figure 2.4 illustrates an example fEPSP, and the parameters of which were 
recorded. Recordings were made using an Axopatch 200B patch clamp amplifier 
(Molecular Devices, Sunnyvale, CA, USA), and data were low pass filtered at 2 kHz. 
Electrical signals were recorded and monitored using the WinLTP software (courtesy of 
Dr. Bill Anderson, University of Bristol, Bristol, UK: Anderson and Collingridge, 
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2001). Both the peak amplitude and initial slope of the fEPSP were monitored; stable 
responses for at least 20 min were required before application of any agents. A baseline 
was considered stable when response amplitude and slope were neither ramping up, 
ramping down nor varying drastically between two consecutive stimuli, this was 
determined by eye. If the responses from a slice were not stabilising after one hour of 
recording, then the slice was discarded. Using these criteria for determining stability, 
the magnitude of the fEPSP slope and amplitude can remain stable for up to 3 hours (the 
longest recording made without application of any agents).For experiments conducted 
in low Mg
2+
 aCSF (0.1 mM), a stable baseline was generated in normal aCSF for at 
least 10 min before low Mg
2+ 
aCSF was perfused over the slice. Perfusion of low Mg
2+ 
aCSF greatly enhanced fEPSP slope and amplitude measurements compared to baseline 
transmission and so in response to this enhancement, stimulus voltage was decreased in 
order to prevent hyper excitability, and population-spike generation. Stimulus intensity 
was reduced to a level approximating 50% maximal response amplitude under normal 
conditions. A 20 min stable baseline in these conditions was required before application 
of any agents. Pharmacological agents were diluted from stock solutions (Table 2.1) 
into oxygenated aCSF immediately before perfusion over the slice. For each set of 
experiments, each n value was obtained from a slice from a different animal. 
 
2.2.4.4:  Paired-pulse facilitation 
For experiments using the paired-pulse stimulation protocol, a stable baseline was 
recorded for at least 10min before the stimulation protocol was initiated. The protocol 
consisted of two identical stimuli separated by a 50ms inter-stimulus interval at a 
frequency of 0.0333 Hz and was maintained throughout the duration of the experiment. 
Paired-pulse facilitation is a type of short term, activity-dependant synaptic plasticity 
and is manifested by an enhancement of a second post-synaptic response, when shortly 
(20 – 200 ms) preceded by a first. It is classically accounted for by the residual calcium 
hypothesis of Katz and Miledi, (1968). The paired-pulse facilitation ratio (PPR) can be 
used to quantify this effect, and is determined by the amplitude of the second response 
divided by the first (see section 2.2.5.2). Changes in the PPR traditionally reflect 
changes in presynaptic neurotransmitter release probability (where the PPR is inversely 
proportional to the initial release probability).  
48 
 
 
 
 
  
Figure 2.3: Cartoon of a parasagittal hippocampal slice from rat. The 
cartoon depicts the positioning of the bi-polar stimulating electrode and glass 
recording electrode within the rat hippocampal slice. The Schaffer collateral-
commissural (Scc) pathway from CA3 provides glutamatergic synaptic input to 
dendrites of pyramidal and inhibitory neurons in area CA1.  
Figure modified from Nishikawa and MacIver (2000) 
Bi-polar stimulating 
electrode 
Glass recording 
electrode 
S. pyramidale 
S. radiatum 
Scc 
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Figure 2.4: Example of an extracellular field excitatory post-synaptic 
potential (fEPSP) recorded from hippocampal region CA1. The fEPSP is 
generated from simultaneous depolarisation of the dendritic field from a 
population of CA1 pyramidal neurons. A negative potential is recorded, as 
positive ions flow into post-synaptic membranes away from the extracellular 
recording electrode. The peak amplitude of the fEPSP and the initial slope of 
the fEPSP are measured. However, the peak amplitude of the fEPSP can be 
contaminated with population spikes or population inhibitory post-synaptic 
potentials (pIPSPs). Therefore, the slope of the response is used for analysis as 
this is a more accurate representation of excitatory synaptic transmission.  
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2.2.5 Data Analysis 
2.2.5.1 : Surface GluA1 expression and Synapsin-1 co-localisation 
For surface GluA1 expression, fluorescence intensity of staining was determined offline 
using LSM Image Browser software, where three analysis lines of 50 µm were drawn 
along randomly selected dendritic regions from each cell image. Data was transferred to 
SigmaPlot11.0 (Systat Software Inc.) and mean fluorescence intensity was calculated. 
In order to quantify experimental data from separate experiments, data were normalized 
relative to mean fluorescence intensity of vehicle treated neurons. For co-localisation 
studies, surface GluA1 staining was compared with synapsin-1 staining. Percentage of 
surface GluA1 at synapses was calculated as number of GluA1-positive puncta that co-
localised with synapsin-1-positive puncta and expressed as a percentage relative to the 
total amount of synapsin-1-positive puncta (Moult et al., 2010). To quantify synapse 
number across treatments, the number of synapsin-1-positive puncta were counted along 
each 50 µm analysis line and normalised relative to vehicle treated neurons. All 
statistical analyses were carried out using SigmaPlot 11.0 (Systat Software Inc.). A one-
way Analysis of Variance (ANOVA) was performed to test for significance between 
treatment groups.  Tukey post-hoc analyses were done only in the case of a significant 
ANOVA. If data failed normality or equal variance tests then a Kruskal-Wallis one-way 
ANOVA on ranks was performed, followed by a Dunn’s post-hoc analysis, as noted. All 
data are expressed as mean ± standard error of mean (SEM) and p < 0.05 was 
considered statistically significant. n represents the total number of neurites assessed in 
each treatment group.  
 
2.2.5.2: Electrophysiology analysis 
Data were analysed off-line using the WinLTP reanalysis software (Anderson and 
Collingridge, 2001). Data was transferred to SigmaPlot 11.0 (Systat Software Inc.) and 
a mean of the raw fEPSP slope measurements (mVms
-1
) from the 20min baseline were 
obtained. Data were transformed to a per cent of mean baseline measurements. 
Transformed data were then averaged with corresponding experiments and plotted 
against time, each data point represents mean ± standard error mean (SEM) for a given 
set of experiments. The paired-pulse facilitation ratio (PPR) was calculated as a ratio of 
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the amplitude of the second fEPSP relative to the amplitude of the first fEPSP (PPR = 
ampfEPSP2/ampfEPSP1).  
All statistical analyses were carried out using SigmaPlot 11.0 (Systat Software Inc.) The 
degree of potentiation or depression was calculated as a mean of normalised fEPSP 
slope measurements from a 5 min period at a given time point and compared with 
baseline values. The time points taken and averaged for each slices were as follows: 
baseline values were taken as the 5 min period before the addition of any agents; 
antagonist values as the 5 min before the addition of any further agents; values for 
agonist effect were taken as the 5 min period before agonist washout; washout effects 
were taken as the 5 min period before termination of the experiment. Using these 
values, the effects of agents on normalised fEPSP slope or the PPR were analysed using 
a one-way repeated measures ANOVA or paired t-test, where appropriate. Thus, the 
data used for statistical comparisons were the means of each of the 5 min time periods 
(as above) for each slice. In this respect, data was analysed as “raw data”. With respect 
to the data subjected to one-way repeated measures ANOVA, baseline, post-drug and 
washout values were included in the analyses.  
Pairwise Tukey post-hoc tests were used in the case of a significant ANOVA. For 
comparison between means of different experimental groups, a one-way ANOVA was 
performed, followed by pairwise Tukey post-hoc analysis. If data failed normality or 
equal variance tests then a Kruskal-Wallis one-way ANOVA on ranks was performed, 
followed by pairwise Dunn’s post-hoc analysis, as noted.  
 
2.2.5.3: Stratification of fEPSP recordings  
It was noted that G1 and E2 elicited different response profiles during ligand application 
and washout (see Chapter 4). For each slice, data was subsequently separated into one 
of three different response types, biphasic, depression only and sustained potentiation, 
according to the following criteria: 
Biphasic: the normalised mean of the 5 min period during agonist application before 
washout (ie: 15 – 20 min of agonist application) was at least 4 % greater than baseline 
and the mean final 20 min of the washout phase (ie: 40 – 60 min after agonist washout) 
was below at least 4 % below baseline. Depression only: the normalised mean of the 5 
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min period during agonist application before washout (ie: 15 – 20 min of agonist 
application) was < 4 % of baseline (100 %), a lack of potentiation during agonist 
application and washout, and the mean final 20 min of the washout phase (ie: 40 – 60 
min after agonist washout) was at least 4 % below baseline. Sustained potentiation: the 
normalised mean of the 5 min period during agonist application before washout (ie: 15 
– 20 min of agonist application) was at least 4 % greater than baseline and the mean 
final 20 min of the washout phase was also at least 4 % greater than baseline. 
 
2.2.5.4: Relative GPR30 and total GluA1 fluorescence after siRNA treatment 
Fluorescence intensity of GPR30 staining or total GluA1 staining in primary 
hippocampal neurons after siRNA treatment were analysed using ImageJ, image 
analysis software. A region of interest (ROI) for analysis was selected for each neuron 
and the following parameters were recorded: area, mean grey value (mean fluorescence 
intensity) and integrated density. Corrected fluorescence intensity was calculated using 
the following equation: 
Corrected fluorescence intensity = integrated density value for the ROI – (area of ROI x 
mean fluorescence value of background) 
This type of analysis takes into consideration the fluorescent intensity of the ROI with 
respect to its area. See: http://sciencetechblog.com/2011/05/24/measuring-cell-
fluorescence-using-imagej/. This method for quantifying fluorescence intensity has been 
used previously by the following authors: Burgess et al., 2010; Gavet and Pines, 2010; 
Potapova et al., 2011. 
In order to quantify experimental data from separate experiments, data were normalized 
relative to the mean corrected fluorescence values from neurons which were not 
subjected to siRNA treatment.  
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Chapter Three 
 
GPR30 localisation  
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3.1:  Introduction 
GPCRs represent the largest family of integral membrane proteins, with over 800 GPCR 
genes identified within the human genome. GPCRs are a target for approximately 40 – 
50% of clinically marketed drugs and so are of great commercial value to the 
pharmaceutical industry (Wheatley et al., 2012). As worldwide life-expectancy rises, so 
does the incidence of age-related neurological disorders, such as dementia and 
Alzheimer’s disease (Gao et al., 1998). Estrogen has a diverse role in CNS; moreover 
animal studies show that estrogen has many beneficial effects within the brain (as 
reviewed in Frick, 2012). However, large randomized clinical trials in humans (such as 
the Women’s Health Initiative Memory Study; WHIMS) suggest that estrogen therapy 
initiated later in life has no beneficial effect on cognition but rather increases the risk for 
dementia, stroke and mild cognitive decline (Shumaker et al., 2004). Therefore 
targeting novel estrogen-sensitive GPCRs, such as GPR30, may provide new 
therapeutics for these age-related disorders, without deleterious effects associated with 
hormone therapy.  
Since the discovery of GPR30 as a putative estrogen-sensing receptor in 2005, the field 
has expanded rapidly, now with over 350 published articles examining its function. 
However, there is currently considerable debate over the cellular localisation, 
endogenous expression and even whether GPR30 functions as an estrogen receptor (for 
reviews see Langer et al., 2010; Maggiolini and Picard, 2010; Levin, 2011).  Thus in 
order to investigate the function of this receptor and its potential as a therapeutic target, 
experimental models that best mirror the endogenous environment are employed. 
Rodent models present an invaluable tool in assessing GPCR function within the CNS, 
however species orthologs may have pronounced differences in expression profiles and 
pharmacology and hence overall function  (for a review on this matter, see Strasser et 
al., 2013).  
The cellular localisation of human GPR30 has long been a topic of controversy. Some 
groups report that GPR30 localisation is restricted to the endoplasmic reticulum and 
Golgi in heterologous (Revankar et al., 2005; Matsuda et al., 2008; Otto et al., 2008) 
and endogenously expressing cells (Brailoiu et al., 2007; Revankar et al., 2007; 
Sakamoto et al., 2007; Matsuda et al., 2008; Otto et al., 2008; Lin et al., 2009; 
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Takanami et al., 2010), and thus functions as an intracellular GPCR. Whereas others 
detect plasma membrane association in heterologous (Funakoshi et al., 2006; Filardo et 
al., 2007; Cheng et al., 2011a, 2011b; Sandén et al., 2011) and endogenously 
expressing cells (Funakoshi et al., 2006; Pang et al., 2008; Gao et al., 2011; Lindsey et 
al., 2011; Maiti et al., 2011), and functions as a classical plasma-membrane associated 
GPCR.   
Although there is significant overall homology between human and rat GPR30 (see 
3.2.1 and Pang et al., 2008), the N-terminus sequence (residues 1 – 62) between the two 
species differs dramatically (only 55% sequence identity). These differences could 
consequently direct the proteins to different cellular compartments, as there is evidence 
to suggest that, in addition to the C-terminus, the N-terminal region can also play a role 
in directing proteins to the plasma membrane (as reviewed in Dong et al., 2007). 
Thus, as a prelude to investigating the role for GPR30 in modulating excitatory synaptic 
transmission in the rodent hippocampus, confocal imaging experiments were conducted 
in a heterologous expression system to compare the cellular localisation of human and 
rat GPR30. Furthermore, an antibody capable of recognising rat GPR30 was utilised to 
examine the endogenous cellular localisation of GPR30 in rat hippocampal neurons.   
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3.2: Results 
3.2.1:  Amino Acid sequence homology between human and rat GPR30 
Amino acid sequences for hGPR30 and rGPR30 were aligned and compared. The 
predicted topological domains from hGPR30 (Q99527) and rGPR30 (O08878) were 
obtained from the protein knowledge database (UniprotKB; version 122 for hGPR30 
and version 90 for rGPR30; modified on 3 April 2013). 
Both hGPR30 and rGPR30 encode a 375 amino acid protein and share 86% sequence 
identity (Fig 3.1), with the N-terminus (residues 1 – 62) being the least conserved region 
with only 55% sequence identity. Three potential N-glycosylation sites (in red) were 
recognised in the N-terminal region for both rat and human GPR30 at residues 25, 32 
and 44. Importantly, the DRY (Asp – Arg – Tyr) sequence (boxed) is conserved 
between rat and human. The DRY motif, located at the boundary between 
transmembrane domain 3 and intracellular loop 2, is typical of most Class A rhodopsin-
like GPCRs (Rovati et al., 2007) and is thought to be involved in stabilising the 
inactive-state conformation (Rovati et al., 2007; Vogel et al., 2008; Rosenbaum et al., 
2009). Conserved cysteine residues (130 and 207; purple) indicate a potential disulphide 
bond site. Disulphide bonds between extracellular loop 2 and the top of transmembrane 
3 provide conformational constraint  and are highly conserved in the majority of family 
A GPCRs (reviewed in Wheatley et al., 2012). Moreover, residues adjacent to the 207-
cysteine in extracellular loop 2 are conserved between the two species and it is thought 
that this area is important for ligand binding in Class A receptors (reviewed in Wheatley 
et al., 2012). 
These highly conserved structural defining regions suggest that both human and rat 
GPR30 share similar regions for potential post-translational modification, tertiary 
structure and ligand binding.  
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Figure 3.1: Amino acid sequence alignment of GPR30 from human and rat.   
Sequences were obtained from Uniprot Knowledge database and aligned. Both 
human and rat GPR30 gene products encode a 375 amino acid protein, and share 
86% sequence identity.   
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3.2.2:  Comparison of intracellular localisation 
In order to investigate and compare the cellular localisations of hGPR30 and rGPR30, 
immortalised human embryonic kidney cells (HEK-293; Graham et al., 1977) were 
transiently transfected overnight with vectors containing hGPR30 with a C-terminus 
SEP tag or with rGPR30 with a C-terminus myc tag (see section 2.1.3) and examined 
using confocal microscopy. Preliminary confocal experiments revealed an intracellular 
localisation which resembled endoplasmic reticulum expression for both human and rat 
constructs. Dual-labelling studies were then employed to verify this expression pattern.  
Dual labelling of hGPR30-SEP or rGPR30-myc (green) transfected HEK-293 cells, 
with an anti-KDEL antibody (red; an antibody specific for the ER retention signal 
sequence, Lys-Asp-Glu-Leu (KDEL); Munro and Pelham, 1987) revealed almost 
complete co-localisation (yellow) for both hGPR30-SEP and rGPR30-myc (Fig 3.2 A). 
In contrast, dual-labelling with a marker for polymerised F-actin (alexa-555 conjugated 
phalloidin; red) revealed no co-localisation (Fig 3.2 B). Conjugated phalloidin staining 
was used here to illustrate cell morphology (cytoskeleton) and to demonstrate the 
intracellular distribution of GPR30. Thus, these data suggest that when expressed in 
heterologous systems, both human and rat GPR30 localise to the endoplasmic 
reticulum. Moreover, the data presented here are in agreement with the reported 
distribution of hGPR30, heterologously expressed in either COS-7 cells (Revankar et 
al., 2005; Bologa et al., 2006; Otto et al., 2008; Dennis et al., 2009) or HEK-293 cells 
(Otto et al., 2008). 
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Figure 3.2: Intracellular expression of both human and rat GPR30 in 
transiently expressing HEK-293 cells.  Representative confocal images illustrating 
HEK-293 cells transiently transfected with tagged human or rat GPR30 cDNA that 
were fixed and stained for GPR30 expression (green) and with organelle markers for 
endoplasmic reticulum (A; KDEL; red) and polymerised actin (B; F-actin; red), 
illustrating the cytoskeleton. Data are representative of at least two individual 
experiments. Scale bars, 10µm 
hGPR30-SEP 
rGPR30-myc 
GPR30 KDEL Merge 
hGPR30-SEP 
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3.2.3: Intracellular localisation of GPR30 is unaltered with specific agonists or 
antagonists  
The localisation of a GPCR to intracellular compartments is atypical; however it is 
feasible that surface expression is very low and undetectable in our system, or it may be 
that GPR30 is functioning as an intracellular receptor. Cell surface expression of the 
human δ-opioid receptor (hδOR) is enhanced by pharmacological chaperones (agonists 
and antagonists of the hδOR), which stabilizes and releases newly synthesised receptors 
from the endoplasmic reticulum (Petäjä-Repo et al., 2002; Leskelä et al., 2007). Newly 
synthesised GPR30 may require pharmacological chaperones for expression at the cell 
surface. Due to the lipophilic nature of GPR30s’ proposed endogenous ligand (E2; 
Muller et al., 1979), this is a reasonable hypothesis. Moreover, GPR30 may be 
constitutively active and require receptor inhibition to enhance cell surface expression 
and prevent constitutive endocytosis. For example, surface expression of heterologously 
expressed cannabinoid receptor type 1 (CB1) is enhanced in cells treated with 
antagonists (Ellis et al., 2006).   
In order to test this, hGPR30-SEP and rGPR30-myc were transiently transfected in 
HEK-293 cells and treated with GPR30 agonists (G1 and E2; 10 nM for both) or 
antagonists (G15 and G36; 1 µM for both) for 30 min or two hours. Confocal 
microscopy revealed that there was no detectable change in the intracellular localisation 
of hGPR30 or rGPR30 after 30 min (data not shown) or two hour (Fig 3.3 A and Fig 3.3 
B) treatment with G1, E2, G15 or G36. Exposure of GPR30 agonists and antagonists  to 
COS-7 cells expressing GPR30-GFP also fails to alter the intracellular localisation in 
studies presented from Eric Prossnitzs’ group (Revankar et al., 2005; Bologa et al., 
2006; Dennis et al., 2009), thereby supporting our findings.  
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Figure 3.3: Exposure of GPR30 ligands does not alter its intracellular 
localisation in transiently expressing HEK-293 cells. Representative confocal 
images illustrating HEK-293 cells expressing either human or rat GPR30 (green) 
and were treated for 2 hours with A) vehicle (0.01% DMSO) or agonists (G1 or E2; 
10nM) or B) vehicle (0.01% DMSO) or antagonists (G15 or G36; 1µM) for GPR30. 
Strong endoplasmic reticulum localisation persists after ligand exposure. Data are 
representative of at least two individual experiments. Scale bars, 10µm. 
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3.2.4: Identifying an antibody suitable for recognizing native rat GPR30 
In order to establish the endogenous localisation of native GPR30 in rat hippocampal 
neurons, an antibody capable of recognising rGPR30 needed to be identified. Here, two 
commercially available polyclonal anti-human GPR30 antibodies were used. The first 
antibody (R + D systems; Catalogue no: AF5534) was derived from recombinant human 
GPR30 with the immunogen directed against residues 1-62 at the N-terminus of 
hGPR30. The second antibody (Abcam; Catalogue no: ab39742) was derived from 
human GPR30 with the immunogen directed against a sequence within residues 350 – 
375, at the C-terminus of hGPR30. A cartoon illustrating their predicted binding sites 
for hGPR30 is shown in Fig 3.4.  
As previously mentioned, the homology between the N-terminus of hGPR30 and 
rGPR30 is low (55% sequence identity; Fig 3.1). Whereas, sequence alignment of 
residues 350 – 375 revealed a 92% sequence identity between hGPR30 and rGPR30 
(Fig 3.1). The specificity of the N-terminal and C-terminal anti-hGPR30 antibodies was 
tested by comparing their localisation against tagged hGPR30-SEP and rGRP30-myc, in 
transiently transfected HEK-293 cells (Fig 3.5).  
Specific GPR30-immunostaining (anti-hGPR30 N-terminal antibody) was detected only 
in cells transfected with hGPR30-SEP, which almost completely co-localised with 
hGPR30-labelling. In contrast, anti-GPR30 immunostaining was absent in cells 
transfected with rGPR30-myc (Fig 3.5A). Conversely, in cells treated with the anti-
GPR30 C-terminal antibody specific labelling was observed in cells transfected with 
either hGPR30-SEP or rGPR30-myc (Fig 3.5B). Importantly, anti-GPR30 C-terminal 
immunostaining completely co-localised with labelling from hGPR30-SEP (yellow; top 
panel) and rGPR30-myc (yellow; bottom panel).  
These results suggest that the C-terminal anti-GPR30 antibody (Abcam) is more 
suitable for identifying endogenous GPR30 in rat tissue. 
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Figure 3.4: Cartoon representation of predicted binding sites for anti 
hGPR30 antibodies. The cartoon depicts the predicted binding sites of the two 
commercial anti-hGPR30 antibodies.  
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Figure 3.5: Characterisation of two commercial anti-hGPR30 antibodies. 
Representative confocal images illustrating HEK-293 cells expressing hGPR30-SEP 
or rGPR30-myc (green) and treated with anti-hGPR30 antibodies (red) directed 
against A) the N-terminus (R+D systems) or B) the C-terminus (Abcam). Only the 
C-terminus antibody was able to detect rGPR30. Data are representative of two 
individual experiments. Scale bars, 10µm. 
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3.2.5: GPR30 staining in primary rat hippocampal cultures. 
Heterologous expression systems with tagged proteins of interest are useful in 
identifying potential endogenous function and localisation; however the environment of 
the host cell is not likely to represent the endogenous environment (intracellularly or 
extracellularly).  
Previous studies using immunohistochemistry have identified GPR30 immunoreactivity 
in cells within the rat (Brailoiu et al., 2007) and mouse (Hazell et al., 2009) 
hippocampal formation. In order to confirm GPR30 expression in hippocampal tissue, 
the C-terminal anti-GPR30 antibody (Abcam) was utilised for staining in primary rat 
hippocampal cultures (DIV 8 – 14). In order to distinguish between neuronal and non-
neuronal cells, co-staining with an antibody for microtubule associated protein-2 
(MAP2; red; Izant and McIntosh, 1980; Dehmelt and Halpain, 2005) was utilised. In 
addition to being used to identify neurons, anti-MAP2 can be used as a soma / dendritic 
marker, thus giving insight into distribution of native GPR30 within different neuronal 
compartments.  
Figure 3.6 illustrates GPR30 staining (green) in both neuronal (MAP2-positive; top 
panel) and non-neuronal (MAP2-negative; bottom panel) cell types. This is in 
agreement with other studies suggesting that GPR30 protein is expressed in rat 
hippocampal neurons (Funakoshi et al., 2006; Brailoiu et al., 2007; Matsuda et al., 
2008; Akama et al., 2013) and in glia (Blasko et al., 2009; Hirahara et al., 2013).  
The staining pattern for GPR30 appears to be intracellular, largely within the soma and 
perhaps associated with perinuclear organelles (Fig 3.6). Thus further co-staining 
studies were conducted to determine the exact intracellular localisation for GPR30 (see 
Fig 3.7).  
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Figure 3.6: GPR30 expression in primary rat hippocampal cultures.  
Representative single plane confocal images illustrating GPR30 immunoreactivity 
(green) in DIV 14 hippocampal cultures. MAP2 immunostaining (red) was used 
to identify neuronal versus non-neuronal cells.  The staining pattern of GPR30 
staining in both neuronal and non-neuronal cells is intracellular and appears to be 
largely perinuclear. Data are representative of at least two individual experiments 
from cultures of different animals. Scale bars represent 10µm.  
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3.2.6: Cellular localisation of GPR30 in primary rat hippocampal cultures. 
If GPR30 does have a role in mediating fast, non-genomic effects of estradiol on 
hippocampal synaptic transmission, one would speculate that cellular expression would 
be at or near synapses. However, previous studies using electron microscopy to 
establish the cellular localisation in hippocampal neurons yielded conflicting results. 
With groups reporting the localisation of GPR30 within intracellular compartments in 
CA3 pyramidal neurons (Matsuda et al., 2008) and conversely a plasma-membrane 
associated localisation in CA2 pyramidal neurons (Funakoshi et al., 2006).  
Thus, to identify the specific localisation of GPR30 staining in hippocampal cultures, 
co-staining with cellular markers for the endoplasmic reticulum (anti-KDEL), trans-
Golgi network (anti-TGN46), cytoskeleton (Alexa fluor-546 conjugated phalloidin) and 
synapses (anti-synapsin-1) were utilised (Fig 3.7).  Hippocampal GPR30 staining did 
not co-localise with the markers for the endoplasmic reticulum (KDEL), cystoskeleton 
(F-actin) or synapses (synapsin-1). However, almost complete co-localisation was 
observed when co-stained with the trans-Golgi network marker (TGN46), a localisation 
which is in agreement with a report by Matsuda et al. (2008). 
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Figure 3.7: GPR30 co-localises with TGN46 in cultured hippocampal neurons. 
Representative single plane confocal images illustrating GPR30 immunoreactivity 
(green) and co-staining with the subcellular markers KDEL, TGN46, F-actin or 
synapsin-1 (red) in DIV 8 – 14 cultured hippocampal neurons. Almost complete co-
localisation of GPR30 labelling is observed with TGN46 (a trans-Golgi network 
marker). Data are representative of at least three experiments from cultures of 
different animals. Scale bars represent 10µm.  
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3.2.7: GPR30 localisation in hippocampal neurons is not altered after treatment 
with specific GPR30 agonists and antagonists. 
In order to establish whether endogenous neuronal rat GPR30 requires pharmacological 
chaperones for its surface expression, primary hippocampal cultures (DIV 8 – 12) were 
treated with GPR30 agonists (G1 and E2; both 10 nM) or antagonists (G15 and G36; 
both 1 µM) for 30 min or two hours. After fixation and permeabilisation the cultures 
were stained with the anti-MAP2 antibody (red) and the C-terminal anti-hGPR30 
antibody (green). Confocal microscopy revealed that there was no detectable change in 
the intracellular localisation of GPR30 after 30min (data not shown) or two hours 
treatment with ligands (Fig 3.8 A and 3.8 B).  
 
 
 
 
 
 
Figure 3.8: Treatment with ligands for GPR30 does not alter GPR30 
localisation in hippocampal cultures. Representative confocal images of GPR30 
expression (green) in hippocampal neurons that were treated for 2 hours with A) 
vehicle (0.01% DMSO) or agonists (G1 or E2; 10nM) or B) vehicle (0.01% DMSO) 
or antagonists (G15 or G36; 1µM) for GPR30. Staining for MAP2 is illustrated in 
red. Data are representative of at least two individual experiments. Scale bars, 10µm. 
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3.3: Discussion 
These data indicate that when expressed in a heterologous system the localisation of 
hGPR30 and rGPR30 is associated with intracellular regions of the cell. Dual-labelling 
studies suggest that GPR30 expression is likely to be localised to the endoplasmic 
reticulum. Moreover, the localisation of hGPR30 and rGPR30 in this system is 
unaltered following exposure to specific GPR30 agonists or antagonists. Conversely in 
native hippocampal neurons, GPR30 localisation is restricted to the TGN, and this 
expression pattern is also unaltered following treatment with specific GPR30 agonists 
and antagonists.  
The finding that GPR30 is expressed intracellulary contrasts with the more typical 
expression of Class A GPCRs at the plasma membrane (as reviewed in Vischer et al., 
2011; Magalhaes et al., 2012). A predominantly intracellular localisation of GPR30 also 
contradicts the classic idea that GPCRs function to quickly relay information from 
extracellular signals. However, the putative endogenous ligand for GPR30 (E2) is 
lipophilic and can readily pass through the plasma membrane (Muller et al., 1979) and 
functional intracellular GPCRs can be expressed at intracellular sites (For reviews see: 
Gobeil et al., 2006; Boivin et al., 2008; Tadevosyan et al., 2012).   
 
3.3.1: GPR30 intracellular localisation in heterologous expression systems. 
This study is the first report to compare the localisations of hGPR30 and rGPR30 in a 
heterologous expression system. These data indicate that both hGPR30 and rGPR30 are 
expressed at the endoplasmic reticulum, suggesting that despite clear differences in N-
terminal sequences, both species orthologs are directed to the same intracellular 
compartment in this expression system (Fig 3.2).  
There are a number of possibilities why GPR30 expression is restricted to the 
endoplasmic reticulum in HEK-293 cells. Firstly, generation of fluorescently-tagged 
chimeric constructs (N- or C- terminal) can influence the surface expression and 
function of a native protein. For example, epitope or chimeric tagging of hGnRH 
receptors can misroute this receptor to the plasma membrane (Brothers et al., 2003) and 
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N-terminally tagged GFP-CB1R chimeras are restricted to the endoplasmic reticulum 
(McDonald et al., 2007a). Thus, it is feasible that the C-terminal tags attached to 
hGPR30 and rGPR30 prevent delivery of GPR30 to the plasma membrane in our 
heterologous expression system. Moreover, the host cell type systems may also 
influence surface expression and function of a protein (Jiang et al., 2012). Indeed, these 
caveats have been attempted to be resolved by a number of groups. For example, 
Funakoshi and colleagues illustrated that GFP tagged GPR30 accumulates within the 
endoplasmic reticulum, whereas GPR30 was expressed at the surface when tagged with 
a smaller epitope (-FLAG) in HeLa cells (Funakoshi et al., 2006). However, using the 
same GPR30-FLAG construct in HeLa cells, Matsuda et al. (2008) failed to replicate 
the findings of Funakoshi and co-workers (2006), and only observed an intracellular 
expression profile for GPR30 (Matsuda et al., 2008). Moreover, Otto et al., (2008) 
consistently observed an intracellular localisation of GPR30 when comparing GFP N- 
and C- terminus tagged GPR30 with untagged GPR30 in COS-7 and HEK-293 cells, 
suggesting that an epitope tag or the host cell type, does not disrupt the intracellular 
localisation of GPR30 in heterologous expression systems (Otto et al., 2008). 
Recent advances in the field suggest the redundancy of using the overexpressing 
heterologous system in assays attempting to determine plasma-membrane associated 
GPR30 function. Indeed, Cheng and colleagues demonstrated that only very low levels 
of N-terminal HA tagged GPR30 (HA-GPR30) are observed in the plasma membrane of 
stably expressing HEK-293 cells; that the receptor undergoes fast constitutive 
endocytosis (whereby surface GPR30 is internalised within 30 min without ligand 
stimulation) and surface (HA-tagged) GPR30 is subsequently degraded quickly (half-
life < 30 min) (Cheng et al., 2011b). Their data suggest that the receptor does have the 
capacity to reach the surface; however levels are very low and are unstable. Thus, if 
GPR30 is a functional membrane associated estrogen-sensitive receptor, one would 
speculate that mechanisms would be put in place in order to conserve energy (ie: why 
would the cell expend energy producing and exporting the receptor to the cell surface, 
where it is not stable and is readily sent for degradation?). A consideration was perhaps 
the requirement for pharmacological chaperones; although results presented here 
suggest that this may not be the case (Fig 3.3), we cannot rule out the possibility that the 
ligands used here are not specific for GPR30. Indeed, the synthetic ligands developed 
for GPR30 have been suggested to specifically bind to the ERα variant, ERα-36, and not 
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GPR30 (Kang et al., 2010). In addition, it has been suggested that aldosterone is the 
endogenous agonist for GPR30 and that eplerenone (a minerocorticoid receptor 
antagonist) can act as a partial antagonist for GPR30-mediated effects (at least in 
vasculature) (Gros et al., 2011).  
Another consideration is that GPR30 contains an endoplasmic retention signal that 
restricts export for surface expression. Association with an interacting protein or another 
GPCR may mask such a sequence. Examination of both hGPR30 and rGPR30 
sequences reveals that they have two conserved RXR endoplasmic reticulum retention 
motifs in the third cytoplasmic loop (at residues 246 – 248 and 251 – 253). Functional 
RXR signals can be found in a variety of cytosolic positions, including intracellular 
loops in transmembrane proteins (Zerangue et al., 1999). Endoplasmic reticulum 
retention sequences can be masked by interacting proteins, which conveys importance 
for function. For example mutating the RKR sequence in SUR1, a β subunit that forms 
part of the ATP-sensitive potassium ion channel that is not expressed at the cell surface 
as a monomer, results in surface expression (Zerangue et al., 1999). This holds true for 
GPCRs as well, as the surface expression of GABAB1 is dependent on the masking of its 
RKR endoplasmic reticulum retention motif by interaction with GABAB2 (Pagano et al., 
2001). 
GPR30 may indeed express a functional endoplasmic reticulum retention sequence, 
which would require masking before export. However, RXR-dependent ER retention 
machinery is sensitive to the length between the RXR signal and transmembrane 
domains (Shikano and Li, 2003). Although the third intracellular loop of GPR30 is the 
largest of the three, these RXR retention signals may not be functional in this respect. 
For example, in GABAB1 receptors the RXR endoplasmic reticulum retention sequence 
was only functional within the cytoplasmic tail and not in any of the intracellular loops, 
when grafted to ectopic sites (Gassmann et al., 2005). Site directed mutagenesis of 
GPR30 at its RXR sites could resolve this and may also give insight as to whether a 
protein-protein interaction is needed for stable surface expression of GPR30.  
To support this idea, evidence is emerging to suggest that GPR30 does indeed associate 
with other proteins, which may encourage surface expression or stabilise the receptor at 
the surface, depending on the endogenous setting. For example GPR30 can associate 
with RAMP-3 in heart tissue of female mice  (Lenhart et al., 2013) and PSD-95 in 
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murine hippocampal neurons (Akama et al., 2013). Moreover, co-expression of murine 
PSD-95-FLAG and HA-GPR30 significantly increases the proportion of HA-GPR30 
expressed at the cell surface in COS-7 cells (Akama et al., 2013).  
It is worth noting that in breast cancer cells, endogenous expression of GPR30 is 
predominately intracellular (Revankar et al., 2005; Bologa et al., 2006; Filardo et al., 
2006; Otto et al., 2008; Lin et al., 2009), whereas GPR30 expression is predominantly 
expressed at the plasma membrane in renal epithelia (Lindsey et al., 2011) and in 
Atlantic croaker oocytes (Pang et al., 2008). Thus, considering the evidence, it is 
plausible that the functional localisation of GPR30 (whether it be intracellular or plasma 
membrane associated), is determined by the endogenous cell type.  
 
3.3.2: localisation of GPR30 in primary rat hippocampal neurons 
However, as with the debate regarding the cellular distribution of hGPR30 in 
heterologous and endogenously expressing breast cell lines, there are also 
inconsistencies within the literature regarding the cellular localisation of GPR30 within 
the rodent central nervous system. For example, using electron microscopy and 
ultrastructure analysis, two independent groups published contradictory findings within 
hippocampal tissue. Funakoshi and co-workers reported GPR30 immunoreactivity at the 
plasma membrane (soma) of CA2 pyramidal neurons with no expression in the 
endoplasmic reticulum (Funakoshi et al., 2006). Whereas in a report from Matsuda and 
colleagues (2008), GPR30 immunoreactivity was absent at the plasma membrane in 
neurons of the CA3 and rather associated with membrane structures of the Golgi 
apparatus and endoplasmic reticulum (Matsuda et al., 2008). Thus, in order to attempt 
to resolve the issue and determine the distribution of GPR30 in our primary 
hippocampal cultures, an antibody capable of recognising rGPR30 was utilised (Fig 
3.5).  
In agreement with Mastuda et al. (2008), our data show GPR30 labelling in primary 
hippocampal cultures is associated with the intracellular TGN compartment as GPR30 
positive staining co-localised with the TGN marker, TGN46 (Fig 3.7). Matsuda et al. 
(2008) also identified GPR30 immunoreactivity in membranes of vesicles localised in 
the dendritic shafts of CA3 neurons. However, as we only found evidence for GPR30 
associated with TGN around the nucleus, this may reflect limitations of using confocal 
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microscopy to visualise very low levels of endogenous receptor expression, or 
limitations of the antibody used (see below).  
Other groups who utilise confocal microscopy have also reported intracellular 
localisation of GPR30 in other neuronal cell types. For example, GPR30 co-localises 
with TGN38 in magnocellular oxytocin neurons in the paraventricular and supraoptic 
nuclei of the rat hypothalamus (Sakamoto et al., 2007), GPR30 is also detected within 
the cytoplasm of primary rat cortical cultures (Liu et al., 2012) and at the endoplasmic 
reticulum and Golgi in rat lumbar dorsal root ganglion (DRG) neurons (Takanami et al., 
2010). In all studies detecting intracellular expression, antibodies directed against the C-
terminal region of human GPR30 were used. Thus it is possible that these antibodies 
may be recognising a form of GPR30 (precursor or ubiquitnated) that is not functionally 
relevant. This is a feasible hypothesis as the endoplasmic reticulum is the site for 
protein translation and Cheng et al., (2011) demonstrated that the TGN serves as a 
checkpoint for GPR30 degradation.  If this is the case, then true functional endogenous 
localisation is not able to be determined with these tools.  
Nevertheless, an intracellular localization of GPR30 is consistent with its function as an 
estrogen receptor. Moreover, endogenous intracellular GPR30 is capable of cellular 
signalling (Revankar et al., 2007). Using a range of cell permeable and impermeable 
charged E2 derivatives, Revankar and co-workers (2007) observed that only with cell 
permeable E2 derivatives were SKBr3 cells (ERα/β –VE, GPR30 +VE) capable of PIP3 
production. 
Although an intracellular (particularly, perinuclear) localisation in hippocampal neurons 
is not consistent with the hypothesis that GPR30 may be involved in rapid non-genomic 
effects of estradiol at excitatory synapses, results from this chapter support evidence for 
hippocampal expression of GPR30, thus further investigation into the role GPR30 may 
have on hippocampal function is warranted. Interestingly, a very recent report illustrated 
using electron microscopy, GPR30 labelling in the peri-synaptic zone adjacent to the 
post-synaptic density (PSD) in a variety of different dendritic spine profiles in adult rat 
CA1 (Akama et al., 2013). Additionally, this group found that GPR30 directly 
associates with a PSD protein, PSD-95, in vitro and in vivo.  
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Chapter Four 
 
Effects of E2 and a GPR30 agonist on 
hippocampal excitatory synaptic 
transmission 
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4.1: Introduction  
There is overwhelming evidence suggesting that GPR30 is expressed within the 
hippocampus and results from the previous chapter support this (O’Dowd et al., 1998; 
Funakoshi et al., 2006; Brailoiu et al., 2007; Matsuda et al., 2008; Dun et al., 2009; 
Hazell et al., 2009; Isensee et al., 2009 and see section 3.2.5). Recent ultra-structural 
analysis indicating GPR30 localisation at CA1 synapses also suggests that this receptor 
is well positioned to mediate fast estrogenic effects on hippocampal excitatory synaptic 
transmission (Akama et al., 2013).  
Ideally, in order to establish whether GPR30 has a role in the non-genomic actions of 
E2 on hippocampal excitatory synaptic transmission, knockout animals would be 
utilised. Although there are four GPR30 knockout animals already described (see 
section 1.3.6), a well-established mutant is not currently available for examining GPR30 
function. Therefore, the GPR30 field relies on pharmacological tools in conjunction 
with receptor knockdown to examine function. 
Nevertheless, since the generation of a selective agonist for GPR30 (G1; Bologa et al., 
2006; see section 1.3.4), numerous groups have speculated roles for GPR30 as a 
mediator of a number of different estrogenic effects within the hippocampus (Hammond 
et al., 2009; Lebesgue et al., 2009, 2010; Gingerich et al., 2010; Kajta et al., 2013; 
Ruiz-Palmero et al., 2013). However, a thorough examination of the effects of the 
GPR30 agonist (G1) on hippocampal excitatory synaptic transmission has not yet been 
conducted. Thus in order to characterise the effects of G1, extracellular field potential 
recordings (fEPSPs) were used to monitor excitatory synaptic transmission at Schaffer-
collateral – CA1 synapses in hippocampal slices from male rodents.  
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4.2: Results 
4.2.1:  G1 induces LTD in juvenile male hippocampal slices under conditions of 
enhanced excitability.  
G1 (1 µM; 20 min) was applied to juvenile (P11 – P18) hippocampal slices in order to 
establish whether activation of GPR30 had any effect on basal hippocampal excitatory 
synaptic transmission (Fig 4.1). During G1 application the magnitude of synaptic 
transmission was unaltered (100 ± 5.7% of baseline; n = 4), although a small depression 
of synaptic transmission was observed after 40 min of drug washout (to 92 ± 4.5 % of 
baseline), these effects were not significant (p > 0.05; one-way repeated measures 
ANOVA).  
Under basal conditions, there is a strong voltage-dependent block of NMDAR by Mg
2+
 
(Mayer et al., 1984; Ascher et al., 1988). Removing this blockade (by means of 
reducing extracellular Mg
2+
 content) enhances NMDAR-mediated events and increases 
overall excitability. Indeed, studies in our laboratory have established that under 
conditions of enhanced excitability, significant effects of hormonal modulators on 
synaptic transmission can be uncovered. Specifically, leptin can induce LTD in the CA1 
region of P11 – P18 rats, when slices are perfused with Mg2+ free aCSF or the GABAA 
receptor antagonist, picrotoxin (Durakoglugil et al., 2005).  
Therefore, hippocampal slices (P11 – 18) were perfused with low Mg2+ aCSF (0.1 mM; 
Fig 4.2). Within 10 min of G1 (1 µM) application, synaptic transmission quickly started 
to depress and significant depression of synaptic transmission (to 71 ± 3.7% of baseline; 
p < 0.001; n = 5; t = 7.461; 4 degrees of freedom) was reached 20 min post G1 washout 
and was sustained for the duration of recordings (a further 20 min). These data suggest 
that under conditions of increased excitability, G1 can induce LTD in juvenile 
hippocampal slices. However, it must be noted that there are caveats in using tissue 
from juvenile animals (P11 – P18). A large number of developmental changes in 
receptors mediating excitatory synaptic transmission, and estrogen-mediated 
physiology, are occurring during this time window. Moreover, mechanisms for inducing 
and maintaining synaptic plasticity differ in adult tissue.  
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Figure 4.1: 1 µM G1 has no effect on basal excitatory synaptic transmission in 
juvenile male hippocampal slices.  A, representative experiment showing G1 (1 
µM; 20 min) application has no effect on basal excitatory synaptic transmission. 
Top, example traces from the experiment are shown at the time points indicated. B, 
data pooled (n = 4) and normalised with respect to baseline are expressed as mean ± 
SEM. NS represents p > 0.05 vs. baseline; one-way repeated measures ANOVA.  
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NS 
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Figure 4.2: Under conditions of enhanced neuronal excitability, 1 µM G1 
induces LTD in juvenile male hippocampal slices.  A, representative experiment 
showing G1 (1 µM; 20 min) application induces LTD in low Mg
2+
 aCSF. Top, 
example traces from the experiment are shown at the time points indicated. B, data 
pooled (n = 5) and normalised with respect to baseline are expressed as mean ± 
SEM. *** represents p < 0.001 vs. baseline; paired t-test.   
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4.2.2:  Estradiol has variable effects on basal excitatory post-synaptic transmission 
in adult male hippocampal slices.  
Thus, in order to overcome the caveats of using juvenile tissue, hippocampal slices from 
adult (12 – 20 weeks) male rats were utilized in the following experiments (Fig 4.3 
onwards). In the adult male model, hormonal systems are fully developed and stable (as 
reviewed in McCarthy, 2008), the influence of circulating estrogens is not an issue and 
acute effects of E2 have been described by others (Teyler et al., 1980; Foy et al., 1999; 
Kramár et al., 2009; Zadran et al., 2009). In this model, GPR30 expression has also 
been observed (Matsuda et al., 2008) and effects of G1 on basal hippocampal excitatory 
synaptic transmission have been revealed, albeit in adult OVX rats (Lebesgue et al., 
2009, 2010).   
Considering the general consensus is that GPR30 is an estrogen-sensitive receptor we 
wanted to establish the effects of its proposed endogenous agonist 17β-estradiol (E2) on 
hippocampal excitatory synaptic transmission. E2 can be synthesised de novo in the 
adult hippocampus, and in gonadally intact adult male rodents hippocampal derived E2 
concentrations reach approximately 8 nM (Hojo et al., 2008, 2009). Thus, E2, at a 
physiologically relevant concentration of 10 nM, was bath applied to hippocampal slices 
from adult male rodents. 
Bath application of E2 (10 nM; 20 min; Fig 4.3) resulted in a transient potentiation of 
synaptic transmission (to 105 ± 1.2 % of baseline after 15 min ligand application; 
F[2,63] = 46.2; p < 0.01; n = 22,). During the 60 min E2 washout phase the magnitude 
of synaptic transmission slowly reduced, where maximal depression of synaptic 
transmission was revealed at the end of washout (to 89 ± 1.6 % of baseline, F[2,63] = 
46.2;  p < 0.001, n = 22).  
However, it was noted that not all of the slices exhibited a transient potentiation in 
synaptic transmission in response to E2 application (10 nM; 20 min). Moreover, in 
some cases where an E2-induced potentiation was observed a slow-onset depression of 
synaptic transmission following washout was not, but rather the E2-induced enhanced 
magnitude of synaptic transmission was sustained. Indeed, within the published 
literature it has been noted that the potentiating effect of E2 is (in some cases) only 
observed in a proportion of slices or cells tested (see Table A1 in Appendix). Thus, in 
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order to probe further the differing effects of E2 application, data was stratified to 
expose the different response profiles of this agonist (see 2.2.5.3 in Methods).    
Out of 22 slices that were exposed to E2 (10 nM; 20 min), 12 slices (55%) showed a bi-
phasic response profile (Fig 4.4). In this group, application of E2 induced an initial 
increase in excitatory synaptic transmission (to 107 ± 1.0% of baseline within 10 min of 
ligand application; F[2,35] = 108.3; p < 0.001; n = 12). Following E2 washout a slow-
onset long-lasting depression of synaptic transmission was revealed, where maximal 
depression (87 ± 1.5 % of baseline; F[2,35] = 108.3; p < 0.001; n = 12) was obtained 
approximately 50 min after E2 removal. In 6 out of 22 slices (27%) application of E2 
failed to induce an increase in synaptic transmission (98 ± 1.5 % of baseline after 15 
min E2 application; p > 0.05; n = 6; Fig 4.5). However, following E2 removal a slow-
onset but sustained depression of synaptic transmission was observed (to 89 ± 2.7% of 
baseline; F[2,17] = 11.0; p < 0.05; n = 6). This magnitude of E2-induced synaptic 
depression was not significantly different from the magnitude of synaptic depression 
elicited in slices which show a bi-phasic response profile (p > 0.05; Kruskal-Wallis 
One-way ANOVA on Ranks). In the remaining four slices (18%; Fig 4.6) an E2-
induced increase in synaptic transmission was observed, which was sustained for up to 
40 min following washout (to 110 ± 3.0 % of baseline; F[2,11] = 6.3;  p < 0.05; n = 4; 
Fig 4.6).  
These results suggest that treatment with E2 can induce bi-directional response profiles. 
The most consistent response observed was the induction of a slow-onset long lasting 
depression of synaptic transmission (E2-induced LTD). This effect was seen in 18 out 
of 22 slices (82 %) and correlates well with previous studies in the laboratory that also 
observed a novel form of LTD induced by E2 in adult hippocampal slices treated with 
0.1mM Mg
2+ 
 (Moult and Findlay, unpublished observation).  
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Figure 4.3: E2 evokes a bi-phasic effect on basal synaptic transmission in adult 
male hippocampal slices.  A, E2 (10 nM; 20 min) application transiently potentiates 
synaptic transmission, followed by a slow onset reduction in synaptic transmission 
following washout. Data are pooled (n = 22 slices) and normalised with respect to 
baseline are expressed as mean ± SEM. ** represents p < 0.01 vs. baseline, *** 
represents    p < 0.001 vs. baseline; one-way repeated measures ANOVA followed 
by tukey post-hoc analyses. 
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Figure 4.4: In a proportion of slices E2 evokes a bi-phasic effect on basal 
synaptic transmission.  A, representative experiment showing E2 (10 nM; 20 min) 
application transiently potentiates synaptic transmission, followed by a long-lasting 
reduction in synaptic transmission upon E2 washout. Top, example traces from the 
experiment are shown at the time points indicated. B, data pooled (n = 12 out of 22 
slices) and normalised with respect to baseline are expressed as mean ± SEM. *** 
represents    p < 0.001 vs. baseline; one-way repeated measures ANOVA followed 
by tukey post-hoc analyses. 
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Figure 4.5: E2 induces LTD without a preceding potentiation of synaptic 
transmission in a subset of experiments.  A, representative experiment showing E2 
(10 nM; 20 min) application results in a slow onset long-lasting reduction in synaptic 
transmission. Top, example traces from the experiment are shown at the time points 
indicated. B, data pooled (n = 6 out of 22) and normalised with respect to baseline 
are expressed as mean ± SEM. * represents p < 0.05 vs. baseline; one-way repeated 
measures ANOVA followed by tukey post-hoc analyses. 
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Figure 4.6: E2 induces a long-lasting potentiation of synaptic transmission in a 
subset of experiments.  A, representative experiment showing E2 (10 nM; 20 min) 
application results in a sustained increase in synaptic transmission. Top, example 
traces from the experiment are shown at the time points indicated. B, data pooled (n 
= 4 out of 22) and normalised with respect to baseline are expressed as mean ± SEM. 
* represents p < 0.05 vs. baseline; one-way repeated measures ANOVA followed by 
tukey post-hoc analyses. 
n = 4 / 22 slices 
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4.2.3:  Effects of the GPR30 agonist on excitatory synaptic transmission in adult 
male hippocampal slices.  
In the next series of experiments the effects of the selective GPR30 agonist (G1) on 
hippocampal excitatory synaptic transmission were examined in order to establish 
whether the effects of this agonist mimicked those of E2. Although G1 has a similar 
binding affinity for GPR30 as E2 (Ki ~ 6nM for E2 vs. Ki = 11nM for G1; Revankar et 
al., 2005; Bologa et al., 2006), initial studies examined the effects of applying a low 
concentration of G1 (1 nM; 20 min) to adult hippocampal slices. At this concentration 
however, G1 had no effect on basal excitatory synaptic transmission such that the 
magnitude of evoked synaptic responses remained unchanged during drug application 
(102 ± 1.1% of baseline; p > 0.05; n=5; Fig 4.7) and after 60 min of washout (98 ± 3.0% 
of baseline; p > 0.05; n = 5).  
Due to the lack of effect at 1 nM, the concentration of G1 was increased. Application of 
G1 at 10 nM (20 min; Fig 4.8) elicited a transient but not significant potentiation in 
synaptic transmission (to 105 ± 2.3 % of baseline; p = 0.078; n = 27) followed by a 
slow-onset depression of synaptic transmission during G1 washout. The magnitude of 
the G1-induced depression peaked approximately 40 min after G1-washout (to 89 ± 2.5 
% of baseline; F[2,80] = 27.4; p < 0.001; n = 27). In a manner similar to E2, it was 
noted that application of G1 at this concentration resulted in differing response profiles, 
thus data was stratified in order to further investigate these (see 2.2.5.3 in Methods). 
Out of the 27 slices that were exposed to G1 at 10 nM (20 min), a bi-phasic response 
profile was evident in 12 slices (44%) (Fig 4.9). In this group, application of G1 induced 
an initial increase in excitatory synaptic transmission (to 110 ± 1.4% of baseline within 
15 min of G1 application; F[2,35] = 67.6; p < 0.001; n = 12). Following G1 removal, 
synaptic transmission quickly began to decrease and a sustained depression of synaptic 
transmission was observed approximately 40 min after G1 washout (to 88 ± 2.0 % of 
baseline; F[2,35] = 67.6; p < 0.001; n = 12). Exposure to G1 (10 nM; 20 min) in another 
12 out of 27 slices (44%), elicited only a slow-onset depression of excitatory synaptic 
transmission. Specifically, during G1 application there was no significant difference in 
the magnitude of synaptic transmission (95 ± 2.1 % of baseline during G1 application; p 
> 0.05; Fig 4.10), whereas by the end of the 60 min washout period, synaptic 
transmission was significantly reduced to 84 ± 2.8% of baseline (F[2,35] = 21.4; p < 
0.001; n = 12). In a manner similar to E2, G1-induced an increase in synaptic 
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transmission in a subset of experiments (3 out of 27 slices; 11%); an effect that was 
sustained for up to 40 min following G1 washout, however due to variability and a low 
number of replicates, this effect was not significant (to 111 ± 6.0 % of baseline; p > 
0.05; Fig 4.11). 
In order to establish whether there are concentration-dependent effects of G1 at this 
synapse, a higher concentration (100 nM) of G1 was also examined. Here we find that 
exposure to 100 nM (20 min) results in a biphasic response profile (n = 6), exposure to 
100 nM results in a rapid and significant potentiation of synaptic transmission (to 110 ± 
2.8 % of baseline; F[2,16] = 36.0; p < 0.05; n = 6; Fig 4.12), followed by a slow onset 
depression of synaptic transmission which peaked 50 min after G1 washout (to 90 ± 1.3 
% of baseline; F[2,16] = 36.0; p < 0.05; n = 6). After data was subjected to 
stratification, it was found that out of the 6 slices that were exposed to 100 nM G1 (20 
min), 4 slices exhibited a bi-phasic response profile (67%). Application of 100 nM G1 
induced a rapid and significant potentiation of synaptic transmission (to 112 ± 3.8 % of 
baseline; F[2,11] = 32.1; p < 0.05; n = 4; Fig 4.13); a magnitude which was not 
significantly different to that evoked at 10 nM G1 which induced a biphasic response 
profile (110 ± 1.4% of baseline for 10 nM G1; p > 0.05; n = 12; one-way ANOVA on 
ranks followed by Dunns’ post-hoc analysis). The G1-induced enhancement was 
followed by a slowly developing reduction of synaptic transmission that peaked 40 min 
after G1 washout (to 90 ± 1.7 % of baseline; n = 4; F[2,11] = 32.1; p < 0.05). Moreover, 
the magnitude of the synaptic depression induced by 100 nM G1 was not significantly 
different to that observed in response to 10 nM G1 application which was preceded by 
an enhancement of synaptic transmission (88 ± 2.0 % of baseline for 10 nM G1; p > 
0.05; one-way ANOVA on ranks followed by Dunns’ post-hoc analysis). Of the two 
remaining slices examined, exposure to 100 nM G1 induced only a slow-onset sustained 
depression of synaptic transmission in one slice (Fig 4.14 A) and in the other, a long-
lasting increase in synaptic transmission in response to 100nM G1 application was 
observed (Fig 4.14 B).  
These results suggest that the GPR30 agonist, G1, like E2, can induce three different 
effects on hippocampal synaptic transmission: A transient potentiation followed by 
LTD; LTD in the absence of prior potentiation and a sustained increase in synaptic 
transmission. Moreover, the magnitude of the depression elicited by G1 (10 nM – 100 
nM) was not significantly different between the different response profiles (Fig 4.15).  
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Figure 4.7: 1 nM G1 has no effect on basal synaptic transmission in adult male 
hippocampal slices.  A, representative experiment showing G1 (1 nM; 20 min) 
application does not alter basal excitatory synaptic transmission. Top, example traces 
from the experiment are shown at the time points indicated. B, data pooled (n=5) and 
normalised with respect to baseline are expressed as mean ± SEM. NS represents a 
non-significant ANOVA (p > 0.05); One-way repeated measures ANOVA.  
A 
B 
NS 
89 
 
 
Time (min)
0 20 40 60 80 100
fE
P
S
P
 S
lo
p
e 
(%
 b
a
se
li
n
e)
0
60
80
100
120 10nM G1
Figure 4.8: 10 nM G1 elicits a bi-phasic effect on basal synaptic transmission in 
adult male hippocampal slices.  A, G1 (10 nM; 20 min) application transiently 
potentiates excitatory synaptic transmission, followed by a reduction in synaptic 
transmission after washout. Data are pooled (n = 27) and normalised with respect to 
baseline and are expressed as mean ± SEM. NS represents p > 0.05 vs. baseline; *** 
represents p < 0.001 vs. baseline; one-way repeated measures ANOVA and Tukey 
post-hoc analysis. 
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Figure 4.9: In a proportion of slices 10 nM G1 elicits a bi-phasic effect on basal 
synaptic transmission.  A, representative experiment showing G1 (10 nM; 20 min) 
application transiently potentiates excitatory synaptic transmission, followed by a 
reduction in synaptic transmission after washout. Top, example traces from the 
experiment are shown at the time points indicated. B, data pooled (n = 12 out of 27) 
and normalised with respect to baseline are expressed as mean ± SEM. *** 
represents p < 0.001 vs. baseline; one-way repeated measures ANOVA and Tukey 
post-hoc analysis. 
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Figure 4.10: 10 nM G1 induces LTD without a preceding potentiation of 
synaptic transmission.  A, representative experiment showing G1 (10 nM; 20 min) 
application results in a slow onset long-lasting reduction in synaptic transmission. 
Top, example traces from the experiment are shown at the time points indicated. B, 
data pooled (n = 12 out of 27) and normalised with respect to baseline are expressed 
as mean ± SEM. *** represents p < 0.001 vs. baseline; one-way repeated measures 
ANOVA and Tukey post-hoc analysis. 
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Figure 4.11: 10 nM G1 induces a long-lasting potentiation of synaptic 
transmission in a subset of experiments.  A, representative experiment showing G1 
(10 nM; 20 min) application results in a sustained increase in synaptic transmission. 
Top, example traces from the experiment are shown at the time points indicated. B, 
data pooled (n = 3 out of 27) and normalised with respect to baseline are expressed 
as mean ± SEM. NS represents p > 0.05; a non-significant ANOVA.  
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Figure 4.12: 100 nM G1 has a bi-phasic effect on basal synaptic transmission in 
adult male hippocampal slices.  A, Data pooled (n = 6) and normalised with respect 
to baseline are expressed as mean ± SEM. * represents p < 0.05 vs. baseline; one-
way repeated measures ANOVA followed by Tukey post-hoc analysis. 
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Figure 4.13: In a proportion of slices 100 nM G1 has a bi-phasic effect on basal 
synaptic transmission.  A, representative experiment showing G1 (100 nM; 20 min) 
application transiently potentiates excitatory synaptic transmission, followed by a 
long-lasting reduction in synaptic transmission. Top, example traces from the 
experiment are shown at the time points indicated. B, data pooled (n = 4 out of 6) 
and normalised with respect to baseline are expressed as mean ± SEM. * represents p 
< 0.05 vs. baseline; one-way repeated measures ANOVA followed by Tukey post-
hoc analysis. 
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Figure 4.14: 100 nM G1 can also induce a sustained depression or a sustained 
potentiation of synaptic transmission in a proportion of slices.  A, Experiment 
illustrating G1 (100 nM; 20 min) application induces a depression of synaptic 
transmission (1 out of 6 slices). B, Experiment illustrating (100 nM; 20 min) induces 
a sustained increase in synaptic transmission (1 out of 6 slices).  Top, example traces 
from the experiments are shown at the time points indicated. 
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Figure 4.15: Comparison of the mean magnitudes of depression of synaptic 
transmission elicited by differing concentrations of G1.  Histogram depicts the 
mean ± SEM % of depression of synaptic transmission 50 – 60 min post washout of 
G1 from the different response profiles. There is no significant difference between 
the magnitudes of depression elicited by 10 nM G1 from the biphasic response 
profile, 10 nM depression only profile and 100 nM Biphasic response profiles. NS 
represents p > 0.05 between the magnitudes of the G1-induced depression from 
differing response profiles and concentrations; One-Way ANOVA followed by 
Tukey post-hoc analysis. 
ns ns 
ns 
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4.2.4:  Comparison of the two most prevalent response profiles of E2 and G1.  
In order to compare the time course and magnitude of the effects of both E2 and G1 on 
synaptic transmission, the pooled data were overlayed. Figure 4.16 A illustrates that the 
time course and magnitudes of the bi-phasic response profiles for E2 and G1 are 
comparable. Specifically, the magnitudes of the agonist-induced transient potentiation 
of synaptic transmission are not significantly different from each other (E2: 107 ± 1.0 % 
of baseline, n = 12 / 22 slices; G1: 110 ± 1.4 % of baseline, n = 12 / 27 slices; p > 0.05; 
Kruskal-Wallis one-way ANOVA on ranks). In addition, the magnitudes of the slow-
onset agonist-induced depression of synaptic transmission are not significantly different 
from each other (E2: 87 ± 1.5 % of baseline; n = 12 / 22 slices; G1: 88 ± 2.0 % of 
baseline, n = 12 /22 slices; p > 0.05; Kruskal-Wallis one-way ANOVA on ranks). 
The time course and magnitudes of the slow-onset depression of synaptic transmission 
without a preceding potentiation of synaptic transmission between E2 and G1 are also 
very similar (Fig 4.16 B). Specifically, the magnitudes of the agonist-induced 
depression of synaptic transmission are not significantly different from each other (E2: 
89 ± 2.7 % of baseline, n = 6 / 22; G1: 84 ± 2.8% of baseline, n = 12 / 27; p > 0.05; 
Kruskal-Wallis one-way ANOVA on ranks).Thus, these data would suggest that the 
GPR30 agonist (G1) can mimic the effects of E2 on excitatory synaptic transmission in 
adult male hippocampal slices.  
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
  
Time (min)
0 20 40 60 80 100
fE
P
S
P
 S
lo
p
e 
(%
 b
a
se
li
n
e)
0
60
80
100
120
Bi-phasic E2 (n = 12 / 22 slices)
Bi-phasic G1 (n = 12 / 27 slices)
Agonist
Time (min)
0 20 40 60 80 100
fE
P
S
P
 S
lo
p
e 
(%
 b
a
se
li
n
e)
0
60
80
100
120
Depression E2 (n = 6 / 22 slices)
Depression G1 (n = 12 / 27 slices)
Agonist
Figure 4.16: The GPR30 agonist mimics the effects of E2 on hippocampal 
excitatory synaptic transmission.  A, Plot of pooled data from the preceding 
experiments illustrating the bi-phasic response profile of E2 and G1 (from Fig. 4.4 
B and Fig. 4.9 B)  B, Plot of pooled data from the preceding experiments 
illustrating the depression only response profile of E2 and G1 (from Fig. 4.5 B and 
Fig. 4.10 B). NS represents p > 0.05 between the magnitudes of the E2 and G1 
effects on synaptic transmission at the time points shown, Kruskal-Wallis one-way 
ANOVA on ranks. 
A 
B 
NS 
NS 
NS 
NS 
99 
Summary of findings from Chapter 4, Part I: 
1) In juvenile hippocampal slices, G1 induces a large depression of excitatory 
synaptic transmission under conditions of enhanced excitability (Fig. 4.2). 
2) Acute administration of E2 induces three different response profiles in adult 
male hippocampal slices (Fig 4.4, 4.5 and 4.6). The predominant effect of 
which, is the induction of LTD 
3) In a manner similar to E2, application of G1 evokes three distinct effects on 
synaptic transmission, with the induction of LTD the predominant response 
observed. Moreover, the time-courses and magnitudes of the two most 
prevalent response profiles of E2 are mimicked by the GPR30 agonist, G1 
(Figure 4.16). 
 
 
 
4.3:  Discussion 
4.3.1:  Developmental differences in G1-mediated effects on hippocampal synaptic 
transmission.  
We show here that there are differences in the effects of the GPR30 agonist, G1, on 
hippocampal excitatory synaptic transmission between slices from juvenile (P11 – P18) 
and adult (12 – 20 weeks) rodents. It is not uncommon for hormone modulators of 
hippocampal function to have differing effects across developmental time periods. For 
example exposure to leptin in juvenile hippocampal slices transiently depresses synaptic 
transmission under normal conditions and induces a novel form of LTD in conditions of 
enhanced excitability (Durakoglugil et al., 2005; Moult and Harvey, 2011). Whereas in 
adult tissue, leptin induces a long lasting potentiation of synaptic transmission (Moult et 
al., 2010; Moult and Harvey, 2011). These leptin-induced effects on synaptic 
transmission in juvenile tissue parallel those which we see with G1, as we were unable 
to see significant effects in basal conditions; however in conditions of increased 
excitability a significant depression of synaptic transmission was observed.  
NS 
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Synaptic maturation at CA3 – CA1 synapses occurs during the first two weeks of post-
natal development. Specifically, early in development, synapses are predominantly 
AMPA silent and express the slowly-deactivating GluN1/GluN2B NMDAR complexes, 
facilitating activity-dependant maturation of glutamatergic synapses (shifting from more 
AMPA-silent to un-silent; Pickard et al., 2000). This transition is also accompanied by a 
change in the expression ratio of NMDAR subunits at synapses from predominantly 
GluN1/GluN2B complexes to the more quickly deactivating GluN1/GluN2A complexes 
(Monyer et al., 1992, 1994; Sheng et al., 1994). Developing neurons also have a higher 
pre-synaptic glutamate release probability (Bolshakov and Siegelbaum, 1995; Wasling 
et al., 2004) and the magnitude and ease at which LTD is induced is significantly 
greater in rodents < 3 weeks old (Dudek and Bear, 1993; Milner et al., 2004; Strandberg 
et al., 2009; Strandberg and Gustafsson, 2011). In addition, there is evidence for a 
developmental switch in the mechanisms of mGluR mediated LTD between P8 – P15 
and P21+ rodents (Nosyreva and Huber, 2005).    
Considering we observe an LTD of synaptic transmission in response to G1 in tissue 
from P11 – P18 rodents only in conditions of enhanced NMDAR-mediated synaptic 
transmission, this may suggest that during development, G1-induced effects require 
enhanced NMDAR activity whereas at more mature synapses, G1-induced effects do 
not require enhanced NMDAR activity. This suggests a shift in the mechanisms by 
which G1 can effect glutamatergic synaptic transmission between juvenile and adult 
tissue, and may illustrate a potential role for GPR30 in mediating maturation of 
synapses.  
Moreover, there is a wealth of evidence beginning to emerge suggesting that all aspects 
related to estrogen physiology within the hippocampus are developmentally regulated. 
For example, in rats, hippocampal derived E2 levels peak at birth and gradually decline 
over the first two weeks of postnatal life (Konkle and McCarthy, 2011). Expression of 
key enzymes required for the conversion of PREG to E2 are significantly higher in P10 
male rodents compared to adult and the rate of metabolism from testosterone and E1 to 
E2 is significantly faster in P10 rodents compared to adult (Higo et al., 2009). 
Hippocampal expression levels of StAR, the protein responsible for the rate-limiting 
step or all steroidogenesis also increases throughout the first few weeks of post natal life 
(Kim et al., 2002; Sierra et al., 2003). In addition, expression levels of estrogen 
receptors fluctuate during development. For example there are significant differences in 
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cortical and hippocampal expression levels of the classical ERα between P10 and adult 
rodents (O’Keefe et al., 1995; Solum and Handa, 2001; Kimoto et al., 2010; Wilson et 
al., 2011). Specifically, in the male rodent hippocampus relative mRNA levels of ERα 
(Esr1) only stabilize to constant levels at 4 weeks of age, to around 70 – 80% of post-
natal day 1 expression levels (Kimoto et al., 2010). However, it is  also worth noting 
that hippocampal mRNA levels of ERβ (Esr2) remain relatively constant throughout 
development (from post-natal day 1 through to 12 week old rodents) (Kimoto et al., 
2010). As GPR30 is generally considered an estrogen-sensitive receptor, it is feasible 
that expression of GPR30 is also developmentally regulated. Although the 
developmental profile of GPR30 expression has not been thoroughly examined in the 
rodent hippocampus, there is evidence for developmental changes in GPR30 expression 
in other animal models. For example, in the zebra finch songbird, telencephalon 
expression of GPR30 mRNA drastically increases from P3 to P30 and drops 
substantially in adult, for both male and female finches (Acharya and Veney, 2012). 
Songbirds are important animal models, often utilised to study behavioural sex-
differences. Acharya and Veney (2012) postulated that GPR30 may contribute to the 
E2-induced organisation of circuits required for song production and memory in male 
finches, considering that expression of GPR30 significantly increased and was 
significantly different from female finches around P25, a time where vocalisation of 
song begins to occur. With respect to the rodent hippocampus, GPR30 has also been 
implicated in having a pivotal role in E2-induced enhancement of neurite outgrowth in 
developing (DIV 3) hippocampal neurons (Ruiz-Palmero et al., 2013).  
As estrogen receptor expression levels and concentrations of E2 within the CNS of 
juvenile rodents are substantially different compared to those in adult, it is likely that 
responses to exogenous application of estrogen receptor agonists will vary throughout 
different stages of development. Further work to characterise the acute effects of 
estrogen and synthetic estrogen receptor agonists across the developmental time period 
would be beneficial to our overall understanding of the role that this hormone has in 
hippocampal function.  
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4.3.2:  E2 elicits different response profiles on basal hippocampal synaptic 
transmission, which are mimicked by the GPR30 agonist, G1.  
Here we find that acute administration of E2 or G1 (10 – 100nM) on adult male 
hippocampal slices can elicit three different response profiles:  
1) A bi-phasic response consisting of an initial increase in synaptic responses, 
followed by LTD. 
2) An induction of LTD without prior potentiation of synaptic transmission.  
3) And in a small proportion of slices, an agonist-induced long-lasting 
increase in synaptic transmission (LTP). 
As we are recording synaptic responses from a population of dendrites at the stratum 
radiatum, the variable response profiles seen here for both E2 and G1 could be 
attributed to number of factors. 
For example, estrogen receptor expression ratios in populations of synapses or in slices 
from different animals may vary.  Indeed ERα, ERβ or GPR30 immunoreactivity is only 
observed in a subset of dendritic spine or shaft profiles in the stratum radiatum 
(specifically only ~30% of synapses in this layer are ERα positive) (Milner et al., 2001, 
2005; Adams et al., 2002; Akama et al., 2013). Moreover, expression of estrogen 
receptors can also be influenced by external factors outside the level of control in this 
study, such as the level of maternal care rodents received as pups, which has been 
demonstrated to influence levels of ERα expression in the CNS (Champagne et al., 
2003). 
Between animal or between slice variations in levels of neuronal excitability and 
synaptic connectivity may also account for the variable response profiles. This is 
feasible considering effects of G1 in juvenile rodents is revealed in hyper-excitable 
conditions (Figure 4.2) and a novel form of E2-induced LTD in adult hippocampal 
tissue is observed in hyper-excitable conditions (Moult and Findlay, unpublished 
findings). Since recent or chronic exposure to corticosteroids can influence many 
aspects of hippocampal glutamatergic synaptic transmission in rodents (as reviewed in 
Popoli et al., 2012), it is reasonable to suggest that individual exposure to stress would 
impact the G1- and E2- induced effects observed here.  Indeed acute exposure to 
corticosterone increases pre-synaptic glutamate release at CA3 – CA1 synapses (Karst 
et al., 2005) and influences the content and mobility of synaptic GluA2 containing 
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AMPARs in hippocampal cultures (Groc et al., 2008; Martin et al., 2009). In addition, 
chronic stress impairs the magnitude of LTP at CA1 – pre-frontal cortex connections 
(Cerqueira et al., 2007) and decreases dendritic spine density in CA3 (Magariños et al., 
2011) and CA1 (Pawlak et al., 2005) neurons. Thus it is feasible that stress induced 
alterations in dendritic morphology, excitability and transmission at CA1 synapses may 
influence the effects of G1 and E2. In support of this, it is becoming increasingly 
evident that these two hormonal systems are closely related and integrate to influence 
hippocampal excitatory synaptic transmission and plasticity (Ooishi et al., 2012b; Wang 
et al., 2013). 
There is a general consensus that E2 has the ability to acutely potentiate hippocampal 
excitatory synaptic transmission (or increase excitability) in a proportion (~50 – 80%) 
of experiments (whether it be population or single cell recordings), table A.1 in the 
appendix summarises this data. With respect to acute administration of G1, Lebesgue 
and colleagues (2010) illustrate that in young-adult OVX female rodents, a 
concentration of G1 (10 nM) can induce an acute potentiation of hippocampal CA1 
excitability in 9 out of 14 slices tested (64 %) (Lebesgue et al., 2010) or (at 100 nM G1) 
in 4 out of 7 cells tested (57 %) (Lebesgue et al., 2009); a rate of response which is 
similar to our data (56% and 83 % of slices exhibited a potentiation upon 10 nM or 100 
nM G1-application, respectively). However, others have shown in OVX and E2-primed 
rodents, the rate of G1-induced enhancement of synaptic responses is very low (2 out of 
15 cells, 13 %; Smejkalova and Woolley, 2010). Moreover, the time course at which we 
see E2- and G1- induced potentiation (within 5 – 10 min of ligand application)  equals 
the time course of these effects which others have observed at this synapse (Teyler et 
al., 1980; Foy et al., 1999; Gu et al., 1999; Sharrow et al., 2002; Kramár et al., 2009; 
Lebesgue et al., 2009, 2010; Zadran et al., 2009; Smejkalova and Woolley, 2010). Thus 
the rate at which we see the G1- or E2- induced enhancement of excitatory synaptic 
transmission, and the time course for which this occurs, parallels those which have been 
observed in other studies. However, the exact molecular mechanisms for the E2-induced 
enhancement of synaptic transmission and excitability within the hippocampus are not 
fully understood and may involve a number of mechanisms. Classic studies reported an 
E2-induced increase in AMPAR conductance (amplitude of kainate-induce currents) via 
a G-protein coupled and cAMP-dependant phosphorylation event (Gu and Moss, 1996, 
1998; Gu et al., 1999). Whereas more recent studies indicate an E2-induced potentiation 
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of Ca
2+ 
influx through L-type Ca
2+ 
channels (Wu et al., 2005; Zhao et al., 2005) and a 
subsequent activation of the Src/MAPK/ERK signalling pathway leading to ERK-
dependant phosphorylation and modulation NMDAR function (Bi et al., 2000, 2003). 
Conversely, the mechanism for rapid effects of E2 have been shown to be calcium 
independent and to involve rapid cytoskeletal arrangement and insertion of synaptic 
GluA1-containing AMPAR, effects which are thought to be mediated via activation of 
ERβ (Liu et al., 2008; Kramár et al., 2009; Zadran et al., 2009). It is also feasible that 
E2, by modulating glutamate and GABA release from presynaptic terminals, enhances 
synaptic transmission (Smejkalova and Woolley, 2010; Huang and Woolley, 2012).  
Nevertheless, the important finding in this study is that following washout of E2 or G1, 
leads to in most cases (in 82% and 89% of slices for E2 and G1, respectively) the 
induction of a long-lasting depression of synaptic transmission. Previous 
electrophysiology studies examining the acute effects of E2 on basal hippocampal 
excitatory synaptic transmission using extracellular recording techniques at CA3 – CA1 
synapses either concluded experiments after a 15 – 30min drug application (Teyler et 
al., 1980; Fugger et al., 2001; Sharrow et al., 2002; Zadran et al., 2009; Lebesgue et al., 
2010) or continued E2 administration for an extended period of time (up to 100 min; 
Kim et al., 2006). Only one other study has followed experiments through a washout 
period, however the group did not observe any significant depression of synaptic 
transmission in response to E2 (Kramár et al., 2009). Although male rodents were used 
in that study (which may exclude the possibility a sex-specific effect) and a comparable 
concentration of E2 was used (1 nM) their washout period lasted only 30 min, which 
may account for this discrepancy (Kramár et al., 2009). Therefore, the data presented 
here demonstrates that long duration experiments with extended washout periods can 
uncover long-lasting changes in excitatory synaptic transmission induced by E2 and G1.  
Although most studies have focused on the ability of E2 to enhance excitability and 
synaptic transmission as well as facilitate LTP (as reviewed in Woolley, 2007; Foy et 
al., 2008; Ogiue-Ikeda et al., 2008; Foy, 2011; Srivastava et al., 2011), our data indicate 
that this hormone also has the capacity to induce LTD at hippocampal CA3 – CA1 
synapses. The slow-onset induction of long-lasting depression begins to occur ~15 min 
– 20 min after agonist washout when preceded by an enhancement of synaptic 
transmission (biphasic response profile) or ~15 – 20 min after agonist application in the 
cases where an enhancement of synaptic transmission was not observed (depression 
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only profile). Due to the time frame of these responses (< 1 hour), the data suggest that 
the induction of this type of LTD is likely to be attributed to a non-genomic mechanism 
of action (ie. activation of extra-nuclear estrogen receptors). Moreover, as the 
magnitude of the E2-induced long-lasting depression of synaptic transmission is not 
significantly different from the G1-induced effect, it is feasible that activation of GPR30 
may be involved in this non-genomic action of E2.  
In accordance with our data, previous studies have demonstrated that E2 (acute or 
chronic application) can enhance the magnitude or facilitate the induction of 
hippocampal LTD. For example, in hippocampal slices from adult male rats, acute 
application of E2 (1 – 10 nM) dose-dependently enhances the magnitude of NMDA-
induced LTD at the CA1, CA3 and DG (Mukai et al., 2007). Interestingly, others have 
shown in the CA1 region that acute administration of E2 (1 nM) can also enhance 
DHPG-induced LTD (Shiroma et al., 2005). A genomic mechanism of E2-induced 
facilitation of LTD has also been observed. Specifically 2 day in vivo treatment of E2 in 
OVX female rats facilitated the induction of  paired-pulse low frequency stimulation-
induced LTD (Zamani et al., 2000). Together, these data would suggest an important 
role for E2 in mediating this type of synaptic plasticity.  
LTD at CA1-synapses can also be induced by acute exposure to other hormonal 
modulators, such as leptin (albeit in juvenile rodents; (Durakoglugil et al., 2005)) and 
insulin (Huang et al., 2004; van der Heide et al., 2005). Moreover, acute exposure to 
another class of steroid hormones – the glucocorticoids (either by acute stress or 
application of corticosterone to slices) can enhance low frequency stimulation-(LFS), 
paired pulse-LFS- and DHPG-induced LTD in the hippocampus (Chaouloff et al., 2008; 
Huang et al., 2012; Popoli et al., 2012). Thus the ability for E2 to mediate hippocampal 
LTD is consistent with the body of literature suggesting that endocrine hormones 
influence hippocampal function.  
LTD of excitatory synaptic transmission is a major form of synaptic plasticity in the 
mammalian CNS that (along with LTP) allows for the refinement of neuronal circuitry 
in response to external stimuli. The observation that E2 (in most cases) induces this 
form of plasticity, and this effect can be mimicked by a GPR30 agonist, is an important 
finding. Considering LTP and LTD of synaptic efficacy are considered the cellular 
correlates of learning and memory (Bliss and Collingridge, 1993), therapies which 
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target estrogen receptors and the synthesis of estradiol, may have long-lasting effects on 
cognition (Agrawal et al., 2010; Espeland et al., 2010; Frick, 2012).  
 
4.3.3: Technical Considerations 
In this study we have chosen to monitor basal synaptic transmission by recording 
evoked population EPSP’s, as opposed to extracellular single unit or whole-cell 
recordings. This recording technique was chosen primarily due to the ease with which 
recordings could be made, moreover with this technique being far less invasive than 
whole-cell patch clamp it can be considered more physiologically relevant (compared to 
whole-cell recordings, as cells within slices remain intact and their intracellular 
constituents are not diluted with artificial intracellular solutions). Importantly, utilizing 
field EPSP recordings one can monitor synaptic transmission for extended periods of 
time more easily than with the patch-clamp technique.  
Previously published literature had not fully investigated the long-lasting washout 
effects of neither estradiol nor the GPR30 agonist at the hippocampal CA3 – CA1 
synapse. Thus, an electrophysiological recording technique which consistently enabled 
one to monitor synaptic transmission during extended agonist washout periods (1 hour) 
was employed, in order to probe for a washout effect. However, there are caveats of this 
technique. For example, unlike using the whole-cell patch clamp technique, one cannot 
manipulate the system as easily (for example, by including agents into the intracellular 
solution such as the calcium buffer BAPTA, or the non-hydrolysing GTPγS analogue, to 
delineate intracellular signalling mechanisms associated with agonist-induced effects). 
Nevertheless, using the extracellular fEPSP recordings, we are able to monitor the 
effects of ligands on a large population of cells, rather than at the single cell level, 
giving greater insight into the global effects of the agonists used.  
Although we suggest here that the long-lasting washout effects of E2 and G1 are due to 
a decrease in synaptic transmission, we cannot exclude the possibility that these 
agonists may be inducing effects other than this. For example, application of these 
agonists may be causing a population of CA1 neurons to depolarise, an effect which is 
not reversed upon washout. If this were the case, then the electrochemical driving force 
for cation (Na
+ 
or Ca
2+
) flux into the post-synaptic cell through activated ionotropic 
glutamate receptors in response to afferent stimulation, would be reduced. Thus, this 
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would manifest itself as a reduction in fEPSP slope measurements, like that which is 
observed here. This is a feasible explanation as it has been previously demonstrated that 
G1 (100 nM) can depolarise some (61 %) motor neurons in rat spinal cord slices by 
approximately 5 mV (Deliu et al., 2012) and in cultured spinal neurons by 
approximately 8 mV (Dun et al., 2009), however these groups demonstrated that this 
effect was readily reversible. In addition, in the seminal study by Wong and Moss 
(1991), it was observed that brief application of E2 (100 pM; 2 min) can depolarise a 
proportion (20 %) of CA1 pyramidal neurons in hippocampal slices from adult male and 
female rats by approximately 7 mV. However, like G1, this E2-induced depolarisation 
was readily reversible upon washout (Wong and Moss, 1991). If a sustained agonist-
induced depolarisation accounts for the E2 and G1-induced reduction in fEPSP slope 
measurements in our study, then it would be worthwhile investigating this possibility by 
employing the whole-cell patch clamp technique in hippocampal slices in order to 
monitor membrane potential (by recording in current clamp mode) during agonist 
administration and importantly after agonist washout.  
Moreover, another possible explanation for our G1- and E2- induced reduction in fEPSP 
slope measurements during washout could simply be due to toxic effects of these 
compounds. However, it should be noted that concentrations of 1 µM G1 failed to 
induce a significant change in fEPSP measurements in the juvenile model (Fig. 4.1) 
suggesting that this is not the case. Although unlikely, this does not exclude the 
possibility that G1 and E2 may have toxic effects in the adult model. In order to control 
for this, quantifying cell death (using propridium iodide staining for example) after 
exposure to these compounds and compared with vehicle controls would be useful in 
this respect.  
 
4.4:  Conclusion 
The GPR30 agonist (G1) is likely to be inducing LTD in the juvenile hippocampus, an 
effect which requires enhanced NMDAR activity. In contrast, acute administration of 
E2 and G1 leads to (in most cases) the induction of a novel form of LTD in adult male 
hippocampal slices. Considering this novel form of LTD in adult tissue can be induced 
in basal conditions, this effect warranted further characterisation (see Chapter 5).  
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5.1: Introduction  
The novel and most consistent effect of E2 and G1 (10 nM) in our model is the slow-
onset LTD of hippocampal excitatory synaptic transmission. LTD of hippocampal 
excitatory transmission can be expressed either pre- or post-synaptically (as reviewed in 
Malenka and Bear, 2004). Specifically, this may involve trafficking of post-synaptic 
AMPAR away from the synapse, changes in pre-synaptic glutamate release either 
directly (as reviewed in Collingridge et al., 2010), or via retrograde messengers (such as 
cannabinoids (Péterfi et al., 2012) or NO (Reyes-Harde et al., 1999)).  
Ultrastructure analysis in adult rodents has revealed localisation of ERα and ERβ in 
both pre- and post- synaptic compartments of CA1 pyramidal neurons (Milner et al., 
2001, 2005; Mukai et al., 2007), and recently it has been reported that GPR30 is found 
at post-synaptic sites in a subset of CA1 dendritic spines (Akama et al., 2013). Although 
numerous studies have investigated the mechanisms of the E2 induced enhancement of 
excitability and synaptic transmission at CA3 – CA1 synapses, there are discrepancies 
regarding the locus of this effect, with groups reporting pre-synaptic (Smejkalova and 
Woolley, 2010) or post-synaptic (Wong and Moss, 1992; Foy et al., 1999; Kim et al., 
2006) mechanisms. Considering the pre- and post-synaptic expression of extra-nuclear 
estrogen receptors’ and as hippocampal LTD can be expressed pre- or post-synaptically, 
it is important to compare the locus of the novel E2- and G1-induced LTD in our model. 
Excitatory synaptic transmission at CA3 – CA1 synapses primarily depends on 
activation of synaptic GluA2/GluA1 heteromeric AMPAR (Lu et al., 2009). Therefore, 
if  E2- and G1- induced LTD involve a post-synaptic expression mechanism, then 
removal of synaptic AMPAR may contribute to the expression of LTD as this is 
generally considered a key event underlying activity-dependant post-synaptically 
expressed LTD (as reviewed in: Malenka, 2003; Shepherd and Huganir, 2007; 
Collingridge et al., 2010). 
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One mechanism by which LTD at CA3-CA1 synapses can be induced is dependent on 
the activity of NMDAR (Malenka and Bear, 2004; Collingridge et al., 2010). Previous 
studies have shown that some E2 induced effects in the rodent hippocampus are 
NMDAR-dependent, for example, E2 effects on dendritic spine density in the adult 
female (Woolley and McEwen, 1994; Woolley et al., 1997) and male (Mukai et al., 
2007). Moreover, in vivo E2 replacement in OVX rats lowers the frequency threshold 
for hippocampal LTD induction in an NMDAR dependent manner (Zamani et al., 
2000). Acute E2 exposure can also enhance LTD induced by exogenous NMDA 
administration (Mukai et al., 2007). In addition, acute application of E2 increases the 
amplitude of pharmacologically isolated NMDAR-mediated EPSPs of CA1 neurons 
(Foy et al., 1999). Thus it is feasible that the E2- and G1- induced depression of 
synaptic transmission may also involve an NMDAR-mediated component. 
Thus, the aim of this chapter was to characterise further the cellular mechanisms 
underlying the novel forms of LTD induced by E2 and G1. We sought to establish the 
locus of the E2- and G1- induced LTD in the adult male hippocampal slice preparation 
and whether these agents could influence trafficking of AMPAR in primary 
hippocampal cultures. Furthermore, a role for NMDA receptors in the E2- and G1- 
induced effects was investigated.      
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5.2: Results 
5.2.1:  The effects of E2 and G1 on excitatory synaptic transmission are likely to be 
expressed post-synaptically.  
To determine the locus of the E2- and G1-induced effects on hippocampal excitatory 
synaptic transmission a paired-pulse facilitation stimulation protocol was implemented, 
whereby slices were stimulated twice every 30s with an inter-stimulus interval of 50 ms. 
After establishing a 20 min stable baseline, E2 or G1 were bath applied to slices (10 
nM; 20 min) followed by a 60 min washout period.  
The E2-induced increase in excitatory synaptic transmission (which was observed in 3 
out of the 4 slices) and LTD generation (observed in all 4 slices) were not accompanied 
by significant changes in pooled PPR (from 1.54 ± 0.02 during baseline, to 1.53 ± 0.01 
during E2 application and 1.53 ± 0.02 during washout; p > 0.05; n = 4; Fig 5.1). Like 
E2, the G1-induced increase in synaptic transmission (observed in 2 out of the 3 slices) 
and LTD generation (observed in all 3 slices) were not accompanied by significant 
changes in the pooled PPR (from 1.49 ± 0.04 during baseline, to 1.49 ± 0.04 during G1 
application and 1.50 ± 0.06 during washout; p > 0.05; n = 3; Fig 5.2). 
 It is well established that adenosine potently depresses synaptic transmission at CA3 - 
CA1 synapses and is a result of pre-synaptic activation of A1 receptors resulting in a 
lowering of initial glutamate release probability (Wu and Saggau, 1994). For this 
reason, the effects of adenosine on the PPR were used as a control. As expected, 
application of adenosine (100 µM; 10 min) quickly depressed synaptic transmission 
(Fig 5.3), and this effect was accompanied by a significant increase in the PPR (from 
1.45 ± 0.01 during baseline recordings to 2.08 ± 0.07 during adenosine application; t = -
6.9, 2 degrees of freedom; p < 0.05; Fig 5.3; n = 3).  
To illustrate the effects of adenonsine on the paired-pulse facilitation ratio, compared 
with E2 or G1, example traces from the different phases of the experiments were scaled 
(Fig 5.4). This figure shows an enhancement of the second response during adenosine-
induced synaptic depression. Moreover, scaling shows that there is no change in the 
magnitude of the second response during E2- or G1- induced synaptic enhancement or 
depression (example traces for E2 and G1 are from experiments which show a bi-phasic 
response profile). These data suggest that both the E2- and G1-induced LTD of 
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hippocampal synaptic transmission are likely to be expressed post-synaptically and are 
not likely to involve alterations in glutamate release probability. Furthermore, these data 
support the hypothesis that GPR30 may be involved in E2 mediated effects on 
hippocampal synaptic transmission as similar expression mechanisms underlie the LTD 
induced by E2 and the GPR30 agonist.   
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Figure 5.1: E2 has no effect on the paired pulse facilitation ratio. A, pooled data 
(n = 4) illustrating the effects of E2 (10 nM; 20 min); 3 out of 4 slices show a 
biphasic response and 1 of the 4 slices show LTD only. B, Corresponding PPR from 
(A). Top, example traces from a representative experiment that illustrated a bi-phasic 
response are shown at the time points indicated. There is no significant change in 
PPR p > 0.05 (one-way repeated measures ANOVA on ranks). 
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Figure 5.2: G1 has no effect on the paired pulse facilitation ratio. A, pooled data 
(n = 3) illustrating the effects of G1 (10 nM; 20 min); 2 out of 3 slices show a 
biphasic response and 1 out of 3 slices show LTD generation only. B, Corresponding 
PPR from (A). Top, example traces from a representative experiment that illustrated 
a bi-phasic response are shown at the time points indicated. There is no significant 
change in PPR p > 0.05 (one-way repeated measures ANOVA). 
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Figure 5.3: Adenosine depresses hippocampal excitatory synaptic transmission 
through a pre-synaptic mechanism. A, pooled data (n = 3) illustrating changes in 
average fEPSP slope after adenosine B, Corresponding PPR from (A) representing 
changes in PPR after adenosine (100 µM; 10 min) administration; Top, example 
traces from a representative experiment.. * represents p < 0.05 vs. baseline; paired t-
test.  
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Figure 5.4: Scaled representation of paired fEPSP: Black traces represent example traces from baseline 
and green traces represent traces from agonist application or washout and have been scaled to the first 
response from the respective baseline trace. Scaling the responses illustrates that after adenosine (100 µM) 
application there is an increase in the magnitude of the second response, whereas there is no change in the 
magnitude of the second response during E2 (10 nM) or G1 (10 nM) application or washout.  
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Scaled: ligand 
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5.2.2: The E2- and G1- induced LTD do not require afferent stimulation 
The E2- and G1- induced LTD are likely to be expressed post-synaptically, however 
expression may require concurrent pre-synaptic activity (ie: post-synaptic AMPAR 
and/or NMDAR activation in conjunction with estrogen receptor activation). Therefore, 
in the following experiments (Fig 5.5), Schaffer-collateral stimulation was ceased 20 
min during agonist application and resumed during the washout phase, to establish 
whether afferent stimulation was necessary for the induction of either E2- or G1- 
induced LTD.  
Without stimulation during agonist application, the E2- and G1-induced depression of 
synaptic transmission was still observed (to 89 ± 3.1% of baseline after E2 washout; t = 
3.5 with 4 degrees of freedom; p < 0.05; n = 5; and 91 ± 1.7% of baseline after G1 
washout; t = 5.3 with 5 degrees of freedom; p < 0.05; n = 6; Fig 5.5). The magnitudes of 
the E2- and G1- induced depression in these experiments were not significantly 
different from each other (p > 0.05; Kruskal-Walls one-way ANOVA on ranks). 
Vehicle (0.01% DMSO) controls were conducted to ensure that these E2- and G1- 
induced effects were not a result of termination of electrical stimulation during agonist 
application. Once electrical stimulation resumed after vehicle application, an initial 
increase in fEPSP response size was seen, which matched those from E2 and G1 
experiments, however responses declined to baseline levels after 60 min (to 102 ± 1% 
of baseline; p > 0.05; n = 6). These data suggest that E2- and G1- induced LTD do not 
require afferent stimulation. 
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Figure 5.5:  E2- and G1- induced LTD do not require presynaptic stimulation. 
Pooled data illustrating E2 (10 nM; 20 min; n = 5), G1 (10 nM; 20 min; n = 6) and 
vehicle (0.01% DMSO; 20 min; n = 6) effects on excitatory synaptic transmission 
after electrical stimulation is ceased during drug application. Top; representative 
traces from each set of experiments are shown for the time points indicated. E2 and 
G1 significantly reduced synaptic transmission (p < 0.05 vs. baseline; paired t-tests).  
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5.2.3:  E2 and G1 modulate the surface expression of GluA1 containing AMPA 
receptors. 
It is likely that the E2- and G2- induced LTD are post-synaptically expressed (section 
5.2.2) thus we then sought to determine if these agonists altered the trafficking of 
AMPAR by monitoring their effects in primary cultured hippocampal neurons. 
Accordingly, we tested the concentration-dependent effects of E2 and G1 (0.01 – 1000 
nM; Fig 5.6 and 5.7) using established immunocytochemical approaches to assay the 
surface expression of GluA1-containing AMPAR in living cultured hippocampal 
neurons (Moult et al., 2010).  
Exposure of neurons to 1 nM and 10 nM E2 resulted in modest but significant 
reductions (to 84 ± 2.0 % and 90 ± 2.0 % of control, respectively; H = 110.9 with 6 
degrees of freedom; p < 0.05 vs. vehicle treated; n = 48; Fig 5.6) in surface GluA1 
expression. In contrast, 100 nM E2 significantly increased surface GluA1 staining (to 
113 ± 2.0 % of control; p < 0.05 vs. vehicle treated; n = 48). Although 1 µM E2 
increased surface GluA1 staining (to 110 ± 2.7 % of control; n = 48), this effect was not 
statistically significant compared to vehicle (p > 0.05 vs. vehicle treated). Exposure of 
neurons to G1 resulted in a similar concentration-response relationship, such that 
concentrations of 1 nM, 10 nM and 100 nM G1 significantly reduced surface GluA1 
expression (to 80 ± 1.8%, n = 48; 81 ± 1.4%, n = 96 and 84 ± 1.5 % n = 84, of control 
respectively; H = 104.6 with 6 degrees of freedom; p < 0.05 vs. vehicle treated; Fig 5.7), 
whereas 1 µM G1 had no significant effect on surface GluA1 staining (98 ± 2.2% of 
control, n = 84; p > 0.05 vs. vehicle treated).  
Although the concentration-dependent effects for G1 and E2 differ at higher 
concentrations, these data suggest that G1 can mimic the effects of E2 at low nanomolar 
concentrations.  Taken together, the E2- and G1- induced decrease in surface GluA1 
containing AMPAR is consistent with the electrophysiology data which suggests that 
the G1- and E2-induced LTD are likely to have a post-synaptic expression mechanism 
and thus may involve the removal of post-synaptic GluA1-containig AMPAR.  
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Figure 5.6: E2 effects surface GluA1 expression in a concentration-
dependent manner. Neurons (DIV 8 -16) were treated with vehicle (0.1 % 
DMSO) or E2 (0.01 nM – 1000 nM; 30 min). A, representative confocal images of 
surface GluA1 staining. B, pooled data (n = 48 neurites; n = 4 independent 
cultures from different animals) showing the concentration-dependant effects of 
E2 on surface GluA1. Scale bars, 20 µm. * represents p < 0.05 vs. vehicle treated, 
ns represents p > 0.05 vs. vehicle treated; Kruskill-Wallis one-way ANOVA on 
ranks, followed by Dunn’s post-hoc analyses. 
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Figure 5.7: The selective GPR30 agonist effects surface GluA1 expression in 
a concentration-dependent manner. Neurons (DIV 8 – 16) were treated with 
vehicle (0.1 % DMSO) or G1 (0.01 nM – 1000 nM; 30min). A, representative 
confocal images of surface GluA1 staining. B, pooled data (n= 48 – 96 neurites; n 
= 4 – 8 independent cultures from different animals) showing the concentration-
dependant effects of G1 on surface GluA1. Scale bars, 20 µm. * represents p < 
0.05 vs. vehicle treated; Kruskill-Wallis one-way ANOVA on ranks followed by 
Dunn’s post-hoc analysis.  
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Internalisation of AMPAR from synaptic sites is necessary for the expression of many 
forms of LTD at the CA1 (Man et al., 2000; Kim et al., 2001; Snyder et al., 2001; 
Huang et al., 2004; Casimiro et al., 2011). Although these data indicate that surface 
AMPAR expression is decreased by low nM concentrations of E2 and G1, it is not clear 
if the agonists promote the removal of AMPAR from synaptic or extra-synaptic sites. 
Moreover, as  E2 is a known modulator of spine and dendritic architecture in vivo 
(Woolley and McEwen, 1992), the effects of these agonists could induce morphological 
changes and alterations in spine density, which would manifest as a reduction in surface 
GluA1-containing AMPAR.  It is worth noting that synapse loss is more likely to occur 
over a time-period greater than that which we see here (> 24 hours), and is more likely 
to be attributed to pathophysiological conditions (such as amyloid-β oligomer 
formation; repeated LTD stimulation, or chronic stress; (Shankar et al., 2007; Shinoda 
et al., 2010; Wei et al., 2010; Liston and Gan, 2011)). Nevertheless, in order to control 
for this and to address if synaptically-located GluA1-containing AMPAR were 
specifically removed from synapses in response to E2 and G1 treatment, we used dual-
labelling immunocytochemical techniques to compare the co-localisation of the synaptic 
marker synapsin-1 and GluA1 (Moult et al., 2010; Doherty et al., 2013).  
To determine the level of AMPAR associated with synapses, surface GluA1 expression 
relative to synapsin-1 staining was assessed in primary hippocampal neurons after 
exposure to vehicle (0.001 % DMSO), G1 (10 nM) or E2 (10 nM; 30 min; Fig 5.8). As 
expected, application of G1 or E2 significantly reduced surface GluA1 staining (to 86 ± 
2% and 74 ± 1% of vehicle control, respectively; H = 78.9 with 2 degrees of freedom; p 
< 0.05 vs. vehicle treated; n = 45; Fig 5.8 D). The relative number of synapsin-1 
positive puncta was not significantly affected by either agonist (G1: 107 ± 4.4 %, E2: 98 
± 4.3 %, of vehicle; n = 45; p > 0.05 vs. vehicle treated; Fig 5.8 B). However, exposure 
to either G1 or E2 decreased surface GluA1-staining that co-localized with synapsin-1 
staining from 54 ± 1.6 % in vehicle treated neurons, to 47 ± 2.4 % and 39 ± 1.8 %, 
respectively (H = 24.6 with 2 degrees of freedom; p < 0.05 vs. vehicle treated; n = 45;   
Fig 5.8 C).  
These data suggest that both G1 and E2 reduce the expression of synaptic GluA1 
containing AMPAR, without affecting synapse number. The ability of G1 and E2 to 
promote the removal of GluA1 from hippocampal synapses may be an important step in 
the expression of G1- and E2-induced LTD at the CA3 – CA1 synapse.   
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Figure 5.8: Both E2 and G1 promote removal of AMPAR from synapses. 
Neurons were treated with vehicle (0.01 % DMSO), E2 or G1 (10 nM; 30 min). A, 
representative confocal images of surface GluA1 staining (green) and synapsin-1 
staining (red) after treatment, both E2 and G1 treatment reduced GluA1 staining, 
but did not affect number of synapsin-1 puncta. B, pooled data illustrating 
normalised number of synapses as determined by synapsin-1 staining after 
treatment. C, pooled data illustrating percentage GluA1 expression that 
colocalized with synapsin-1 staining after treatment. D, pooled data illustrating the 
relative expression of surface GluA1 labelling after treatment. Scale bars, 20 µm. 
* represents p < 0.05 vs. vehicle treated; Kruskill-Wallis-one way ANOVA 
followed by Dunn’s post-hoc analyses; n = 45 neurites from 3 independent 
cultures from different animals.  
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5.2.4:  G1- induced LTD is likely to be independent of NMDAR activation, 
whereas E2-induced LTD may involve an NMDAR mediated component 
In order to test if the E2- or G1- induced LTD involved an NMDAR-mediated 
component,  hippocampal slices were perfused with the competitive NMDAR 
antagonist, D-AP5 (50 µM) for 20  -  45 min before application of either E2 or G1 (both 
at 10 nM; 20 min). 
In the presence of D-AP5, the magnitude of the E2-induced LTD was significantly 
attenuated (from 86 ± 2.4% of baseline in E2 treated slices, [F2,14] = 10.1; p < 0.05 vs. 
baseline; n = 5; to 93 ± 2.0 % of baseline in D-AP5 treated slices, n = 6,  t = 2.3 with 9 
degrees of freedom, p < 0.05 vs. E2 treated, Fig 5.9). However, the residual depression 
was still significant (F[2,17] = 11.1; p < 0.01 vs. baseline), suggesting that a component 
of the E2- induced LTD is NMDAR-mediated. The E2-induced increase in synaptic 
transmission was only observed in 2 out of 5 control slices, and was not observed in any 
of the slices treated with D-AP5. Therefore a definitive conclusion as to whether the 
initial E2- induced increase in excitability is dependent on NMDAR activity cannot be 
made. 
In contrast to E2, the magnitude of the G1-induced depression in the presence of D-AP5 
is not significantly different to that in G1 control experiments (Fig. 5.10 B) (G1: 84 ± 
3.8 % of baseline, n = 5, F[2,14] = 14.4;  p < 0.05 vs. baseline; G1 + D-AP5: 87 ± 1.9 % 
of baseline, n = 9, F[2,26] = 23.9; p < 0.05 vs. baseline, p > 0.05 vs. G1 alone, unpaired 
t-test).  
Moreover, subsequent stratification of the data revealed that out of the nine slices that 
were exposed to G1 in the presence of D-AP5, four exhibited a bi-phasic response 
profile (Fig 5.11), four a depression-only response profile (Fig 5.12) and in one slice a 
sustained increase in synaptic transmission was observed (data not shown).  
Specifically, in the slices which exhibited a bi-phasic response profile, the magnitude of 
the G1-induced potentiation of synaptic transmission in the presence of D-AP5 was not 
significantly different from control slices (G1: 108 ± 2.3 % in of baseline, n = 3 /5; G1 
+ D-AP5: 109 ± 1.3 % of baseline, n = 4 / 9; F[2,11] = 110.7, p < 0.05 vs. baseline; p > 
0.05 vs. G1 alone; Fig 5.11). In addition, the magnitude of the G1-induced depression of 
synaptic transmission in the presence of D-AP5 was not significantly different from 
control (G1: 87 ± 5.5 % of baseline, n = 3 / 5; G1 + D-AP5: 84 ± 2.3 % of baseline, n = 
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4 / 9; F[2,11] = 110.7, p < 0.05 vs. baseline; p > 0.05 vs. G1 alone; unpaired t-test; Fig 
5.11). In slices where a G1-induced potentiation of synaptic transmission was not 
observed, the magnitude of the G1-induced LTD was not significantly different in slices 
treated with D-AP5 (G1: 80 ± 4.7 of baseline, n = 2 / 5; G1 + D-AP5: 87 ± 1 % of 
baseline D-AP5 treated slices, n = 4 / 9; F[2,11] = 35.9; p < 0.05 vs. baseline; p > 0.05 
vs. G1 alone; unpaired t-test; Fig 5.12). 
Taken together, these results suggest that the E2-induced depression of synaptic 
transmission may have a D-AP5-sensitive and a D-AP5-insensitive component, whereas 
the G1-induced effects are not sensitive to D-AP5.    
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Figure 5.9: D-AP5 attenuates the E2- induced depression 
of synaptic transmission in adult male hippocampal slices.  
A, representative experiment showing effects of D-AP5 (50 
µM) and E2 (10 nM; 20 min) on fEPSP amplitude. Top, 
example traces from the experiment are shown at the time 
points indicated. B, data pooled (n = 6) and normalised with 
respect to baseline are expressed as mean ± SEM; * represents 
p < 0.05 vs. baseline; one-way repeated measures ANOVA 
followed by Tukey post-hoc analyses. C, Data from B, 
comparing the effects of E2 in the presence (filled circles) and 
absence (open circles) of D-AP5; * represents p < 0.05 vs. E2 
alone; unpaired t-test.   
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Figure 5.10: D-AP5 does not block the G1-induced effect on synaptic 
transmission in adult male hippocampal slices.  A, Data pooled (n = 9) and 
normalised with respect to D-AP5 baseline, illustrating that in the presence of D-
AP5 (50 µM), G1 (10 nM; 20 min) can still induce a slow-onset depression of 
synaptic transmission.  B, comparing the effects of G1 in the presence (filled circles) 
and absence (open circles) of D-AP5. Data are expressed as mean ± SEM; * 
represents p < 0.05 vs. baseline (in figure A); NS represents p > 0.05 vs. baseline (in 
figure A), One-way repeated measures ANOVA followed by Tukey post-hoc 
analyses; NS represents p > 0.05 vs. the magnitude of G1-induced effects in control 
slices at the time point indicated; unpaired t-test (in figure B).  
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Figure 5.11: D-AP5 does not block the G1-induced bi-
phasic effect of synaptic transmission in adult male 
hippocampal slices.  A, representative experiment showing 
effects of D-AP5 (50 µM) and the bi-phasic effects of G1 (10 
nM; 20 min) on fEPSP amplitude. Top, example traces from 
the experiment are shown at the time points indicated. B, data 
pooled (n= 4 / 9) and normalised with respect to baseline are 
expressed as mean ± SEM. C, Data from B, comparing the 
effects of G1 in the presence (filled circles) and absence (open 
circles) of D-AP5. * represents p < 0.01 vs. baseline; NS 
represents p > 0.05 vs. the magnitude of G1-induced effects in 
control slices; unpaired t-test.  
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Figure 5.12: D-AP5 does not block the G1-induced 
depression of synaptic transmission in adult male 
hippocampal slices.  A, representative experiment showing 
effects of D-AP5 (50 µM) and the G1-induced depression (10 
nM; 20 min) on fEPSP amplitude. Top, example traces from 
the experiment are shown at the time points indicated. B, data 
pooled (n= 4 / 9) and normalised with respect to baseline are 
expressed as mean ± SEM. C, Data from B, comparing the 
effects of G1 in the presence (filled circles) and absence (open 
circles) of D-AP5. * represents p < 0.01 vs. baseline; NS 
represents p > 0.05 vs. the magnitude of G1-induced effects in 
control slices; unpaired t-test..  
A B 
C 
* 
ns 
131 
5.2.5: The effects of G1 and E2 on AMPAR trafficking are NMDAR dependent 
In contrast to the electrophysiology data, both the E2- and G1- induced reduction in 
surface AMPAR expression in hippocampal neurons were attenuated by D-AP5 (Fig 
5.13). Specifically, the magnitude of the G1-induced reduction in surface AMPAR 
expression (from 84 ± 2.3 % of vehicle; p < 0.05 vs. vehicle treated) was significantly 
attenuated by D-AP5 (to 95 ± 1.7 % of vehicle; H = 63.4 with 5 degrees of freedom;  p 
< 0.05 vs. G1 treated; n = 48).  Furthermore, the E2-induced reduction in surface GluA1 
expression (from 81 ± 2.5 % of vehicle; p < 0.05 vs. vehicle treated) was blocked in the 
presence of D-AP5 (to 98 ± 2.0 % of vehicle; H = 63.4 with 5 degrees of freedom; p < 
0.05 vs. E2 treated; n = 48;). D-AP5 exposure (50 µM; 45 min) alone had no effect on 
surface AMPAR expression compared to vehicle treated neurons (100 ± 1.3%; p > 0.05 
vs. vehicle treated; n = 60). These data suggest that in primary hippocampal cultures, 
the effects of G1 and E2 on surface GluA1 expression require NMDAR activity. 
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Figure 5.13: The G1- and E2- induced reduction in surface GluA1 expression 
is attenuated by D-AP5. DIV 8 –16 neurons were pre-treated with vehicle (0.01 
% DMSO) or D-AP5 (50 µM; 15 min) and then G1 or E2 (10 nM) or vehicle, or 
in combination with D-AP5 (30 min). A, representative confocal images of surface 
GluA1 staining. B, pooled data showing relative changes in surface GluA1 after 
exposure to D-AP5 alone and in the presence of G1 or E2. Scale bars, 20 µm. A 
Kruskal-Wallis one way ANOVA on ranks followed by Dunn’s post-hoc analyses 
was performed. * Represents p < 0.05 vs. vehicle; # represents p < 0.05 between 
the indicated treatments; n = 48 – 60 neurites from 4 - 5 individual cultures from 
different animals.  
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5.2.6:  An mGluR antagonist does not inhibit the G1-induced reduction in surface 
AMPAR expression 
Although both NMDA- and mGluR- dependent LTD induce mechanistically distinct 
forms of LTD, both phenomena involve the internalization of surface AMPAR 
(Malenka and Bear, 2004; Moult et al., 2006; Collingridge et al., 2010; Casimiro et al., 
2011).  
Our results suggest that in hippocampal cultures the E2- and G1-induced reduction of 
surface AMPAR expression are via an NMDAR dependent mechanism, however recent 
studies indicate that extra-nuclear estrogen receptors can associate with and signal via 
mGluRs (Boulware et al., 2005, 2007; Boulware and Mermelstein, 2009; Meitzen et al., 
2012). Therefore, it is plausible that the E2- or G1- induced effects on surface AMPAR 
expression may involve signalling via Group I or Group II mGluR’s. In order to test 
this, we utilised LY 341495, a compound which selectively antagonises group II 
mGluRs (Kingston et al., 1998) and can inhibit group I mGluR at high concentrations 
(Fitzjohn et al., 1998). Application of LY 341495 (20 µM; 45 min) had no significant 
effect on surface AMPAR expression compared to vehicle (97 ± 2.4 % of vehicle; n = 
36; p > 0.05 vs. vehicle treated, Fig 5.14), in hippocampal cultures. Moreover the ability 
of G1- and E2- (for both 10 nM; 30 min) to reduce surface GluA1-staining was not 
inhibited in the presence of LY 341495 (to 82 ± 2.8 % of vehicle and 88 ± 2.9 % of 
vehicle for G1 and E2, respectively; H = 42.9 with 5 degrees of freedom; p < 0.05 vs. 
vehicle treated; p > 0.05 vs. G1 or E2 treated, respectively; Fig 5.14). Thus, these data 
suggest that in hippocampal cultures, the E2- and G1- induced reduction in surface 
AMPAR expression is likely to be independent of mGluR–mediated signalling.  
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Figure 5.14: The G1- and E2- induced reduction in surface GluA1 expression 
is not effected by a Group I/II mGluR antagonist. DIV 8 –16 neurons were 
pre-treated with vehicle (0.01 % DMSO) or LY 341495 (20 µM; 15 min) and then 
G1 or E2 (10 nM) or vehicle, or in combination with LY 341495 (30 min). A, 
representative confocal images of surface GluA1 staining. B, pooled data showing 
relative changes in surface GluA1 after exposure to LY341495 alone and in the 
presence of G1 or E2. Scale bars, 20 µm. A Kruskal-Wallis one way ANOVA on 
ranks followed by Dunn’s post-hoc analysis was performed. * represents p < 0.05 
vs. vehicle; ns represents p > 0.05 between the indicated treatments; n = 36 
neurites from 3 individual cultures from different animals.  
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Summary of findings from Chapter 5: 
1) Acute E2- and G1- induced LTD generation is not likely to be a consequence 
of an altered glutamate release probability and does not require afferent 
stimulation (Fig 5.1, 5.2 and 5.5). 
2) E2 and G1 exposure leads to a reduction in synaptic GluA1-containing 
AMPAR expression in hippocampal cultures (Fig 5.8). 
3) E2 induced LTD of synaptic transmission may (at least in part) involve 
NMDAR activation, whereas it is likely that the G1-induced LTD does not 
(Fig 5.9, Fig 5.10, Fig 5.11 and Fig 5.12). 
4) The E2- and G1- induced reduction in surface AMPAR expression is 
NMDAR dependent (Fig 5.13).  
5) It is likely that the E2- and G1-induced reduction in surface AMPAR 
expression does not involve mGluR signalling (Fig 5.14). 
 
 
5.3: Discussion 
5.3.1.  E2- and G1- induced LTD at hippocampal synapses are likely to have a 
post-synaptic expression mechanism.  
Here we demonstrate that the E2- and G1- induced LTD are not likely to be attributed to 
alterations in the probability of pre-synaptic glutamate release, as no alterations in PPR 
accompanied LTD induced by either E2 or G1. However in parallel control studies the 
synaptic depression induced by adenosine was coupled with a marked increase in the 
PPR, which is consistent with a presynaptic mechanism mediating synaptic depression 
at this synapse (Wu and Saggau, 1994). 
In agreement with a possible post-synaptic expression mechanism for E2-induced LTD, 
acute E2-induced increases in excitability and potentiation of synaptic transmission at 
CA3 – CA1 synapses have previously been suggested to occur via post-synaptic 
mechanisms (Wong and Moss, 1992; Foy et al., 1999; Gu et al., 1999; Kim et al., 
2006). In contrast, recent data suggests pre-synaptic mechanisms for the potentiation of 
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synaptic transmission by E2, an effect which may be sex-specific  (Smejkalova and 
Woolley, 2010; Huang and Woolley, 2012). Specifically, E2 acutely potentiates 
synaptically evoked EPSCs in slices from female rats through an ERβ-mediated 
increase in pre-synaptic glutamate release probability (Smejkalova and Woolley, 2010). 
Moreover, in slices from OVX and E2 primed rodents, acute E2 exposure enhances the 
excitability of CA1 neurons via an ERα mediated inhibition of GABA release, via a 
mechanism which involves retrograde signalling of anandamide and pre-synaptic CB1R 
activation, an effect not present in male rodents (Huang and Woolley, 2012).  
It should be noted that another possible explanation for the agonist induced depression 
of synaptic transmission is an agonist-induced reduction in the number of presynaptic 
fibres generating action potentials rather than effects which are expressed post-
synaptically. We cannot exclude this possibility as the amplitude of the presynaptic 
fibre volley was not monitored throughout the duration of recordings (the amplitude of 
the fibre volley is a measure of the number of presynaptic fibres generating action 
potentials in response to electrical stimuli).  
Nevertheless, recent evidence adds weight to the concept that the G1- and E2 induced 
LTD are expressed post-synaptically, as GPR30 associates with the dendritic 
scaffolding protein post-synaptic density-96 (PSD-95) in close proximity to the  post-
synaptic density (PSD) in a subset of dendritic spines in the rodent CA1 (Akama et al., 
2013). In view of this and the fact that the response profiles of E2- and G1- are 
analogous, it is possible that E2 may be activating GPR30 located at post-synaptic sites 
on dendrites in the CA1 region, which culminates in the induction of LTD (in most 
cases).  
 
5.3.2:  The E2- and G1- induced LTD does not require afferent stimulation  
The results presented here suggest that the E2- and G1- induced LTD do not require 
evoked glutamate release as LTD persisted even in the absence of synaptic stimulation 
(Fig 5.5). The protocol used here is primarily designed to test whether concurrent 
activation of post-synaptic AMPAR and NMDAR are required for agonist-induced 
effects on synaptic transmission. However, considering the CA3 is still intact in our 
preparations, spontaneous glutamate release from pre-synaptic inputs is likely to occur, 
therefore we cannot rule out this possibility. Other forms of chemically induced LTD at 
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the CA3 - CA1 synapse do not require stimulation of the presynaptic terminal, for 
example LTD induced by the mGluR agonist, DHPG (Fitzjohn et al., 1999; Huber et 
al., 2001) or the muscarinic agonist, carbachol (Kumar, 2010). Thus, the E2- and G1- 
induced LTD, like those mentioned above; involve mechanisms distinct from forms of 
chemically induced-LTD which involve afferent stimulation, including insulin-LTD 
(van der Heide et al., 2005) or LTD-induced by low-frequency stimulation (as reviewed 
in Collingridge et al., 2010).  
 
5.3.3:  AMPAR trafficking  
LTD that is expressed post-synaptically is most likely attributed to a reduction in 
synaptic GluA1-containing AMPAR (Malenka, 2003; Kessels and Malinow, 2009). The 
data here indicate that at physiological concentrations (1 – 10 nM) both E2 and G1 
reduce the surface expression of GluA1-containig AMPAR in DIV 8 –16 primary 
hippocampal neurons, thus potentially providing a mechanism for the observed 
depression of synaptic transmission in response to these agonists. Moreover, the data 
presented here is directly supported by results from another group who show in cortical 
cultures, exposure to E2 (10 nM; 30 min) results in a reduction in surface GluA1-
expression and in parallel, a reduction in the frequency of AMPAR-mediated mEPSC’s 
(Srivastava et al., 2008).  However, contrary to these results, acute application of  the 
same concentration of E2 (10 nM; 5 min) in adult male hippocampal slices can increase 
the surface expression of GluA1 in the CA1 region (Zadran et al., 2009). In this study, 
the authors did not examine GluA1 expression after longer time periods of E2 exposure 
and their assay was not sensitive to changes in synaptic GluA1, providing a reasonable 
explanation for this discrepancy. Their results may also suggest that the E2-induced 
effects on AMPAR-trafficking may occur in a time- dependant manner. 
In our study, we chose to investigate the effects of G1 and E2 after 30 min ligand 
exposure, a time point where E2 has previously been demonstrated to have effects on 
surface GluA1 expression in primary cortical cultures (Srivastava et al., 2008) and 
primary hippocampal cultures  (unpublished observations by Farquharson and Moult, 
2010). This time point correlates with a point during electrophysiological recordings 
when GluA1 trafficking away from synaptic sites in response to agonist exposure may 
be occurring and may be observed at the level of the individual cell. However, in order 
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to fully correlate our findings from primary hippocampal cultures with the results from 
electrophysiological recordings, it would be worthwhile to subject slices exposed to E2 
or G1, to GluA1 cell surface biotinylation assays at different experimental times points 
during ligand application and washout. 
Nevertheless, supporting the hypothesis that E2 may be acting at GPR30 to effect 
surface AMPAR expression, were the characteristics of the concentration-response 
relationships between the two agonists (E2 and G1). Application of either agonist did 
not result in a linear nor a threshold concentration-response relationship, but rather an 
inverted-U shaped concentration response. Exposure to E2 resulted in what may be a 
hormetic concentration response relationship, characterised by an inverse-U shaped 
concentration response and the reversal of response at high concentrations (Kendig et 
al., 2010), as at a concentration of 100 nM E2, an increase in GluA1-staining was 
observed. This intriguing concentration-response relationship is not uncommon for E2 
at  different biological endpoints, although usually a response attributed to toxic-effects 
of high concentrations of E2 (Strom et al., 2011). The reversal of response seen here 
may be attributed to preferential signalling mediated by different estrogen receptor sub-
types. This hypothesis is supported by unpublished observations from our laboratory, 
which suggests that exposure to selective ERα and ERβ agonists have opposing effects 
on surface GluA1 expression (unpublished observations by Farquharson and Moult, 
2010). Specifically, a selective ERα agonist (0.2 – 20 nM PPT; 30 min) significantly 
reduces, whereas a selective ERβ agonist (50 – 100 nM DPN; 30 min) significantly 
increases, surface GluA1-expression in hippocampal neurons (unpublished observations 
by Farquharson and Moult, 2010). In addition, similar effects of selective estrogen 
receptor agonists on GluA1-trafficking within hippocampal neurons have been reported 
by others. For example, Liu and colleagues (2008) demonstrate that in hippocampal 
extracts from OVX rats dosed with a bolus subcutaneous injection of either selective 
ERα (PPT; 10 mg kg-1) or ERβ (WAY-200070; 10 mg kg-1) agonists, selective 
activation of ERβ significantly increases hippocampal GluA1 expression, whereas 
although not statistically significant, selective activation of ERα shows a trend towards 
reducing hippocampal GluA1 expression (Liu et al., 2008). Thus, we and others have 
demonstrated that trafficking of GluA1-containing AMPAR in response to estradiol, is 
differentially regulated depending on the estrogen receptor subtype activated.   
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Here we show that G1 did not result in a reversal of response (ie: an increase in surface 
GluA1-staining), however an inverted-U concentration relationship was observed, 
mimicking part of the effects of E2 at lower concentrations. As selective ERα agonists 
induced a decrease in surface GluA1-expression (unpublished findings from 
Farquharson and Moult, 2010) and considering signalling via GPR30 may require 
association with ERα (Levin, 2009a; Vivacqua et al., 2009) and/or G1 may be 
selectively activating a variant of ERα, ERα36 (Kang et al., 2010), the G1-induced 
concentration-response observed here may be a reflection of this.  
Nevertheless, rapid effects of E2 in spatial recognition memory tasks (object-placement) 
have been recently reported to exhibit an inverted-U concentration-response (Luine and 
Frankfurt, 2012). This type of behavioural task is dependent on the intact hippocampus, 
which perhaps gives an in vivo role for the type of concentration-response relationship 
we see in our molecular assay. 
 
5.3.4:  NMDAR involvement  
Another novel finding here is that the G1-induced LTD and a component of the E2-
induced LTD are NMDAR-independent, as the competitive NMDAR antagonist D-AP5 
failed to alter the magnitude of G1-induced LTD and failed to fully inhibit the E2-
induced LTD. In agreement with the data presented here, unpublished findings from our 
laboratory suggest that in adult male rodents, the novel form of LTD induced by E2 in 
conditions of hyper excitability is not fully blocked by D-AP5 (Findlay and Moult, 
unpublished findings, 2010). However in contrast, E2-mediated alterations in CA1 
dendritic morphology involve D-AP5 sensitive mechanisms (Woolley and McEwen, 
1994; Woolley et al., 1997) and recent evidence in primary pre-frontal cortical cultures, 
suggest that GPR30 initiated signalling can modulate the phosphorylation state of 
NR2B subunits (Liu et al., 2012). 
Another type of hormonally-induced LTD (insulin-induced LTD) is also NMDAR-
independent (Huang et al., 2004) and is associated with a reduction in surface AMPAR 
expression in slices (Huang et al., 2004) and in DIV 21 – 28 hippocampal cultures (Man 
et al., 2000). Therefore, it is feasible that signalling induced by E2 and G1 in adult 
hippocampal slices, may lead to direct down-regulation of surface GluA1-containing 
AMPAR, without the requirement of NMDAR-dependant Ca
2+ 
influx. The finding that 
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there is a component of the E2-induced LTD sensitive to D-AP5, may reflect the 
involvement of a multitude of estrogen receptors and differing mechanisms by which 
E2 induces its effects at these synapses. In support of this hypothesis, ERα-mediated 
reductions in surface GluA1-containing AMPAR in primary hippocampal cultures are 
NMDAR-dependant, whereas ERβ-mediated increases in surface GluA1 are NMDAR-
independent (unpublished findings from Farquharson and Moult, 2010).  
The immunocytochemistry data presented here however conflicts with the results from 
the electrophysiology experiments. The data here would suggest that in primary 
hippocampal cultures the G1- and E2-induced reduction in surface-AMPAR expression 
does indeed involve NMDAR activation. In our study, primary hippocampal cultures 
were used between 8 and 16 DIV, as in our laboratory, cultures older than 7 DIV are 
deemed mature (Shanley et al., 2002; McDonald et al., 2007b) and at this age, effects of 
neuromodulators (leptin) on surface GluA1 expression mimic those in adult slices 
(Moult et al., 2010). However, in a study by Srivastava et al., (2008), E2-induced 
reduction in surface GluA1 expression in cortical cultures occurred in the presence of 
D-AP5, yet the age of the cultures used in their study were DIV 28 (Srivastava et al., 
2008). Considering the media we use in the AMPAR-trafficking assay contains glycine 
(co-agonist for NMDAR), and in juvenile slices effects of G1 were only uncovered in 
conditions of enhanced NMDAR activity (Fig 4.2) and there are likely to be 
developmental differences in estradiol-induced effects within the hippocampus (see 
section 4.3.1). The mechanisms by which estrogen receptor agonists affect GluA1-
trafficking in primary hippocampal neurons may depend on basal NMDAR activity 
which may differ depending on the maturity of hippocampal cultures.  
 
5.3.5: mGluR involvement 
The immunocytochemistry results do not support a role for mGluRs in E2- or G1- 
mediated reduction in surface AMPAR-expression. However, it should be noted that 
estradiol-induced effects can be mediated via mGluRs. Indeed, the Mermelstein group 
have established that rapid effects of E2 in different brain regions can occur via 
association of membrane estrogen receptors (mERα or mERβ) and mGluR’s (Group I 
and Group II/III; as reviewed in Meitzen and Mermelstein, 2011), however only in 
female hippocampal neurons are mER functionally coupled to mGluR (Boulware et al., 
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2005, 2007). Specifically rapid E2-induced CREB phosphorylation via ERα-mGluR1a 
signalling is observed only in hippocampal cultures from female pups and not in 
cultures from male pups or in female pups which have been masculinised (Meitzen et 
al., 2012). Moreover, Hunag and Woolley (2010) demonstrate that E2-induced 
reduction of pre-synaptic GABA release at CA1 neurons occurs via ERα-mGluR1a 
signalling, and is only observed in slices from female rodents (Huang and Woolley, 
2012). As all experiments here were conducted using male hippocampal slices, it is 
unlikely that ERα-mGluR signalling would account for the observed E2-induced LTD. 
Although, it is not known whether GPR30 can associate with mGluR’s, GPR30 does 
have the capacity to associate with other GPCRs at CA1 synapses (Akama et al., 2013), 
moreover it has also been speculated that G1 directly stimulates mGluR1a in 
hypothalamic astrocytes (Kuo et al., 2010). Although unlikely, currently we cannot 
conclusively rule out the possibility that components of the G1- and E2- induced LTD 
are mediated via mGluRs.  
 
 
 
5.4: Conclusion 
Overall, this chapter has characterised the E2- and G1- induced long-lasting depression 
of hippocampal synaptic transmission. Here we find that in the adult hippocampus E2- 
and G1- induce a novel form of LTD which is likely to be expressed post-synaptically 
and may be attributed to a reduction in synaptic GluA1-containing AMPAR. 
Furthermore, this data supports the hypothesis that GPR30 may be (at least in part) 
contributing to these E2 induced effects. In order to fully establish a role for GPR30 in 
E2 mediated physiology, a pharmacological evaluation of the G1-induced effects is 
necessary (see Chapter 6).  
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Establishing a mechanism for the G1-
mediated LTD 
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6.1: Introduction 
The previous chapter describes the properties of acute exposure of E2 and the GRP30 
agonist (G1) on basal excitatory hippocampal synaptic transmission and surface 
AMPAR expression in neurons.  
Although widely used as a selective GPR30 agonist, the findings of Kang et al, (2010) 
suggest that G1-induced effects are mediated by an estrogen receptor splice variant 
(ERα-36). Another complexity to GPR30 pharmacology arises from the recent evidence 
which suggests that the steroid aldosterone can also activate GPR30, at least in 
vasculature (Gros et al., 2011, 2013; Batenburg et al., 2012), in addition to the known 
capacity of this steroid hormone to modulate hippocampal synaptic function (Pavlides 
and McEwen, 1999; Maggio and Segal, 2009, 2012). Thus, it is important to 
characterise the pharmacology fully, in order to establish whether GPR30 mediates the 
observed effects of G1 in this study.  
In order to explore further the target for G1 action in hippocampal neurons, the use of 
selective GPR30 and estrogen receptor antagonists needs to be employed. In 2009, 
Dennis and colleagues described a putative GPR30 selective antagonist (G15), that 
competes with E2 at GPR30 with a Ki of approximately 0.3 – 0.5nM and has a binding 
affinity for GPR30 of approximately 20 nM (Dennis et al., 2009). G15 can block 
GPR30 mediated effects in heterologous over expression systems and endogenously 
expressing cancer cell lines (Dennis et al., 2009, 2011; Notas et al., 2012). 
Importantly, in vivo effects of G1 in rodents can be blocked by G15 for example; in a 
mouse model of depression G15 blocked the G1-induced decrease in immobility time in 
the tail suspension test (Dennis et al., 2009), moreover G1-induced pain-related 
behaviour in mice (licking, biting and scratching) are blocked by G15 (Deliu et al., 
2012).  
Therefore the aim of this series of experiments was to establish using pharmacological 
approaches whether the G1-induced effects on hippocampal synaptic transmission and 
AMPAR expression are mediated by GPR30 or another estrogen-sensitive receptor, and 
also to investigate potential down-stream signalling pathways involved. 
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6.2: Results 
6.2.1: GPR30 antagonists do not block the G1-induced effects on hippocampal 
synaptic transmission and AMPAR trafficking. 
Previous studies have demonstrated the ability of G15 to block E2-mediated effects in 
hippocampal neurons. For example, G15 can inhibit E2-mediated protection against 
glutamate-induced neurotoxicity in immortalised hippocampal cell lines (Gingerich et 
al., 2010). Chronic treatment with G15 also blocks the effect of E2 in hippocampal 
dependent learning tasks (delayed matching-to-position acquisition) in OVX rats 
(Hammond et al., 2012). Therefore, in order to establish whether the G1-induced effects 
on excitatory hippocampal synaptic transmission are sensitive to the GPR30 antagonist, 
G15 (200 nM) was bath applied to adult male (12 – 16 weeks) hippocampal slices for 
20min before co-application with G1 (10 nM). 
Application of G15 (200nM; 20 min) had no significant effect on baseline transmission 
(100 ± 1.1 % of baseline; p > 0.05; n = 8). In the presence of G15 (200 nM), the G1-
induced (10 nM; 20 min) LTD is still observed (to 87 ± 3.2 % of baseline; F[3,30] = 
17.6; p < 0.001 vs. baseline; n = 8). Subsequent stratification revealed that out of the 
eight slices exposed to these conditions, four elicited a bi-phasic response profile in 
response to G1 (Fig 6.1 B) such that G1 induced a significant potentiation of synaptic 
transmission (to 108 ± 2 % of baseline; F[3,15] = 22.4; p < 0.05; n = 4) followed by a 
slow-onset depression of synaptic transmission after G1 washout (to 87 ± 6.7 % of 
baseline; F[3,15] = 22.4; p < 0.05; n = 4). In the other four slices exposed to G15, G1 
depressed synaptic transmission without a preceding potentiation (Fig 6.1 C). Thus, 
during G1 application no effect on baseline transmission was observed (to 99 ± 1.0 % of 
baseline; p > 0.05; n = 4), however following washout of G1 and in the continued 
presence of G15, synaptic transmission was significantly reduced (to 87 ± 2.2 % of 
baseline; F[3,14] = 21.2; p < 0.05; n = 4). In control slices, G15 was applied for an 
extended period of time (up to 100 min) to ensure the induction of long-lasting 
depression of synaptic transmission was not attributed to an extended application of 
G15 (Fig 6.1 D). Long duration exposure to G15 failed to alter the magnitude of 
synaptic transmission (to 98 ± 2.2% of baseline at 115 – 120 min; n = 4; p > 0.05), 
suggesting that G15 does not contribute to LTD. 
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In parallel immunocytochemistry studies, exposure of primary hippocampal cultures 
(DIV 8 – 16) to G15 (200 nM; 45 min) also failed to inhibit the G1-induced effects on 
surface GluA1 staining (Fig 6.2).  Specifically, in the presence of G15 (200 nM) 
application of G1 (10 nM) significantly reduced surface GluA1 staining (to 86 ± 1.6 % 
of vehicle; n = 48; H = 60.9 with 3 degrees of freedom; p < 0.05 vs. vehicle treatment), 
which was not significantly different from the reduction induced by G1 alone (to 79 ± 
2.2% of vehicle treated cultures; n = 48; p < 0.05 vs. vehicle treatment; p > 0.05 vs. G15 
+ G1 treatment).  
Recently, another compound, G36 was developed as an antagonist for GPR30, with 
improved selectivity and less off target effects compared to G15 (Dennis et al., 2011). 
We obtained G36 from Dr. Arterburn and assessed its effects in the AMPAR trafficking 
assay. Here we find that exposure of hippocampal neurons to G36 (1 µM; 45 min) was 
also unable to inhibit the G1-induced reduction in surface AMPAR expression (Fig 6.3). 
Thus application of G1 (10 nM), in combination with G36 significantly reduced surface 
GluA1 staining (to 85 ± 3.0 % of vehicle; n = 36; H = 20.7 with 3 degrees of freedom; p 
< 0.05 vs. vehicle treatment;); the magnitude of which was not significantly different to 
that induced by G1 alone (84 ± 2.7%; n = 36; p <0.05 vs. vehicle treated cultures; p > 
0.05 vs. G36 + G1 treatment). Although there was a slight reduction in surface GluA1 
staining with G36 alone, this effect was not significantly different from vehicle treated 
cultures (to 92 ± 3.3%; p > 0.05 vs. vehicle treatment; n = 36).  
Taken together, these results suggest that GPR30 antagonists are unable to inhibit the 
effects of G1 on hippocampal excitatory synaptic transmission and surface AMPAR 
expression.  
Figure 6.1: G15 does not block the G1-induced effects on basal synaptic 
transmission in adult male hippocampal slices. A, Pooled data (n = 8 slices) 
illustrating that in the presence of G15 (200 nM), the G1-induced (10 nM) 
depression of synaptic transmission is still observed. B, stratification reveals a bi-
phasic response profile of G1 in the presence of G15 in 4 out of 8 slices C, a 
depression only response profile is observed in the other 4 out of 8 slices. D, Pooled 
data illustrating that G15 (200 nM) in combination with vehicle treatment (0.01% 
DMSO, 20 min, open bar) had no effect on synaptic transmission (n = 4). Example 
traces from a representative experiment from each data set are shown at the time 
points indicated. Data are normalised with respect to baseline and are expressed as 
mean ± SEM.  
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Figure 6.2: G15 does not inhibit the G1-induced reduction in surface 
AMPAR expression. Neurons were pre-treated with vehicle (0.01% DMSO) or 
G15 (200 nM; 15 min) and then G1 (10 nM) or vehicle, or in combination with 
G15 (30 min). A, representative confocal images of surface GluA1 staining in 
hippocampal cultures. B, pooled data showing relative changes in surface GluA1 
expression after exposure to G15 alone and in the presence of G1. Scale bars, 20 
µm. A Kruskal-Wallis one way ANOVA on ranks followed by Dunn’s post-hoc 
analysis was performed. * represents p < 0.05 vs. vehicle treatment; ns represents 
p > 0.05 between the indicated treatments; n = 48 from 4 individual cultures from 
different animals.  
Vehicle G15 G1 G15 + G1 
B 
* * 
ns 
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Figure 6.3: The GPR30 antagonist (G36) does not block the G1-induced 
reduction in surface AMPAR expression. Neurons were pre-treated with 
vehicle (0.01 % DMSO) or G36 (1 µM; 15 min) and then G1 (10 nM) or vehicle, 
or in combination with G36 (30 min). A, representative confocal images of 
surface GluA1 expression. B, pooled data showing relative changes in surface 
GluA1 after exposure to G36 alone and in the presence of G1. Scale bars, 20 µm. 
A Kruskill-Wallis one way ANOVA on ranks followed by Dunn’s post-hoc 
analysis was performed. * represents p < 0.05 vs. vehicle treatment and ns 
represents p > 0.05 between the indicated treatments; n = 36 neurites from 3 
individual cultures from different animals. 
Vehicle G36 G1 G36 + G1 
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6.2.2:  The Estrogen Receptor α antagonist does not attenuate the G1-induced 
effects on hippocampal synaptic transmission and AMPAR trafficking.  
It has been suggested that G1 binds to and activates a 36kDa ERα splice variant (ERα-
36; Kang et al., 2010), which may provide an explanation as to why the GPR30 
antagonist (G15) failed to block the G1-induced effects. Moreover, it has been 
suggested that signalling via GPR30 may require association with mERα (Albanito et 
al., 2007; Levin, 2009a; Notas et al., 2012), in support of this idea a direct interaction 
between GPR30 and ERα has been observed in breast cancer cells (Vivacqua et al., 
2009). Thus, in order to examine whether G1-mediated effects on excitatory synaptic 
transmission involve ERα or its variant ERα-36, MPP dihydrochloride (MPP) was 
utilised. This compound was developed as a selective antagonist against nuclear ERα 
(ERα-66), with a Ki of 2.7nM and over 200-fold selectivity over ERβ (Sun et al., 2002). 
Although it is not known if MPP can bind to and inhibit ERα-36, there is evidence to 
suggest that this compound can inhibit non-genomic effects of E2 via inhibition of 
membrane associated ERα (Lin et al., 2011; Tuo et al., 2012; Zárate et al., 2012).  
Thus, MPP (1 µM) was applied to slices for 20 – 35 min prior to G1 (10 nM; 20 min) 
administration. In these conditions, the G1-induced LTD was still observed (to 86 ± 2.8 
% of baseline; F[2,17] = 23.8; p < 0.001 vs. MPP baseline; n = 6; Fig 6.4 A). 
Subsequent stratification revealed that three out of the six slices exhibited a bi-phasic 
response profile in response to G1 (Fig 6.4 B). G1 induced a significant potentiation of 
synaptic transmission (to 110 ± 3.4 % of baseline; F[2,8] = 27.3; p < 0.05; n = 3) that 
was followed by a slow-onset significant depression of synaptic transmission after G1 
washout (to 90 ± 3.8 % of baseline; F[2,8] = 27.3; p < 0.05; n = 3). In the other three 
slices, a persistent depression of synaptic transmission was induced by G1 without a 
preceding potentiation (Fig 6.4 C). Specifically, in the presence of MPP, G1 had no 
significant effect on basal excitatory synaptic transmission (100 ± 3.9 % of baseline; p > 
0.05; n = 3), however following washout a significant reduction in transmission was 
observed (to 83 ± 3.1 % of baseline; F[2,8] = 8.6; p < 0.05; n = 3). In control 
experiments, exposure of slices to MPP for extended periods of time (100 min) had no 
significant effect on basal synaptic transmission (p > 0.05; n = 4; Fig 6.4 D). 
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The effects of MPP on surface AMPAR expression were also examined in hippocampal 
cultures (Fig 6.5). Addition of MPP (1 µM; 45 min) had no effect on surface AMPAR 
expression (99 ± 2% of vehicle; p > 0.05 vs. vehicle treatment; n = 36), moreover MPP 
failed to block the G1-induced reduction in surface GluA1 staining as there was no 
significant difference between G1 treatment (10 nM; 88 ± 2% of vehicle; F[3,143] = 
12.9; p < 0.001 vs. vehicle treatment) and co-treatment with MPP (86 ± 2% of vehicle; 
F[3,143] = 12.9; p < 0.001 vs. vehicle treatment; p > 0.05 vs. G1 alone;). Taken 
together these data suggest that in the presence of an ERα antagonist, the ability of G1 
to reduce surface GluA1-containing AMPAR expression and induce LTD in 
hippocampal slices is retained.  
  
Figure 6.4: A selective ERα antagonist (MPP) does not block the G1-induced 
effects on basal synaptic transmission in adult male hippocampal slices. A, 
Pooled data (n = 6 slices) illustrating that in the presence of MPP (1 µM), the G1-
induced (10 nM) depression of synaptic transmission is still observed. B, 
stratification reveals a bi-phasic response profile of G1 in the presence of MPP in 3 
out of 6 slices. C, a depression only response is observed in the other 3 (out of 6) 
slices. D, pooled data illustrating MPP (1 µM) in combination with a vehicle 
treatment (0.01% DMSO; 20 min; open bar) had no effect on basal excitatory 
synaptic transmission (n = 4).  Example traces from a representative experiment 
from each data set are shown at the time points indicated. Data are normalised with 
respect to baseline and are expressed as mean ± SEM.  
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Figure 6.5: MPP does not block the G1-induced effects on surface AMPAR 
expression. Neurons were pre-treated with vehicle (0.01 % DMSO) or MPP (1 
µM; 15 min) and then G1 (10 nM) or vehicle, or in combination with MPP (30 
min). A, representative confocal images of surface GluA1 staining. B, pooled data 
showing relative changes in surface GluA1 after exposure to MPP alone and in 
the presence of G1. Scale bars, 20 µm. A one way ANOVA, followed by Tukey 
post-hoc anlaysis was performed.  *** represents p < 0.001 vs. vehicle treatment, 
and ns represents p > 0.05 between the indicated treatments; n = 36 neurites from 
3 individual cultures from different animals. 
Vehicle MPP G1 MPP + G1 
B 
*** *** 
ns 
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6.2.3:  The Estrogen Receptor β antagonist does not block the G1-induced effects 
on hippocampal synaptic transmission and AMPAR trafficking.  
ERβ has been implicated as being an important modulator of hippocampal LTP (Day et 
al., 2005; Kramár et al., 2009) and estradiol-induced alterations in hippocampal 
excitatory synaptic transmission (Smejkalova and Woolley, 2010). Moreover, 
application of ERβ agonists regulate the expression of synaptic proteins important for 
plasticity (Spencer-Segal et al., 2012) and disruption of the ERβ gene impairs 
hippocampal dependant spatial learning (Rissman et al., 2002). In addition it has been 
recently demonstrated that both ERβ and GPR30 are implicated in the neuroprotective 
effects of the phytoestrogen, daidzen (Kajta et al., 2013). Thus, a possible interaction 
between GPR30 and ERβ cannot be overlooked. In order to test this, we utilised a 
selective ERβ antagonist (PHTPP), a compound which selectively binds to and 
competes with E2 at nuclear ERβ to inhibit ERβ-mediated gene transcription (Compton 
et al., 2004). Currently, there is no direct evidence to suggest that this compound does 
not inhibit non-genomic effects of E2.  
It was observed that PHTPP administration (1 µM) potentiated basal synaptic 
transmission in a proportion of slices (50%, 7 out of 14 slices; from 11 animals; Fig 
6.6). The mean magnitude after 20 min PHTPP exposure in this group was significantly 
larger than baseline transmission (to 108 ± 2.3 % of baseline; p < 0.05). Therefore, in 
the slices that were exposed to G1 in the presence of PHTPP, the data were normalised 
to the magnitude of synaptic transmission 15 min prior to G1 administration (Fig 6.7 A, 
B and C). In the presence of PHTPP, exposure to G1 (10 nM; 20 min) still induced a 
significant depression of synaptic transmission after G1 washout (to 90 ± 2.3 % of 
PHTPP baseline; n = 8; F[2,23] = 29.2; p < 0.001 vs. PHTPP baseline). Subsequent 
stratification of response profiles revealed that in the eight slices that were exposed to 
G1 in the presence of PHTPP, four slices elicited a bi-phasic response profile in 
response to G1 (Fig 6.7 B). Specifically, a significant potentiation (to 105 ± 1.0 % of 
PHTPP baseline; n = 4; F[2,11] = 55.7; p < 0.05) and depression (to 91 ± 1.4 % of 
PHTPP baseline; n = 4; F[2,11] = 55.7; p < 0.05) was observed. Three out of eight 
slices elicited a depression only profile in response to G1 (Fig 5.7 C). Specifically, G1 
exposure did not significantly potentiate synaptic transmission (101 ± 1.0 % of PHTPP 
baseline; n = 3; p > 0.05), however following G1 washout, a significant depression of 
synaptic transmission was still observed (to 85 ± 2.9 % of PHTPP baseline; n = 3; 
156 
F[2,8] = 26.3; p < 0.01). In one slice, in the presence of PHTPP, administration of G1 
resulted in a sustained increase in synaptic transmission (data not shown).  PHTPP 
controls were run to ensure the depression of synaptic transmission was not an artefact 
of extended PHTPP administration (Fig 6.7 D). At the end of 100 min PHTPP exposure, 
the magnitude of synaptic transmission was not significantly different from baseline 
(102 ± 1.3 % of baseline; n = 5; p > 0.05). 
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Figure 6.6: The selective ERβ antagonist (PHTPP) can potentiate synaptic 
transmission in a proportion of slices. Pooled data (n = 7 / 14 slices) illustrating 
that PHTPP can rapidly potentiate synaptic transmission in a proportion of adult 
hippocampal slices. Data are normalised with respect to baseline and are expressed 
as mean ± SEM.  
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Despite having an effect on synaptic transmission in a proportion of slices, PHTPP (1 
µM; 45 min) did not affect surface GluA1 expression (98 ± 2.2 % of vehicle; p > 0.05 
vs. vehicle treatment; n = 48; Fig 6.8), moreover PHTPP was unable to block the G1-
induced reduction in surface AMPAR expression (G1: 84 ± 1.6 % of vehicle, p < 0.05 
vs. vehicle; G1 + PHTPP: 80 ± 1.3 % of vehicle, p < 0.05 vs. vehicle, p > 0.05 vs. G1 
alone; n = 48; H = 65.5 with 3 degrees of freedom). Together, these results suggest that 
a selective ERβ antagonist does not block the G1-induced effects on synaptic 
transmission and surface GluA1 expression.  
 
 
 
 
 
 
 
 
 
Figure 6.7: The selective ERβ antagonist, PHTPP does not inhibit the G1-
induced effects on basal synaptic transmission in adult male hippocampal slices. 
A, Pooled data (n = 8 slices) illustrating that in the presence of PHTPP (1 µM), the 
G1-induced (10 nM) depression of synaptic transmission is still observed. B, 
stratification reveals a bi-phasic response profile of G1 in the presence of PHTPP in 
4 out of 8 slices. C, a depression only response is observed in another other 3 (out of 
8) slices. D, pooled data illustrating PHTPP (1 µM) in combination with a vehicle 
treatment (0.01% DMSO; 20 min; open bar) did not induce a depression of synaptic 
transmission (n = 5).  Example traces from a representative experiment from each 
data set are shown at the time points indicated. Data are normalised with respect to 
baseline and are expressed as mean ± SEM.  
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Figure 6.8: PHTPP does not inhibit the G1-induced reduction in surface 
AMPAR expression. Neurons were pre-treated with vehicle (0.1 % DMSO) or 
PHTPP (1 µM; 15 min) and then G1 (10 nM) or vehicle, or in combination with 
PHTPP (30 min). A, representative confocal images of surface GluA1 staining. B, 
pooled data showing relative changes in surface GluA1 after exposure to PHTPP 
alone and in the presence of G1. Scale bars, 20 µm. A Kruskal-Wallis one way 
ANOVA on Ranks was performed, followed by Dunn’s post-hoc analysis. * 
represents p < 0.05 vs. vehicle treatment and ns represents p > 0.05 between the 
indicated treatments; n = 48 neurites from 4 individual cultures from different 
animals.  
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6.2.4:  ICI has no effect on basal synaptic transmission in adult hippocampal slices.  
As the selective ER antagonists failed to inhibit the effects of G1, another approach is to 
establish if another compound capable of selectively activating GPR30, without any 
known agonist activity at other receptors, can mimic the effects of G1. Previous studies 
indicate that selective estrogen receptor downregulator (SERD) ICI 182,780 (ICI) can 
mimic the non-genomic effects of E2 in heterologous and breast cancer cell based-
assays (Aronica et al., 1994; Filardo et al., 2002; Thomas et al., 2005). Moreover, ICI 
can displace E2 in binding assays for GPR30 (Thomas et al., 2005), suggesting that it is 
a potential GPR30 agonist. In addition, ICI can mimic non-genomic effects of E2 in 
hippocampal neurons (Zhao et al., 2006; Smejkalova and Woolley, 2010). This 
compound classically acts as a competitive antagonist of the genomic mechanism of 
action of E2. ICI prevents E2 binding to both intracellular ERα and ERβ, prevents 
receptor dimerization and nucleo-cytoplasmic shuffling and ultimately increases the 
degradation of these receptors (Wakeling et al., 1991; Dauvois et al., 1993; Bemd and 
Kuiper, 1999).  
Therefore, we utilised ICI in order to test whether it would mimic the effects of G1 in 
our system. However, in adult hippocampal slices, application of ICI (100 nM; 20 min) 
had no significant effect on basal excitatory synaptic transmission during application, or 
after a 30min washout period (Fig 6.9 A). Specifically, during ICI application baseline 
transmission was unchanged (to 101 ± 2.7 % of baseline; n = 4; p > 0.05), moreover 
baseline transmission was unaffected after the 30 min ICI washout (to 104 ± 1.5 % of 
baseline; n = 4; p > 0.05).  
In contrast, however, our preliminary data in juvenile hippocampal slices (P16 – P17) 
illustrates that application of 500 nM ICI can mimic the effects of G1 in low Mg
2+ 
aCSF 
(0.1 mM; Fig 6.9 B). Specifically, in one slice, ICI application rapidly (within 10 min) 
potentiated synaptic transmission (to > 10 %). However in the other slice ICI had no 
potentiating effect. Importantly, after ICI washout, a slow onset depression of synaptic 
transmission was observed in both slices, reaching maximum magnitude approximately 
60 min after washout (to 76 ± 2.9 % of baseline; n = 2; Fig 6.9 B). These data suggest 
that under certain conditions and at specific stages of postnatal development, ICI can 
induce a persistent depression of excitatory synaptic transmission. However as these 
data are only preliminary, further examination into the effect of ICI in the juvenile 
model needs to be conducted.  
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Figure 6.9: ICI 182,780 (ICI) has no effect on baseline transmission in adult 
slices, however induces a large depression of synaptic transmission in hyper-
excitable juvenile slices.  A, Pooled data (n = 4) illustrating no change in baseline 
transmission or washout after ICI (100 nM; 20 min) exposure in adult slices.  B, 
Preliminary pooled data (n =2) illustrating that ICI (500 nM; 20min) can induce a 
significant slow-onset but sustained depression of synaptic transmission in juvenile 
slices bathed in aCSF containing 0.1 mM Mg
2+
. Example traces from a 
representative experiment from each data set are shown at the time points indicated. 
Data are normalised with respect to baseline and are expressed as mean ± SEM  
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6.2.5:  ICI reduces GluA1 surface expression and can attenuate G1-induced effects 
in primary hippocampal cultures.  
As ICI was unable to mimic the effects of G1 on basal excitatory synaptic transmission 
in adult hippocampal slices but induced a significant depression in juvenile tissue, we 
explored the actions of ICI further by evaluating its effects on surface GluA1 staining in 
primary hippocampal cultures.  
Application of ICI (1 µM; 45 min) resulted in a significant reduction in surface GluA1-
staining (to 90 ± 1.9 % of vehicle treated neurons; F[3,143] = 30.1; p < 0.01 vs. vehicle 
treatment; n = 36; Fig 6.10). Moreover, the magnitude of the G1 induced reduction in 
surface GluA1 was significantly different from ICI alone (G1: 74 ± 2.4% of vehicle 
treated neurons; F[3,143] = 30.1; p < 0.001 vs. vehicle treatment; p < 0.001 vs. ICI 
alone). However, in combination with ICI, the magnitude of the G1 induced reduction 
of surface GluA1 was significantly attenuated, and this was not significantly different 
from ICI alone (ICI + G1: 93 ± 2.0 % of vehicle; F[3,143] = 30.1; p < 0.001 vs. G1 
treatment and  p > 0.05 vs. ICI alone). These data suggest that in this assay, the ICI 
compound can reduce surface GluA1-trafficking, however not to the same magnitude 
that which G1 can elicit. Importantly, ICI treatment in combination with G1 can 
attenuate G1-induced effects in this assay.  
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Figure 6.10: ICI can reduce surface AMPAR expression and attenuate the 
G1-induced effects in primary hippocampal cultures.  Primary cultured 
hippocampal neurons were pre-treated with vehicle (0.01% DMSO) or ICI (1 
µM; 15 min) and then G1 (10 nM) or vehicle, or in combination with ICI (30 
min). A, representative confocal images of surface GluA1 staining. B, pooled data 
showing relative changes in surface GluA1 immunostaining after exposure to ICI, 
G1 and in combined presence of ICI and G1. Scale bars, 20µm. A one way 
ANOVA followed by Tukey post-hoc analysis was performed.  ** and *** 
represent p < 0.01 and p < 0.001 vs. vehicle respectively, and ns represents p > 
0.05 between the indicated treatments; n = 36 neurites from 3 individual cultures 
from different animals.  
*** 
ns 
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ICI + G1 ICI G1 Vehicle 
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6.2.6:  ICI can attenuate the magnitude of the G1-induced depression of synaptic 
transmission.   
As exposure to ICI attenuates the effects of G1 in the surface AMPAR expression assay, 
in the next series of experiments we examined if ICI also attenuated effects of G1 in 
adult hippocampal slices. Thus, ICI (1 µM) was applied to adult hippocampal slices 20 
min before co-application with G1 (10 nM). Application of ICI had no effect on basal 
synaptic transmission (100 ± 1.0 %; n = 6; p > 0.05, Fig 6.11 A). However in slices 
exposed to ICI, the magnitude of the G1-induced LTD was significantly attenuated 
(from 87 ± 2.4% of baseline in G1 treated slices, F[2,17] = 19.2; p < 0.01 vs. baseline; n 
= 6; to 96 ± 3.0 % of baseline in ICI treated slices, p > 0.05 vs. baseline; F[6,41] = 7.2;  
p < 0.05 vs. G1 treated; Fig 6.11 B). Moreover, an extended application of ICI 182,780 
(1 µM; 100 min) had no significant effect on basal synaptic transmission (p > 0.05; n = 
4; Fig 6.11 C)  
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Figure 6.11: ICI attenuates the G1-induced LTD in adult hippocampal slices. A, 
Pooled data (n = 6 slices) illustrating that in the presence of ICI (1 µM), the 
magnitude of LTD induced by G1 (10 nM) is attenuated. B, Pooled data illustrating 
that there is a significant difference between the magnitude of LTD induced by G1 
slices (n =5) and with G1 in combination with ICI (n = 6). C, Pooled data illustrating 
that an extended application of ICI (1 µM; n = 5 slices) in combination with vehicle 
treatment (0.01 % DMSO; 20 min; open bar) does not cause a significant depression 
of synaptic transmission. Example traces from a representative experiment from each 
data set are shown at the time points indicated. Data are normalised with respect to 
baseline and are expressed as mean ± SEM.  
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6.2.7:  Selective ER antagonists do not inhibit the G1-induced LTD or reduction of 
surface AMPAR expression.   
Although G1-induced effects were not inhibited by individual application of either ER 
antagonists, it is feasible that the observed effects of G1 are due to the activation of both 
ERα or ERβ, rather than GPR30. In order to explore this possibility, the effects of 
PHTPP and MPP in combination were examined. In these studies a combination of 
PHTPP (1 µM) and MPP (1µM) were applied to adult hippocampal slices 20 min prior 
to G1 (10 nM; 20 min) application. Considering the variable effects of PHTPP on 
baseline transmission (Fig 6.6 and Fig 6.7 C), data were normalised to the mean values 
of fEPSP slope measurements 15 min prior to G1 application.  
Out of the 6 slices that were treated in these conditions, only one slice elicited a bi-
phasic response profile in response to G1, however a significant G1-induced reduction 
in synaptic transmission was observed in all 6 slices (to 89 ± 4.2 %; F[2,17] = 7.8; p < 
0.05; n = 6; Fig 6.12 A). Moreover, the magnitude of this effect was not-significantly 
different from control slices treated with G1 alone (88 ± 2.8 %; F[2,14] = 39.4; p < 0.05 
vs. baseline; p > 0.05 vs. PHTPP + MPP + G1; n = 5; Fig 6.12 B). It should be worth 
noting that a G1-induced transient increase in synaptic transmission was observed in 4 
of the 5 control slices. Considering the variable nature of the G1-induced transient 
increase in synaptic transmission and considering that G1-induced biphasic effects were 
observed when the antagonists were administered alone (Fig 6.7 A/B and Fig 6.4 A/B), 
it is likely that a combination of the antagonists does not block the G1-induced transient 
increase.  
In immunocytochemistry studies in hippocampal cultures, a combination of MPP and 
PHTPP (1 µM for each; 45 min) had no effect on the relative intensity of surface 
GluA1-staining (to 98 ± 1.9 % of vehicle; p > 0.05 vs. vehicle treatment; n = 36). 
Furthermore, the ability of G1 to reduce surface GluA1 expression was unaffected by 
ERα and ERβ inhibition, as the relative intensity of surface GluA1-staining was not 
significantly different between neurons treated with G1 and those treated with G1 in 
combination with the two antagonists (G1: 82 ± 1.8 % of vehicle; p < 0.05 vs. vehicle; 
MPP + PHTPP + G1: 74 ± 2.2 % of vehicle; p < 0.05 vs. vehicle; p > 0.05 vs. G1 alone; 
n = 36; H = 71.0 with 3 degrees of freedom; Fig 6.13). Thus these data indicate that the 
G1-induced LTD and decrease in surface AMPAR expression are not attenuated when 
in the presence of a combination of ER antagonists.  
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Figure 6.12: A combination of PHTPP and MPP does not block the G1-induced 
effects on basal synaptic transmission in adult hippocampal slices. A,  Pooled 
data (n = 6 slices) illustrating that in the presence of MPP and PHTPP (1 µM), 
application of G1 (10 nM) induces LTD. .B, Pooled data illustrating that there is no 
difference in the magnitude of the synaptic depression induced by G1 (n =5) and 
slices treated with G1 in combination with the antagonists. Example traces from a 
representative experiment are shown at the time points indicated. Data are 
normalised with respect to baseline (as indicated in text) and are expressed as mean 
± SEM.  
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Figure 6.13: A combination of PHTPP and MPP fails to inhibit the G1-
induced effects on surface GluA1-staining. Div 8 – 16 cultured hippocampal 
neurons were pre-treated with vehicle (0.1% DMSO) or PHTPP and MPP in 
combination (1 µM; 15 min) and then G1 (10 nM) or vehicle, or in combination 
with the antagonists (30 min). A, representative confocal images of surface GluA1 
staining. B, pooled data showing relative changes in surface GluA1 after exposure 
to the combination of antagonists, G1 alone and G1 in the presence of both 
antagonists. Scale bars, 20 µm. A Kruskal-Wallis one way ANOVA on Ranks 
was performed, followed by Dunn’s post-hoc analysis.  * represents p < 0.05 vs. 
vehicle treatment and ns represents p > 0.05 between the indicated treatments; n = 
36 neurites from 3 individual cultures from different animals.  
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6.2.8:  siRNA against rGPR30 does not affect GPR30 staining in primary          
hippocampal cultures 
Considering the interesting pharmacology of our G1-induced effects, it was worth 
establishing whether selective knockdown of GPR30 expression in hippocampal 
cultures would abolish the G1- or E2-induced effects on surface GluA1 staining. It is 
known that delivery of genetic material into post-mitotic cells is notoriously difficult 
(Karra and Dahm, 2010). The use of cationic-lipid based transfection reagents (such as 
DharmaFECT), although reliable in easy to transfect cell lines (such as HEK-293 cells), 
often has low efficiency in neurons. As a positive control, we confirmed protein 
knockdown of hGPR55 in hGPR55-HEK-293 cells using Dharmafect 1 and 
SMARTpool siRNA (see section 2.2.2.3 of methods). Thus, in order to establish 
whether efficient protein knockdown in primary hippocampal neurons could be 
achieved using this protocol, we transfected DIV 5 neurons for 48, 72 or 96 hours with 
siRNA against rGria-1, the gene for which encodes rat GluA1.  
Using immunofluorescence, preliminary results suggest that significant knockdown of 
GluA1 expression could be achieved in primary hippocampal neurons after 72 and 96 
hours of siRNA treatment (Fig 6.14). Specifically, 46 hours of siRNA treatment reduced 
relative total GluA1 expression to 84 ± 5.5 % of total GluA1 expression in control 
neurons, however this reduction was not significant (p > 0.05 vs. untreated; n = 20 
cells;). After 72 and 96 hours of siRNA treatment, relative total GluA1 expression was 
significantly reduced to 66 ± 10 % and 73 ± 6.9 % of control levels, respectively (p < 
0.05 vs. untreated; n = 20 cells; H = 25.2 with 5 degrees of freedom). It is worth noting 
that after 96 hours in siRNA, the viability of some neurons became impaired.  
Considering we were able to achieve a significant knockdown of GluA1 expression, an 
attempt was made to knockdown GPR30 protein expression. DIV 5 hippocampal 
cultures were treated with rGPR30 siRNA, hGPR55 siRNA or were left untreated for 
46, 72 or 96 hours. hGPR55 siRNA was utilised as a negative control. Relative GPR30 
expression was examined using the GPR30 antibody previously described in Chapter 3 
(see figures 3.5 and 3.6), and quantified as relative corrected fluorescence intensity (see 
section 2.2.5.3 of methods). Fig 6.15 illustrates that relative fluorescence intensity of 
GPR30 staining in primary hippocampal cultures is not significantly altered after 46, 72 
or 96 hours of siRNA treatment when compared with untreated neurons, suggesting that 
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GPR30 staining is unaffected in primary hippocampal neurons after treatment with 
siRNA against rGPR30. 
 
 
               
 
 
 
 
 
Figure 6.14: siRNA against rGria-1 reduces total GluA1 expression in 
primary rat hippocampal cultures. Relative total GluA1 expression after DIV 5 
hippocampal cultures were treated with rGria-1 siRNA for 46, 72 or 96 hours, or 
left untreated for the indicated times. A, representative confocal images of total 
GluA1 staining after 72 hours siRNA treatment. B, pooled data illustrating 
relative total GluA1 expression after siRNA treatment for the indicated time 
periods. A Kruskal-Wallis one way ANOVA on Ranks was performed followed 
by Dunn’s post-hoc analysis. n = 20 cells from two individual cultures from 
different animals. * represents p < 0.05 between the indicated groups and ns 
represents p > 0.05 between the indicated groups. Scale bars, 20µm.  
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Figure 6.15: siRNA against rGPR30 does not alter relative levels of GPR30 
staining in primary rat hippocampal cultures. Relative GPR30 fluorescence 
intensity expression after DIV 5 hippocampal cultures were treated with rGPR30 
or hGPR55 siRNA for 46, 72 or 96 hours, or left untreated for the indicated times. 
A, representative confocal images of GPR30 staining after 72 hours siRNA 
treatment. B, pooled data illustrating relative GPR30 immunofluorescence after 
siRNA treatment for the indicated time periods. A one way ANOVA was 
performed. n = 20 cells from two individual cultures from different animals. ns 
represents p > 0.05, a non-significant ANOVA. Scale bars, 10µm. 
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6.2.9:   siRNA against rGPR30 does not inhibit the E2- or G1 –induced reduction of 
surface AMPAR expression in primary hippocampal cultures 
As alluded to in Chapter 3, there is the possibility that the antibody used here may not 
be recognising functional GPR30, and without confirmation of gene knockdown by 
quantification of mRNA expression, we cannot conclusively rule out the possibility that 
expression of GPR30 is attenuated after siRNA treatment. Moreover, others have 
established that functional effects of E2 and G1 can be mitigated by GPR30 gene 
silencing in primary cultures of developing rat hippocampal neurons (Ruiz-Palmero et 
al., 2013) and mature cortical neurons (Liu et al., 2012). 
Therefore we tested whether siRNA treatment (72 hours) against GPR30 could 
attenuate the effects of E2 and G1, using the surface AMPAR expression assay (Fig 
6.16). In this set of experiments, surface GluA1 staining was normalised to vehicle 
(0.01 % DMSO) treated neurons which were not subjected to siRNA treatment. 
Treatment with hGPR55 siRNA was utilised as a negative control.  
As shown previously, E2 and G1 (10 nM; 30 min) significantly reduced surface GluA1 
expression in neurons which were not treated with siRNA (to 85 ± 1.9 % and 80 ± 2.4 
% of vehicle, respectively; p < 0.05 vs. vehicle treated neurons not subjected to siRNA 
treatment; n = 36; H = 84.6 with 8 degrees of freedom). Relative surface GluA1 staining 
of vehicle controls was not significantly altered in neurons subjected to either rGPR30 
or hGPR55 siRNA (to 94 ± 1.7 % and 99 ± 2.3 % of untreated vehicle, respectively; p > 
0.05 vs. vehicle treated neurons not subjected to siRNA treatment; n = 36), suggesting 
that treating cultures with siRNA does not compromise surface GluA1-expression. In 
cultures subjected to rGPR30 siRNA, E2 and G1 treatment still significantly reduced 
surface GluA1 staining in neurons (to 80 ± 2.3 % and 80 ± 2.0 % of untreated vehicle, 
respectively; H = 84.6 with 8 degrees of freedom; p < 0.05 vs. rGPR30 siRNA treated 
vehicle controls; n = 36). Moreover, there was no significant difference in the 
magnitudes of the E2- or G1-induced reduction of surface GluA1 expression between 
neurons which were treated with siRNA against rGPR30 or hGPR55 or neurons which 
were left untreated (p > 0.05).  
Therefore, these results demonstrate that the effects of E2 and G1 on surface AMPAR 
expression could not be mitigated in neurons which were treated with siRNA against 
rGPR30.  
175 
 
 
 
 
 
 
 
 
Untreated rGPR30 siRNA hGPR55 siRNA
S
u
rf
a
ce
 G
lu
A
1
 E
x
p
re
ss
io
n
(R
el
a
ti
v
e 
In
te
n
si
ty
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Vehicle
10 nM E2
10 nM G1
A 
Figure 6.16: siRNA against rGPR30 does not inhibit the ability of E2 or G1 
to reduce surface GluA1-expression. Relative surface GluA1 expression after 
DIV 5 - 6 hippocampal cultures were treated with rGPR30 or hGPR55 siRNA, or 
left untreated for 72 hours. A, representative confocal images of surface GluA1 
staining after 72 hours GPR30 siRNA exposure illustrating a reduction in surface 
GluA1 expression after E2 or G1 (10 nM) treatment (30 min) . B, pooled data 
illustrating relative surface GluA1 expression after ligand treatment in 
hippocampal cultures treated with siRNA against rGPR30. A Kruskal-Wallis one 
way ANOVA on Ranks was performed followed by Dunn’s post-hoc analysis. n = 
36 neurites from two individual cultures from different animals. * represents p < 
0.05 vs. respective vehicle treatment. Scale bars, 20µm.  
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6.2.10:  G1-induced effects are likely to be mediated via the MAPK signalling 
pathway. 
Early evidence from breast cancer cell lines suggested that E2-induced activation of 
GPR30 can stimulate ERK1/2 signalling via a mechanism involving transactivation of 
EGFR (Filardo et al., 2000, 2002; Maggiolini et al., 2004). Moreover, it is known that 
acute effects of E2 on hippocampal synaptic architecture are mediated via ERK 1/2 
signalling (Mukai et al., 2007; Srivastava et al., 2008; Zadran et al., 2009). In addition, 
in cortical neurons, G1 mediated depression of NMDA induced currents and inhibition 
of NR2B phosphorylation is sensitive to MEK inhibition  (Liu et al., 2012). In view of 
this evidence, we utilised the MEK inhibitor PD 98059 (25 µM), to determine whether 
G1-induced LTD involves ERK1/2 signalling. It is worth noting here that PD 98059 
inhibits ERK 1/2 signalling by preventing activation of MEK  by upstream kinases 
(Dudley et al., 1995; Davies et al., 2000). 
It was observed (post-hoc) that basal synaptic transmission was transiently altered 
during bath administration of PD 98059 (25 µM; 100 min; Fig 6.17 A; n = 3). Though, 
after 100 min PD 98059 exposure, synaptic transmission was not significantly different 
from baseline (to 96 ± 2.5 % of baseline; p > 0.05; n = 3).  Although application of this 
compound has previously been shown to have no effect on CA3 – CA1 basal excitatory 
synaptic transmission (English and Sweatt, 1997) on close examination of their 
published data it would appear that there is an effect of PD 98059 similar to the effect 
observed here.  
Importantly, the ability for G1 (10 nM; 20 min) to induce a depression of synaptic 
transmission was inhibited when co-applied with PD 98059 (25 µM; Fig 6.18 A). 
Specifically, by the end of G1 washout (100 min; in the presence of PD 98059) the 
mean magnitude of synaptic transmission was above but not significantly different from 
baseline (106 ± 6.4 % of baseline; p > 0.05; n = 6). Moreover, there was no significant 
difference in the mean magnitude of synaptic transmission between the PD 98059 
control slices and the slices treated with PD 98059 and G1 (p > 0.05) at the conclusion 
of the experiments. In control slices treated with G1 (10 nM; 20 min) alone, a bi-phasic 
profile was exhibited in 2 of the 5 slices, and in 3 of the 5 slices a depression only 
profile was observed. For clarity, all 5 slices were pooled (Fig 6.18 B), and a significant 
depression of synaptic transmission was observed after 60 min washout of G1 (to 89 ± 
2.5 % of baseline; F[2,14] = 12.1; p < 0.05; n = 5). In combination with a MEK 
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inhibitor, it would appear that the ability of G1 to induce a depression of synaptic 
transmission may be blocked. However, due to the large between slice variability in the 
magnitude of the fEPSP responses during the washout phase in these conditions and the 
small number of replicates in the extended MEK inhibitor only controls, a conclusive 
statement regarding whether the G1-induced LTD involves ERK1/2 activation cannot 
be made, and further investigation is require.   
In parallel immunocytochemistry studies, the G1-induced reduction in surface GluA1 
staining was blocked by both of the two structurally diverse inhibitors PD 98059 (25 
µM) and U0126 (5 µM). Neither of the MEK inhibitors had any significant effect on 
surface GluA1 expression (PD 98059: 97 ± 1.8 % of vehicle, n = 48; p > 0.05 vs. 
vehicle treatment; U0126: 97 ± 2.1 % of vehicle; n = 36; p > 0.05 vs. vehicle treatment). 
Moreover, there was no significant difference between the PD and U0126 compounds 
alone and in combination with G1 (97 ± 1.6 % of vehicle, n = 48, and 96 ± 2.2 % of 
vehicle, n = 36, respectively, p > 0.05 vs. PD or U0126 alone, F[5,335] = 20.9; p < 0.05 
vs. G1 alone). Further supporting the evidence that MEK signalling is involved in the 
G1-mediated effects on surface GluA-1 expression, co-administration of the inactive 
analogue for U0126 (U0124; 5 µM), did not affect the ability of G1 (10 nM) to reduce 
surface AMPAR expression (to 86 ± 3.0 % of U0124 alone, n = 36, H = 10.9 with 1 
degree of freedom; p < 0.05;  Fig 6.20).   
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Figure 6.17: The MEK inhibitor PD 98059 has a variable effect on synaptic 
transmission.  A, Pooled data (n = 3 slices) illustrating that an extended application 
of PD 98059 (25 µM) can firstly rapidly potentiate synaptic transmission followed 
by a reduction in synaptic transmission in adult hippocampal slices. Example traces 
from a representative experiment are shown at the time points indicated. Data are 
normalised with respect to baseline and are expressed as mean ± SEM.  
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Figure 6.18: PD 98059 blocks the G1-induced depression of synaptic 
transmission.  A, Pooled data (n = 6 slices) illustrating that in the presence of 
PD98059 (25 µM), a depression of synaptic transmission is not observed following 
G1 (10 nM) washout. B, Pooled data from control slices (n =5) illustrating a G1-
induced depression. Example traces from a representative experiment are shown at 
the time points indicated. Data are normalised with respect to baseline and are 
expressed as mean ± SEM.  
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Figure 6.19: Inhibitors of the MEK signalling pathway block the G1-induced 
reduction in surface AMPAR expression. Div 8 – 16 cultured hippocampal 
neurons were pre-treated with vehicle (0.1% DMSO), PD 98059 (25 µM) or 
U0126 (5 µM) for 30 min and then G1 (10 nM) or vehicle, or in combination with 
inhibitors (30 min). A, representative confocal images of surface GluA1 staining. 
B, pooled data showing relative changes in surface GluA1 after exposure to the 
MEK inhibitors alone and in the presence of G1. Scale bars, 20 µm. A one way 
ANOVA was performed, followed by Tukey post-hoc analysis.  * represents p < 
0.05 vs. vehicle treatment; n = 36 neurites from 3 individual cultures from 
different animals.  
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Figure 6.20: An inactive analogue for U0126 does not inhibit the G1-induced 
reduction in surface AMPAR expression. Div 8 – 16 cultured hippocampal 
neurons were pre-treated with U0124 (5 µM) for 30 min and then G1 (10 nM) in 
combination with U0124 (30 min). A, representative confocal images of surface 
GluA1 staining. B, pooled data showing relative changes in surface GluA1 after 
exposure to U0124 alone or in the presence of G1. Scale bars, 20 µm. A Kruskal-
Wallis one way ANOVA on Ranks was performed, followed by Dunn’s post-hoc 
analysis.  * represents p < 0.05 vs. U0124 treatment; n = 36 neurites from 3 
individual cultures from different animals. 
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6.2.11:  An inhibitor of PI3K activity does not block the G1-induced effects on 
surface AMPAR expression 
In breast cancer cell lines, GPR30 activation can increase PIP3 accumulation via PI3K 
activity (Revankar et al., 2005). Activation of the PI3K/Akt pathway is also thought to 
mediate GPR30-induced neuroprotection in immortalised hippocampal cell lines 
(Gingerich et al., 2010) and neuritogenesis in primary hippocampal cultures (Ruiz-
Palmero et al., 2013). Moreover, activation of PI3K/Akt signalling cascade is 
implicated in various forms of hippocampal LTD, for example inhibitors of PI3K 
signalling attenuates NMDAR dependent HFS-LTD in juvenile rodents (Daw et al., 
2002), DHPG-induced LTD in adult mice (Hou and Klann, 2004) and insulin-induced 
LTD in juvenile rodents (van der Heide et al., 2005). Moreover, genetic deletion of 
PI3Kγ impairs NMDAR mediated LTD in juvenile mice (Kim et al., 2011). Therefore, 
it is feasible that PI3K signalling plays a role in the G1-induced effects on AMPAR 
trafficking. In order to examine the potential role of PI3K signalling, wortmannin, a 
metabolite found in fungal species, was utilised to inhibit PI3K activity (Arcaro and 
Wymann, 1993; Powis et al., 1994).  
Application of wortmannin (50 nM; Fig 6.21) to hippocampal cultures caused a small 
but non-significant increase in surface GluA1-staining (to 109 ± 4.0 % of vehicle; p > 
0.05 vs. vehicle treatment; n = 36). Moreover, co-treatment of hippocampal neurons 
with G1 (10 nM) and wortmannin (50 nM) did not inhibit the ability of G1 to reduce 
GluA1-surface staining (to 88 ± 3.2 % of vehicle; H = 44.5 with 3 degrees of freedom;  
p > 0.05 vs. Gl alone; p < 0.05 vs. vehicle; n = 36). Therefore these results suggest that 
it is likely that PI3K signalling is not required for the reduction in surface AMPAR 
expression induced by G1.   
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Figure 6.21: PI3K signalling does not underlie the G1-induced reduction in 
surface AMPAR expression. DIV (8 – 16) hippocampal neurons were pre-
treated with vehicle (0.01% DMSO) or wortmannin (50 nM; 30 min) and then G1 
(10 nM) or vehicle, or in combination with wortmannin (30 min). A, 
representative confocal images of surface GluA1 staining. B, pooled data 
illustrating relative changes in surface GluA1 after exposure to wortmannin, G1 
alone and in the presence of wortmannin. Scale bars, 20 µm. A Kruskal-Wallis 
one way ANOVA on Ranks followed by Dunn’s post-hoc analysis was 
performed.  * represents p < 0.05 vs. vehicle treatment, ns represents p > 0.05 
between the indicated treatments; n = 36 neurites from 3 individual cultures from 
different animals.  
Vehicle Wort G1 Wort + G1 
ns 
* * 
B 
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Summary of findings from Chapter 6: 
1) G1-induced effects on hippocampal synaptic transmission and AMPAR 
trafficking are not blocked by antagonists for GPR30, ERα or ERβ  
2) The SERD and putative agonist for GPR30, ICI had no effect on excitatory 
synaptic transmission in adult hippocampal slices, but preliminary data suggests 
that it mimics the effects of G1 in hyper-excitable hippocampal slices from 
juvenile rodents. 
3) Application of ICI attenuated both the G1-induced LTD in adult hippocampal 
slices and the reduction of surface AMPAR expression in cultured hippocampal 
neurons.  
4) siRNA against GPR30 did not affect relative GPR30 staining or inhibit G1- and 
E2-induced effects on surface AMPAR expression in cultured hippocampal 
neurons.  
5) The G1-induced effects may involve signalling via ERK 1/2, however further 
investigation into this signalling mechanism is required.  
 
 
6.3: Discussion 
6.3.1: Lack of inhibition of G1- induced effects from selective GPR30, ER α or ER 
β antagonists 
The data presented here indicates that the ability of G1 to induce LTD in adult 
hippocampal slices is not blocked by the putative GPR30 antagonist, G15. Moreover, 
treatment of hippocampal neurons with G15 or another putative GPR30 antagonist, G36 
also failed to prevent G1-induced reduction of surface AMPAR expression. 
These findings are in contrast to recent reports, suggesting that G15 is a selective 
antagonist for GPR30. For example, G15 is reported to block G1- and E2- induced 
intracellular Ca
2+ 
mobilization and PIP3 accumulation in a human breast cancer cell line, 
SKBr3 cells, which express GPR30 and ERα-36, but which do not express classical 
ERα or ERβ (Dennis et al., 2009). One possibility for the lack of observed effects of 
G15 in this study could be due to species differences in the selectivity of this 
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compound, as differing pharmacological profiles of synthetic compounds between 
human and rodent GPCRs has been observed (Jenkins et al., 2010). However, this is 
unlikely as G15 is reported to block G1-induced membrane depolarization and 
intracellular Ca
2+ 
mobilization in rat spinal sensory neurons (Deliu et al., 2012). Thus 
the results presented in this thesis would suggest that in our assays, either G1 is acting at 
another receptor, the potency of G15 at GPR30 differs markedly between different 
neuronal populations or rat hippocampal GPR30 is insensitive to G15.  
Evidence contrary to the latter hypothesis has been recently reported (Ruiz-Palmero et 
al., 2013). In their report, G15 was able to completely inhibit G1-, ICI- and E2-induced 
neuritogenesis in developing hippocampal neurons, suggesting GPR30 is the sole 
receptor responsible for this E2-mediated effect in hippocampal neurons and that 
GPR30 expressed in developing hippocampal neurons is sensitive to G15 (Ruiz-
Palmero et al., 2013). However, in an earlier report of similar design, the effects of E2 
on neurite outgrowth were inhibited by ICI (von Schassen et al., 2006). Thus, the 
picture for GPR30 pharmacology and the selectivity of the compounds used to probe for 
GPR30 function is not clear, particularly in native tissue. In addition, the specificity of 
G15 has come into question due to the ability of this compound to induce low levels of 
estrogen-responsive gene transcription via classical estrogen-receptors in MCF-7 cells, 
hence the generation of G36, a proposed GPR30 antagonist with less off-target effects 
(Dennis et al., 2011).  
Moreover, there is evidence which suggests that not all G1- or E2-induced effects, 
thought to be mediated via GPR30, are inhibited by G15. For example, in embryonic 
zebrafish, G15 was unable to inhibit G1-induced cAMP accumulation (Jayasinghe and 
Volz, 2012). In the same model, despite GPR30 knockdown inducing morphological 
changes in embryogenesis (suggesting a critical role for GPR30 in development), G15 
failed to induce similar effects (Shi et al., 2013). The inability of G15 to block G1 
effects has also been reported in in vivo models for pain-related behaviours, where only 
very low concentrations of G1 (0.1 nmol) could be blocked by G15 (Deliu et al., 2012). 
Interestingly, in two immortalised embryonic hippocampal cell lines which express 
GPR30, E2 protects against glutamate-induced neurotoxicity, an effect which is 
although reproduced by G1, was only antagonised by G15 in one of the cell lines 
(Gingerich et al., 2010). In the same study the authors not only failed to examine 
whether G15 blocked the effects of G1, but also suggested that E2-inudced 
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neuroprotection was mediated via activation of GPR30, even though G15 failed to 
inhibit the effects of E2 in one of the GPR30 expressing cell lines (Gingerich et al., 
2010). Interestingly, both immortalised hippocampal cell lines expressed similar levels 
of ERα, ERβ and GPR30, however they differed in their expression of another steroid-
sensing receptor, the androgen receptor (Gingerich et al., 2010). Thus it is tempting to 
speculate that an interaction between GPR30 and androgen receptors contributes to the 
different pharmacological profiles observed in their study (Gingerich et al., 2010).  
Thus, it is plausible that heterodimerization of GPR30 with other receptors (either 
GPCRs or membrane bound steroid receptors) within hippocampal neurons, influences 
the pharmacology and signalling capacity of GPR30. This notion is supported by recent 
evidence which suggests that GPR30 can interact with other GPCRs, specifically 
corticotrophin releasing hormone receptor-1 (CRHR1), progestin membrane receptor-β 
(PMRβ), and the 5-HT1a receptor (Akama et al., 2013). Expression of these receptors is 
observed within the rodent CNS, and specifically hippocampal expression of the 5-
HT1aR (Zavitsanou et al., 2010) and CHCR1 (Williams et al., 2011) has been reported. 
Moreover, accumulating evidence suggests that GPCR oligomerization may be an 
important feature of GPCR signalling in the CNS allowing for fine-tuning and 
functional diversity in response to a single neurotransmitter or neuromodulator (as 
reviewed in Franco, 2009; González-Maeso, 2011).  
Thus, in a few reported contexts in native tissue, this GPR30 antagonist fails to inhibit 
GPR30-mediated signalling. It would appear that the working hypothesis by numerous 
groups suggests that GPR30 may be interacting with other receptors (such as those 
mentioned above) in a cell specific manner, which may result in diverse 
pharmacological and signalling profile of this receptor (as reviewed in Srivastava and 
Evans, 2013).  
Previous reports suggest that effects of G1 in GPR30-recombinant and human breast 
cancer cell lines may be attributed to the ERα splice variant, ERα-36 (Kang et al., 
2010). Thus we hypothesised that if the G1-induced effects were mediated via this 
receptor, then competitive inhibition by an ERα antagonist (MPP) may inhibit the G1-
induced effect; however this antagonist failed to block the G1-induced LTD and 
reduction of surface AMPAR expression. It must be emphasised that these results do 
not exclude the possibility that G1 may still be exerting its actions via this ERα splice 
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variant, particularly as there is recent evidence suggesting that ERα-36 is expressed in 
pyramidal neurons of the adult rodent hippocampus (Liu et al., 2013). As this variant 
possesses a truncated ligand binding domain suggestive of a different ligand binding 
spectrum from classical ERα-66 (Wang et al., 2006), there is the possibility that MPP 
has no affinity for ERα-36, and thus no antagonist action.  
In addition we show that the SERD, ICI was able to attenuate G1-induced LTD in adult 
slices, however application of ICI mimicked the effects of G1 on synaptic transmission 
in juvenile slices. Treatment of hippocampal cultures with ICI also mirrored the actions 
of G1 as the ICI compound promoted a modest but significant reduction of surface 
GluA1-staining. Thus our data suggest that the ICI compound possesses agonist or 
antagonist activity depending on the model system or age of tissue examined.   
Previous reports have shown that ICI can mimic the rapid non-genomic effects of E2 
and G1 in hippocampal neurons. For example, in DIV 7 primary hippocampal cultures, 
ICI induces rapid intracellular Ca
2+ 
mobilization, ERK 1/2 and Akt phosphorylation and 
protects against glutamate and amyloid β toxicity in a manner similar to E2 (Zhao et al., 
2006). Moreover, in adult hippocampal slices from OVX rats, ICI potentiates 
synaptically evoked EPSCs and importantly can occlude any further potentiation 
elicited by E2 (Smejkalova and Woolley, 2010). The results from these reports suggest 
that the effects of ICI are likely to be mediated via a membrane-associated estrogen 
sensitive receptor, and are in agreement with the effects of ICI observed in juvenile 
tissue and in hippocampal cultures in this study. Although this is the first reported 
evidence for antagonistic activity of ICI for G1-induced effects, it is generally accepted 
that ICI inhibits genomic actions of E2 within the hippocampus (Zurkovsky et al., 2006; 
Jelks et al., 2007). This intriguing finding may be explained by the ability for ICI to 
inhibit the physical interaction between GPR30 and ERα, as has been observed in the 
Ishikawa human breast cancer cell line (Vivacqua et al., 2009), and for ICI to inhibit 
membrane associated E2 signalling in a breast cancer cell line only expressing GPR30 
and the ERα variant, ERα-36 (Notas et al., 2012). Thus, if the G1-induced effects in our 
assays are mediated by GPR30 (or specifically an interaction between GPR30 and 
another receptor), then the ICI compound may be preventing receptor-receptor 
interaction, thereby inhibiting G1-induced effects. There is also the possibility that ICI 
may be acting on another, unidentified receptor in these assays, which has opposing 
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signalling mechanisms in adult hippocampal tissue thereby preventing G1-induced 
LTD.  
Nevertheless, despite failure to block G1-induced effects with selective GPR30 
antagonists, occluding the effects with a ligand for GPR30 suggests the involvement of 
this receptor. Whether GPR30-initiated signalling occurs independently or via 
association with another receptor within the hippocampus is an important avenue worth 
exploring in the future.  
 
6.3.2: Inability to inhibit G1- and E2- induced effects with siRNA against rGPR30 
Here we have demonstrated that we were unable to inhibit the effects of G1 and E2 on 
surface AMPAR expression in cells which were treated with siRNA against rGPR30. 
Bearing in mind that knockdown of GluA1 expression was only modest (Fig 6.14) and 
GPR30 staining was unchanged after siRNA treatment (Fig 6.15), it is likely that this 
protocol has failed to inhibit the expression of a significant proportion of GPR30. 
Considering the likely possibility that surface GPR30 expression is very low (Cheng et 
al., 2011a, 2011b), physiological effects in response to GPR30 agonists may only 
require a small number of activated receptors. This concept is supported by the inverted-
U shaped concentration response relationship of G1 on surface AMPAR expression (Fig 
5.7), where low nanomolar concentrations of G1 were able to illicit significant effects. 
Thus it may be very difficult to discern the contribution of GPR30 to G1 and E2 
mediated responses without a significantly large knockdown of protein expression.  
Another concept which cannot be ignored is that G1 may be a promiscuous ligand. 
Although G1 is reported to have no binding affinity to a panel of 25 well established 
GPCR’s (Blasko et al., 2009), the possibility that G1 may have activity at other GPCRs 
or other targets in neurons (for example, ion channels) cannot be excluded. This is a 
reasonable possibility as the structure of G1 is modelled on a steroid backbone and 
steroids are well known modulators of ligand gated ion-channel function (Majewska, 
2007; Cameron et al., 2012). Moreover, preliminary data in our laboratory suggests that 
G1 can stimulate the release of intracellular calcium in hGPR55-HEK-293 cells, albeit 
only at very high concentrations, EC50 ~ 1 -2 µM (Unpublished findings from 
Henstridge, 2009 and Alexander, 2011; see appendix), supporting the notion that G1 
may have off-target effects.  
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6.3.3: Potential downstream signalling pathways associated with G1-induced 
effects 
Although further investigation is required to determine whether the G1-induced LTD 
requires ERK1/2 activity, G1-induced reduction in surface AMPAR expression is 
blocked when an inhibitor of MEK signalling is present. ERK 1/2 kinases are serine / 
threonine kinases (also known as p44 and p42 MAPK, respectively) which within 
hippocampal neurons have a multitude of targets; including transcription factors, 
cytoskeletal proteins and other kinases (as reviewed in Thomas and Huganir, 2004). 
ERK signalling was first implicated in hippocampal plasticity in the late 1990’s, when it 
was found that induction of LTP increased ERK 2 phosphorylation (English and Sweatt, 
1996), and inhibition of ERK1/2 signalling abrogated LTP induction at CA3 – CA1 
synapses, thus implying signalling via ERK critical for hippocampal LTP (English and 
Sweatt, 1997; Zhu et al., 2002; Selcher et al., 2003). Activation of the ERK 2 signalling 
cascade is also implicated in hippocampal LTD as Thiels and colleagues have 
demonstrated significant ERK 2 phosphorylation after induction of NMDAR-dependent 
LTD in the CA1 region of adult hippocampus, moreover this form of LTD is blocked 
with MEK inhibitors (Thiels et al., 2002).  
Interestingly, the ability of mGluRs to induce LTD in the juvenile hippocampus 
(DHPG-induced) is also blocked by inhibitors of the MEK pathway (Gallagher et al., 
2004), whereas in adult slices synaptically-induced mGluR-dependent LTD involves 
p38 MAPK signalling (Moult et al., 2008). Considering the G1-induced LTD is 
independent of NMDAR activation in adult hippocampal slices, this may illustrate a 
novel form of LTD in adult rodents which may involve ERK 1/2 signalling.  
In further support of a role for ERK 1/2 signalling is that the ability of G1 to reduce the 
surface expression of AMPARs is blocked when either of the two structurally distinct 
MEK-inhibitors (PD 98059 or U0126) are present, but unaffected by inhibition of PI3K 
signalling. These results parallel those from Srivastava and colleagues’ (2008), who 
illustrate that E2-induced reduction of surface GluA1 and E2-induced ERK 1/2 
phosphorylation in cultured cortical neurons, occurs on the same time scale, where 
significant effects are observed after 30 min E2 treatment (Srivastava et al., 2008). 
Although in their study a direct link was not examined, rapid modulation of dendritic 
spine stability via ERK 1/2 signalling was hypothesised to be a mechanism by which E2 
reduces surface GluA1 (Srivastava et al., 2008).  
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A number of different signalling mechanisms underlying the removal of AMPAR from 
hippocampal synapses has been described (Lin et al., 2000; Man et al., 2000; Moult et 
al., 2006; Casimiro et al., 2011; Henley et al., 2011). The phosphorylation states of 
specific regions at the C-terminal domains of GluA1 or GluA2 subunits, 
phosphorylation states of associated proteins (PSD-95), or the ability of interacting 
proteins (TARPs) to associate with endosomal transport and machinery, have all been 
reported to influence AMPAR endocytosis or retention of constitutively recycling 
AMPAR (as reviewed in Santos et al., 2009; Henley et al., 2011; Anggono and 
Huganir, 2012). Thus, it may be feasible that G1 mediated signalling via ERK1/2 could 
lead to the modulation of the activity of phosphatases or other kinases, thus altering the 
phosphorylation states of target proteins mentioned above and hence leading to the 
reduction in synaptic GluA1-containig AMPAR.  
Indeed, Liu and colleagues (2012) recently demonstrated G1-induced ERK 1/2 
signalling can modulate the phosphorylation state of ionotropic glutamate receptors. 
This group observed rapid (within 30 min) ERK 1/2 phosphorylation in pre-frontal 
cortical neurons treated with G1. The authors found that this G1-mediated ERK 1/2 
activity supressed dephosphorylation of death associated protein kinase-1 (DAPK-1), 
thus resulting in an inhibition of DAPK-1 mediated Ser-1303 phosphorylation of NR2B 
subunits (Liu et al., 2012). If GPR30 is responsible for the effects described in this 
thesis, a similar convoluted mechanism may be involved in the G1-induced reduction of 
surface AMPAR expression (ie: activity of ERK 1/2 may modulate (indirectly) the 
phosphorylation state of AMPAR subunits or their associated proteins and thus induce 
the removal of; or inhibit the insertion of; GluA1 containing AMPAR). Indeed, protein 
phosphatase 1 (PP1) mediated dephosphorylation of Ser 845 on GluA1-containig 
subunits has been implicated in hippocampal LTD (as reviewed in Collingridge et al., 
2010), and there is evidence to suggest (albeit in human aveola macrohpages) that 
activity of ERK 1/2 influences PP1 activation (Monick et al., 2006). Thus, it may be 
feasible that G1 induced activation of ERK 1/2 promotes dephospohrylation and 
internalization of GluA1-containing AMPAR via activation of PP1. However, this 
signalling scenario is purely speculative and the exact mechanisms as to how G1-
induced signalling mediated via ERK 1/2 converges to regulate surface AMPAR 
expression and the expression of long-term depression of synaptic transmission, is yet to 
be determined. 
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6.4: Conclusion 
Through the use of a variety of pharmacological tools and siRNA gene silencing 
approaches, the potential mechanisms underlying G1-induced LTD and reduction of 
surface AMPAR expression were examined. A definitive conclusion as to the target for 
G1 action cannot be made, however our data indicate that the likeliest targets for G1 in 
the hippocampus are either GPR30 and/or ERα-36. Moreover, we examined 
downstream signalling mechanisms that may be initiated upon G1 application. We find 
here that the G1-induced reduction in surface AMPAR expression is likely to involve 
the ERK1/2 MAPK signalling pathway; however whether the G1-induced LTD of 
synaptic transmission involves the activation of ERK-mediated signalling requires 
further investigation.   
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7.1: Summary of Principal Findings: 
 Expression of GPR30 within hippocampal neurons and glia is located primarily 
in an intracellular, peri-nuclear compartment. 
 E2 can bi-directionally influence glutamatergic synaptic transmission; effects 
which are mimicked by the GPR30 agonist, G1.  
 E2 and G1 can induce LTD in adult hippocampal slices; effects which are likely 
to be post-synaptically expressed, do not require afferent stimulation and are 
likely to involve a reduction in the surface expression of post-synaptic 
AMPARs. 
 G1-induced LTD cannot be attenuated by antagonists for GPR30 (G15) ERα 
(MPP) or ERβ (PHTPP), however can be attenuated by the selective estrogen 
receptor downregulator and putative GPR30 ligand, ICI.  
 G1-induced effects on hippocampal synaptic transmission and surface AMPAR 
expression may involve ERK1/2 mediated signalling, however further 
investigation of this signalling mechanism is required. 
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7.2: Implications for current hormone therapy 
There are currently many pharmaceutical products on the market which target estrogen 
receptors and the synthesis of estradiol for the treatment of hormone-responsive breast 
cancer (eg: Tamoxifen, Raloxifene and aromatase inhibitors such as Letrozol and 
Anastrozole). Moreover, in June of this year (2013) both Tamoxifen and Raloxifen were 
approved in the UK (under the National Institute for Clinical Care and Excellence 
guideline 164) to be used as chemopreventatives for postmenopausal woman with a 
high risk of familiar breast cancer. Although these hormone treatments have unarguably 
beneficial effects in this highly prevalent disease, some clinical trial data would suggest 
that women using these endocrine therapies have increased cognitive deficits (Agrawal 
et al., 2010).  
E2 is an important modulator of excitatory synaptic transmission in the adult 
hippocampus, and the data presented in this thesis support this. Moreover, the data 
presented here suggest that at nano-molar concentrations both E2 and the GPR30 
agonist (G1) induce a novel form of LTD. Tamoxifen (specifically, its’ metabolite 4-
OH Tamoxifen) is a proposed GPR30 agonist (Revankar et al., 2005; Thomas et al., 
2005) and there is evidence to suggest that it can cross the blood brain barrier (Biegon 
et al., 1996). Moreover, it has recently been demonstrated that the induction of 
hippocampal LTP is abolished in female rodents after chronic intraperitoneal treatment 
with the aromatase inhibitor Letrozol (Vierk et al., 2012) and the magnitude of 
hippocampal LTP is impaired in male rodents after acute treatment with Letrozol 
(Grassi et al., 2011). Therefore, interference of the neuro-estrogen system by these 
marketed pharmaceutical products may underlie the cognitive deficits reported in 
clinical trials. Thus, further investigation into the molecular mechanisms by which E2, 
Figure 7.1: Proposed mechanism by which E2 and G1 induce hippocampal 
LTD. GPR30, located within the Golgi or associated with synapses in adult 
hippocampal neurons, enhances the removal of synaptic GluA1-containing AMPAR 
expression potentially via an ERK1/2-dependent pathway which may underlie the 
expression of LTD of glutamatergic synaptic transmission. Whether modulation of 
ERK1/2 facilitates the internalisation and degradation of GluA1-contining AMPAR 
or inhibits the surface expression of recycling AMPAR is yet to be determined. It is 
not clear if ICI is acting as an antagonist at GPR30, or is functioning as a partial 
agonist thereby competing with GPR30 in hippocampal slices, and thus is yet to be 
determined.  
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potentially via GPR30, modulates hippocampal transmission is necessary, such that in 
the future, drug design for estrogen-responsive diseases would involve limiting 
potentially detrimental off-target CNS side effects. Or conversely, with a greater 
understanding of the involvement of estrogens in the aging brain, selectively targeting 
novel estrogen-sensing receptors within in the CNS could be utilized as cognitive 
enhancers in age-related cognitive decline and age-related pathologies such as 
Alzheimer’s disease.       
 
7.3: Future Directions:   
7.3.1:  GPR30 or not GPR30? 
Although we cannot conclusively identify GPR30 as the receptor responsible for 
mediating E2-induced effects, the possibility that GPR30 may be involved cannot be 
excluded, particularly as the ICI compound (proposed GPR30 ligand) inhibited G1-
induced effects on hippocampal synaptic transmission and surface AMPAR expression. 
However, due to the potential off target effects of G1 (such as ERα-36 (Kang et al., 
2010) and GPR55 (see section A.2 and A.3 of appendix)) this may be a limiting factor 
in truly establishing GPR30 involvement.  
Based on the tools currently available, the ideal experiment to conclusively determine 
whether the G1- and E2-induced LTD are mediated by GPR30 would involve culturing 
organotypic adult hippocampal slices. Subsequently, ensuring LTD is generated after 
E2 and G1 administration in this model and with the use of siRNA against GPR30, 
optimize a protocol whereby GPR30 gene expression is knocked down, without 
affecting expression of other estrogen receptors, specifically ERα-36. Thus this would 
allow one to test whether G1 and E2 mediated LTD are ameliorated in these slices, 
without the requirement for knockout mice.  
  
7.3.2: A bottom up approach?  
Whether GPR30 truly is an estrogen-sensing receptor is still currently a matter of debate 
(Levin, 2009a; Langer et al., 2010; Srivastava and Evans, 2013). Moreover, evidence 
for GPR30 interacting with other receptors such as GPCRs (e.g.: CRHR1, PMRβ and 5-
HT1aR; Akama et al., 2013) and ER’s (e.g.: ERα66; Notas et al., (2012), and 
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associating proteins (e.g.: RAMP3; Lenhart et al., (2013) and PSD-95; Akama et al., 
(2013)) is beginning to emerge. Thus, it would be worth initiating a “bottom-up” 
approach to test for GPR30 interacting partners, and whether these partners are 
necessary for efficient surface expression of GPR30, and E2-mediated signal 
transduction.  
An approach could involve first screening for GPR30 interacting proteins in a native 
GPR30-expressing cell type of interest using co-immunoprecipitation techniques. 
Following this, developing chimeric constructs of GPR30 and putative interacting 
proteins, which would utilize fluorescence resonance energy transfer (FRET) 
technology. This sensitive technique is useful for detecting whether two proteins 
interact, as a FRET signal is emitted when the donor fluorophore and acceptor 
fluorophore are in close proximity to each other. Importantly this technique can also be 
employed in living cells which enables users to examine the effects of ligands on 
protein-protein interactions (Comps-Agrar et al., 2011). This approach would be 
coupled with downstream signalling assays which would test functionality and 
pharmacology for GPR30 and its potential interacting partners. With respect to native 
tissue, FRET-based technology to test for GPR30 interactions can be employed through 
the development of fluorescent ligands.   
 
7.4: Concluding Remarks 
In summary, the data presented here suggests that E2 is an important regulator of 
hippocampal excitatory synaptic transmission, eliciting bi-directional effects on 
glutatmatergic neurotransmission and surface AMPAR expression, and importantly 
inducing (in most cases) a novel form of LTD at CA3 to CA1 synapses. Moreover, 
investigation into whether the putative estrogen-sensing GPCR (GPR30) has a role in 
these E2 mediated effects, although not conclusive as we were unable to successfully 
knockdown GPR30, has provided evidence implicating this GPCR in E2-mediated 
effects as the G1-induced LTD and E2-induced LTD share common mechanisms.  
The bi-directionality of the E2 and G1 responses on glutamatergic synaptic transmission 
could implicate estrogen receptors as important physiological targets which may 
contribute to the modulation of synaptic tone. This reasoning emanates from evidence 
suggesting that E2 can facilitate the induction, and enhance the magnitude of both LTP 
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(Córdoba Montoya and Carrer, 1997; Foy et al., 1999) and LTD (Zamani et al., 2000; 
Mukai et al., 2007), coupled with the data suggesting that estradiol is synthesised within 
the hippocampus (Hojo et al., 2004), potentially in response to afferent activity 
(Balthazart et al., 2003). Such that E2-induced effects may be mediated by the 
frequency and timing of incoming afferent stimuli. Moreover, the ability of estrogen 
receptor agonists to influence the expression of surface AMPAR may provide a 
molecular mechanism whereby levels of post-synaptic excitation could be dynamically 
controlled in response to locally produced E2. In addition, it is well established that 
estradiol has the capacity to modulate GABAergic transmission in the adult 
hippocampus via transiently suppressing GABA synthesis (Rudick and Woolley, 2003) 
and acutely inhibiting pre-synaptic GABA release (Huang and Woolley, 2012), thereby 
influencing the balance between excitation and inhibition of principal neurons. The 
physiological implications for these effects on glutamatergic synaptic transmission and 
AMPAR trafficking in the hippocampus and the exact molecular mechanisms involved 
remain to be determined.  
Moreover, it is unlikely that the estrogen system will be functioning independently, and 
rapid cross-talk with other hormonal systems will influence glutamatergic synaptic 
transmission together with memory formation and consolidation in vivo. Indeed, there is 
already evidence to suggest that estradiol and glucocorticoid interactions have opposing 
influences on hippocampal excitatory synaptic transmission (Ooishi et al., 2012b). 
Furthermore, the relative responsiveness of estrogen-sensitive neurons from extra-
hippocampal regions which send afferents to hippocampal regions (such as cholinergic 
neurons in the basal forebrain (as reviewed in (Gibbs, 2010)) may contribute to the 
overall effect estradiol has on hippocampal function in vivo.  
With the addition of GPR30 to the ever growing list of estrogen-sensing receptors and 
functional estrogen receptor splice variants, it is vital that there is development of more 
selective pharmacological tools with less potential off-target effects in order to fully 
elucidate the role of individual estrogen receptor subtypes within the CNS.  
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Reference 
Sex  
(if OVX; primed or unprimed) 
Synaptically evoked EPSCs / 
EPSPs or fEPSP recordings from 
CA1 
% slices or cells exhibiting an 
enhancement of synaptic 
transmission 
(Foy et al., 1999) Adult male gonadally intact rats 
Synaptically evoked and 
pharmacologically isolated AMPA 
and NMDA EPSPs from CA1 
pyramidal neurons (bath application 
of 1nM E2) 
NMDA-mediated: 9 / 13 cells  (69%) 
AMPA-mediated:  5 / 14 cells (36%) 
(Fugger et al., 2001) 
Adult (1 ½ month +) castrated male 
and OVX female (unprimed) C57 
mice 
fEPSP recordings from stratum 
radiutum of CA1 (bath application of 
100pM E2) 
Male:      7 / 10 slices (70%) 
Female:  6/10 slices (60%) 
(Sharrow et al., 2002) 
Adult (3 month) OVX female rats 
(unprimed) 
fEPSP recordings from stratum 
radiatum of CA1 (bath application of 
100pM E2)  
14 / 21 slices (67%) 
(Rudick and Woolley, 2003) 
Adult female rats (OVX and estrogen 
primed or gonadally intact)  
Synaptically evoked EPSCs from 
CA1 pyramidal neurons (bath 
application of 100pM E2) 
34 / 55 cells (62%) 
(estradiol priming of OVX rats 
increased response rate from 33% to 
73%)  
TABLE A1: COMPARISON OF LITERATURE REGARDING THE FREQUENCY OF CELLS OR SLICES WHICH RESPOND TO E2 AND G1 BY 
EXHIBITING AN ENHANCEMENT IN GLUTAMATERGIC SYNAPTIC TRANSMISSION.  
200 
(Kramár et al., 2009) 
Young Adult (1 – 1 ½ month) 
gonadally intact male rats 
fEPSP recordings from stratum 
radiutum of CA1 (Bath application of 
1nM E2) 
Did not state rate of response: 
“highly reproducible responses” 
(Zadran et al., 2009) 
Adult ( 2-4 month) gonadally intact 
male rats 
fEPSP recordings from stratum 
radiutum of CA1 (Bath application of 
10nM E2) 
Did not state rate of response 
i.e. all 10 slices responded to 
estradiol treatment (100%) 
(Lebesgue et al., 2009) 
Adult (~ 2month) OVX female rats 
(unprimed) 
Synaptically evoked EPSCs from 
CA1 pyramidal neurons (bath 
application of 100nM G1 or E2) 
G1:  4 / 7 cells (57%) 
E2:  3 / 5 cells (60%) 
(Lebesgue et al., 2010) 
Adult  (~ 2month) OVX female rats 
(unprimed) 
fEPSP recordings from Stratum 
Radiutum of CA1 
(bath application of 10nM G1 or E2) 
G1:  9 / 14 slices (64%) 
E2:  8 / 9 slices (89%) 
(Smejkalova and Woolley, 2010) 
Adult female (2 ½ - 3 month) OVX 
rats (E2 primed) 
Synaptically evoked EPSCs from 
CA1 pyramidal neurons (Bath 
application of  100pM - 100nM E2 
and 100nM G1) 
100pM E2:    6 / 14 cells (43%) 
1nM E2:        9 / 22 cells (41%) 
10nM E2:      8 / 17 cells (47%) 
100nM E2:   18 / 28 cells (64%) 
100nM G1:   2 / 15 cells (13%) 
(Alexander, 2013 (unpublished)) 
Adult ( 3 – 5 month) gonadally intact 
male rats 
fEPSP recordings from stratum 
radiutum of CA1 (bath application of 
1 – 100nM G1 or 10nM E2) 
1nM G1:        0 / 5 slices (0%) 
10nM G1:   15 / 27 slices (55%) 
100nM G1:   5 / 6 slices (83%) 
10nM E2:   16 / 22 slices (72%) 
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A.2:  PROMISCUITY OF THE GPR30 AGONIST, G1 
Follow up experiments from the unpublished observations by Chris Henstridge (2009), 
suggest that the GPR30 agonist (G1) can activate hGPR55 and regulate intracellular 
calcium levels in hGPR55-HEK-293 cells. A brief (5 min) exposure of G1 to hGPR55-
HEK-293 cells produced a concentration-dependent increase in peak Ca
2+ 
transients, 
with an EC50 of 1.18 ± 0.05 µM (Fig A.1).  
 
 
 
 
A.3: OTHER PROPOSED GPR30 LIGANDS DO NOT ACTIVATE HGPR55 
Preliminary studies with other proposed structurally similar GPR30 ligands (E2, ICI, 
G15) were conducted in order to test if activation of hGPR55 was specific for G1. In 
these studies, application of E2 (3 µM; 5 min) ICI (10 µM; 5 min) or G15 (10 µM; 10 
min) were able to induce Ca
2+
 transients in hGPR55-HEK-293 cells (Fig A.2). 
Furthermore, the ability for G1 (2 µM) to activate hGPR55 was not inhibited by co-
application of either ICI (10 µM), a compound which can inhibit G1-induced 
modulation of excitatory synaptic transmission in adult slices or the proposed GPR30 
antagonist, G15 (10 µM). The finding that G15 does not stimulate or inhibit G1-induced 
Figure A.1: The GPR30 agonist G1 induces intracellular Ca
2+
 responses in 
hGPR55-HEK 293 cells. i,  Representative calcium transients induced by G1 (2 
µM; 5 min) induces in an individual cell. Calcium transients are expressed as a 
change in the fluorescence ratio of the Ca
2+
 sensitive dye, Fura-2 AM. ii, 
Concentration-response curve of the mean peak values of Ca
2+
 transients. Data are 
mean ± SEM from a total of 30 cells for each concentration, from two individual 
experiments.  
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Ca
2+ 
transients in these cells is interesting, considering that the only difference in the 
two structures is the presence of an ethanone moiety in G1 (Fig 1.5). 
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Figure A.2: Other proposed GPR30 ligands do not activate hGPR55.  
Representative calcium traces from individual cells illustrating that i) E2 (3 µM; 
5min), ii) ICI (10 µM; 5 min) and iii) G15 (10 µM; 10 min) do not induce Ca
2+
 
transients. Co-application of iii) G15 (10 µM) or iv) ICI (10 µM), with G1 (2 µM) 
does not inhibit the G1-induced Ca
2+ 
responses. v) Histogram representing the 
mean peak Ca
2+
 responses after ligand application, data are mean ± SEM from a 
total of 15 cells for each treatment group, from an individual experiment.  
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